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Introduction 
INTRODUCTION 
1.1 Function and morphology of the lung 
The primary function of the lung is intake of oxygen from the air and release of carbon dioxide 
from the body. This process of gas exchange is based on gas diffusion laws. Since the diffusion 
rate of oxygen in tissue is very small (about 5 nmol-cm^atm'-s"1), gas exchange between the 
external and internal environment has to take place in near contact. This near contact is 
accompanied by increased risks of dehydration, supercooling and infection. It is the lungs 
secondary function to prevent these phenomena. 
The airways of the lung can be described as a tree. Air enters at the nose, and follows its way 
via the trachea and the primary bronchi through an elaborate system of airways into the blind 
ending alveolar sacs (Fig. 1 A). The airways of the human lung branch into an average of 23 
generations (1,2). The first 15 generations, which end in the terminal bronchioles, belong to the 
conduction zones of the lung and channel air into the respiratory part of the lung. They also take 
care of part of the secondary function of the lung (i.e. regulation of air humidity, temperature and 
filtering of dust and microorganisms). The terminal part of the lung, the 16,h up to the 23rd gene­
ration, comprehending the transitional and respiratory zone of the lung, is called the acinus. An 
acinus is defined as that portion of lung parenchyma that is supplied by a first-order respiratory 
bronchiole, i.e. a parenchymal unit in which all airways participate in gas exchange (3)(Fig. 1 A). 
Alveoli are the actual gas-exchanging elements of an acinus. The human alveolus has a cup-like 
form (Fig. 2) with an average diameter of 200-300 μπι; the alveolar wall (the septum) has a width 
οί5-15μπι(3,4). 
Although the airway tree is not branched by regular dichotomy (the diameter and angle of 
the conjugated two daughter branches are not the same), assumption of this branching pattern is 
used as a model (5). In this model the human conducting zone of the airway tree is branched into 
approximately 16,000 (i.e. 214) bronchioles, which branch into about 32,000 acini (2). During 
branching of the conducting airways the diameter of the airway decreases, but it remains constant 
in the airways of the acinus (about 700 μπι, outer diameter). The inner surface area of one acinus 
is estimated at 3260 mm2; the total gas-exchange surface of a whole lung is about 100 m2 (2). 
Π 
Fig. 1: A. Scheme of the airway branching tree Z, order of generation, (after Weibel (5), and adjusted on base 
of data of Haefeli-Bleuer (2)) 
B. Structural presentation of the alveolar wall, at the position of an attachment to a bronchiole The basement 
membrane (bm), containing heparan sulphate 
proteoglycans (HSPG), is associated with blood vessel 
endothelial cells (EC), and type I and 11 epithelial cells 
Fiber strands (fi) form a continuum throughout the 
interstitium, and are built by collagen fibrils, which are 
decorated by dermatan sulphate proteoglycans (DSPG), 
and by elastic fibers, occasionally accompanied by large 
chondroitin sulphate proteoglycans (CSPG) Interstitial 
cells further include fibroblasts (FB), myofibroblasts 
(MF), smooth muscle cells (SM), interstitial and 
alveolar macrophages (IM and AM respectively), mast 
cells (MC), pericytes (PC) and various immune 
"competent" cells (ICC) Other cells comprising the 
alveolar and bronchiolar walls are lymphatic endothelial 
cells (LyC), Clara cells (Clara) and ciliated epithelial 
bronchus cells (Cilia) 
bm HSPG CSPG 
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Air transport through large 
airways is mainly by flow, which 
gradually changes to diffusion in 
the peripheral airways. Since 
oxygen transport from the alve­
olar airspace to erythrocytes is 
exclusively by diffusion, the 
alveolar wall has to be extremely 
thin. Furthermore, since air is 
constantly pumped in and out the 
lung, alveoli undergo a contin­
uous change in volume and thus 
have to cope with mechanical 
stress. The alveolar wall is adap­
ted to meet these challenges, and 
this is reflected in its highly 
specialized cellular composition. 
The most important alveolar 
cells are represented in Fig. IB: 
Type I epithelial cells, 
which are characterized by their attenuated form and which cover about 93% of the alveolar 
surface (6). 
Type II epithelial cells, which are cuboidally formed cells making up about 7% of the 
epithelial surface (6). They contain surfactant storage bodies (the multilamellar bodies) 
which consist of multilayered membranes organized around a protein-rich core and 
surrounded by a limiting membrane that can fuse with the apical plasma membrane. 
Surfactant is a complex and highly surface-active material which lines the alveolar surface. 
It reduces the surface tension, and contains about 90% lipids and 5-10% surfactant-specific 
proteins (7). 
Fibroblasts, which are amoeboidal cells which are responsible for the synthesis of most of 
the extracellular matrix components. 
Interstitial and alveolar macrophages, which move through the alveolar interstitium, or are 
submerged in the alveolar lining fluid. They fulfill a defensive role in removing invasive 
bacteria and/or dust particles. 
Endothelial cells, which consist of a nucleus surrounded by a thin layer of cytoplasm, similar 
to type I epithelial cells. Together with type I cells, the thin interstitium and the alveolar 
13 
Fig. 2: Scanning electron micrograph of human peripheral lung tissue. 
Alveoli consist of alveolar airspaces (a), surrounded by alveolar walls 
(aw), in which the gas exchange takes place. Bar represents 100 μπι. 
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lining fluid. the\ form the blood-air barrier This barrier is extremely thin (to ensure 
sufficient gas transport), and is the last obstacle between the external and internal 
environment 
In addition the alveolar wall contains various kinds ot immune-competent cells (e g 
lymphocytes), pericytes, which are contractile cells around capillaries, and myofibroblasts 
and smooth muscle cells, which are mainly located at the end of an alveolar septum 
Lymphatic vessels are not present in the alveolar septa 
1.2 The alveolar connective tissue 
Connective tissue is characterized b> a limited number of cells and a large amount oi 
extracellular structures (the extracellular matrix) The extracellular matrix components provide 
the alveolar wall with the appropriate structural integrity, but also allow plastic deformation and 
modulation The extracellular matrix (Fig IB) consists of some major structural elements 
including basement membranes, fibrillar components (collagen fibrils and elastic fibers) and the 
ground substance (c g proteoglycans and fibronectin) Due to the highly specialized lunctions, 
and the high mechanical forces which are applied to the extremely thin alveolar walls, the 
connective tissue ot the alveolus is a dedicated and specialized structure, with a special 
composition 
During lung development the extracellular matrix regulates cellular growth, migration, and 
differentiation Pulmonary cells respond to and regulate extracellular matrix formation by 
liberating a variety of components (e g cytokines (8) and prostaglandins (9)) that affect gene 
transcription, RNA processing, translation, and posttranslational modifications of proteins This 
regulation encompasses prenatal and postnatal events such as the branching of airways and 
formation of alveolar septa Airway branching requires multiple extracellular matrix proteins 
(e g proteoglycans) and the expression of cellular receptors for these molecules Alveolar septa 
formation exemplifies how cells regulate the production, export, and deposition of important 
structural proteins (collagen and elastin) which are essential for the development of normal gas 
exchange units (10) 
1.3 The alveolar basement membrane 
Normal lung function is maintained partly by the characteristics of extracellular matrix 
components Both the alveolar epithelium and the capillary endothelium synthesize a specialized 
extracellular matrix, the basement membrane 
Basement membranes are thin layers of a specialized extracellular matrix that form a 
supporting structure at the basal site of cells (epithelial and endothelial cells), or that completely 
encompass cells (e g muscle cells, adipocytes) Basement membrane proteins influence cellular 
14 
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behaviour such as adhesion, shape, migration, proliferation, and differentiation The major 
molecular constituents ot basement membranes are type IV collagen, laminin, entactin/nidogen 
complexes and proteoglycans Proteoglycans are anchored into the membrane by an unknown 
mechanism, and provide clusters of negativel} charged groups 
1 he overall composition of the alveolar basement membrane is similar to that in other organs 
and include type IV collagen, laminin, entactin/nidogen and heparan sulphate proteoglycans 
These components arc considered to assemble differently in the epithelial and endothelial 
basement membranes The epithelial basement membrane is more negatively charged (11 ), and 
contains more regularly orientated heparan sulphate proteoglycans than the endothelial basement 
membrane (12) The basement membranes of type I epithelial cells and of capillary endothelial 
cells form a double basement membrane (12-14) 
In the following the three major components of the alveolar extracellular matrix, collagen, 
elaslin and proteogl>cans are discussed 
1.4 Collagen 
Collagens comprise a lamilv ot structural macromolecules of the extracellular matrix which 
contain at least one domain in a characteristic triple-helical conformation L ike most structural 
proteins they display a high capacity for diversity In the past decade collagen research has 
resulted in the identification of at least 18 (or 19 when cd(Y) is included (15)) different collagen 
molecules (16 18) Besides the structural collagenous proteins there are some other non­
structural proteins that contain collagen triple helices (eg surfactant proteins A and D, 
complement laclor Clq, conglutimn mannose binding protein and acetylcholinesterase) 
Collagens arc characterized as (structural) proteins with three polypeptide α-chains, which 
each contain a stretch ol the repeating triplet amino acid sequence (Gly-X-Y)
n
, in which X and 
Y can be an\ amino acid but orten are proline and hydroxyprohne respectively Each repeating 
triplet sequence is oriented in a helix By the intertwining of three individual α-chains a coiled 
coil triple helix is formed, which is characteristic for collagens The three α-chains can be 
identical (homolnmers) or consist of either two or three different kinds of oc-chains 
(helero tri mers) In collagen nomenclature, different α-chains within a single collagen molecule 
are distinguished by Arabic numbers, while the collagen types have Roman numbers in 
parenthesis For example, type I collagen has a chain composition [al(I)]2cc2(l) Vertebrate 
collagens can be classified on basis of their size and self assembly (17) The classical collagen 
fibril form is characterized bv a 64-67 nm (D) repeating banding pattern (D-stagger), and is the 
form of assembly favoured by type I, II III V and XI collagens The non-fibrillar collagens (IV, 
VII VIII, IX X XII, XIII and XIV) are more difficult to classify and distinct kinds of assembly 
of these types occur 
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Collagen assembly 
Collagen is initially produced as a 
precursor, i.e. procollagen consisting of 
three pro-cc-chains, which are synthesised 
as prepro-a-chains (Fig. 3). On these 
prepro-a-chains. several post-translational 
modifications occur (19. 20). Cleavage of 
the signal peptide takes place after 
insertion into the rough endoplasmic 
reticulum, pro-a-chains undergo prolyl 3-
and 4-hydroxylation, lysyl hydroxylation, 
O- and N-linked glycosy lalion, interchain 
disulphide cross-linking, and occasionally 
a glycosaminoglycan chain is attached to 
the collagen molecule (type IX collagen). 
After chain association and triple helix 
formation, the processed procollagen 
molecules are secreted into the 
extracellular matrix, where they assembly 
into - dependent on their type - fibrillar or 
non-fibrillar structures. The N- and C-
terminal domains of "fibrillar" 
procollagens are cleaved from the 
molecules (21), and the collagen 
protomers are assembled into a ID-
staggered array (Fig. 3). The assembled 
collagen molecules are stabilized by 
crosslinking of lysine and hydroxylysine 
residues at specific positions, a process 
which is catalysed by lysyl oxidase (22) 
(Fig. 4). Collagen fibrils vary in length 
and diameter, dependent on their 
composition (17, 23). 
ROUGH ENDOPLASMIC 
RETICULUM 
Synthesis and modification 
of procollagen chains 
Chain association and nuclealion 
Triple helix formation and secretion 
INTRACELLULAR 
EXTRACELLUAR 
'
i a f e a f f l 
Cleavage of N and С propeptides j 
Assembly and cross-linking 
of fibrils 
* 
Fig. 3: Schematic representation of the intracellular and 
extracellular steps involved in the synthesis, processing, 
and assembly of type I collagen molecules into fibrils The 
individual collagen polypeptide chains are synthesized in 
the rough endoplasmic reticulum In the Golgi apparatus 
they undergo enzymatic modifications prior to chain 
association and triple helix formation The newly formed 
procollagen molecules are secreted via secretory vacuoles 
In the extracellular space they undergo cleavage of the bl­
and C-propeptides The tropocollagen molecules thus 
formed participate in fibril formation by aligning in a 
characteristic D-staggered array, which is stabilized by 
covalent crosslinks (adapted from Kielt et al ( 16)) 
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Assembly of non-fibrillar 
collagen (e.g. type IV 
collagen) occurs in a different 
way (24-26). Type IV 
collagen does not undergo 
proteolytic cleavage at its C-
and N-terminals. The 
structure of type IV collagen 
molecules, which are located 
in the basement membrane, 
differs from that of the fibril 
forming collagens in several 
ways The triple helix domain 
is interrupted at several 
positions by short non-triple 
helical sequences, and is 
therefore more flexible than 
the corresponding domains of 
type I and III collagens. At 
the N-terminal region of the 
molecule a further triple-
helical region is located (the 7 
S-domain) that is separated 
from the main triple helix part 
by a kink. This domain is 
very rich in carbohydrates, 
and can interact with the same 
region of three adjacent 
collagen molecules, forming a 
four armed "spider-shaped" 
structure (25) (Fig. 5). The C-
terminal side contains a non-
collagenous globular domain 
(NCI-domain), which can 
interact head-to-head with the 
NCI domain of another type 
I 
c=o 
I 
H-C-(CH2).-NH ! 
lysyloxydase 
Cu , 0 , 
N 
( l y s i n e ) 
2 allysine 
aldol 
condensation 
c=o 
I 
H-C-(CH:)rCH=0 
I 
N 
| (allysine) 
I I 
c=o нс=о o=c 
I I I 
H-C-(CH2)2-CH=CH-(CH2h-CH 
I I 
Ν N 
| allysine aldol | 
I 
o=c 
Schiff base 
lysine +allysine 
c=o 
I I 
H C-(CH2) rCH=N-(CH2)«-CH 
I I 
Ν N 
I dehydrolysmo- | 
norleucine 
Fig. 5: Cross-linking of lysine residues by lysyl oxidase. 
NC 
b. NCI domain 
e. 7S domain 
Fig. 4: Schematic model of (a) a type IV collagen molecule, (b) us 
assembly into a dimer by crosslinking of lhe NCI domains and (c) 
assembly into a tetramer by crosslinking of the 7S domains Crosslinking 
occurs via disulphide bonds of cysteine residues (24). or via lysine / 
hydroxylysine residues (see Fig 4) 
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IV collagen molecule, forming a dimer The combination of the NCI and 7S domain interactions 
allows the formation of a three-dimensional network, which can serve as a scaffold for the 
basement membrane (26) 
I I 
c=o нс=о o=c 
I I I 
H-C-(CH2)2-CH=CH-(CH2),-CH 
I I 
NH NH 
allysine aldol | 
desinosi ne 
1.5 Elastic fibers 
Elastic fibers are widespread components of vertebrate connective tissues. They are mainly found 
in tissues in which reversible deformations are crucial, such as lung, skin and blood vessel walls 
The elastic fiber is a complex structure which is mainly composed of microfibrils and elastin 
Elastin is the component which provides the elastic fiber with its actual elastic properties 
Formation of elastic fibers starts with the synthesis of the soluble precursor of elastin 
(tropoelastin). Tropoelastin is a protein 
of 62-75 kDa, depending on animal 
species and protein soform More than 
75% of the amino acid residues of this 
protein are nonpolar or uncharged (27), 
and are often organized into hydro 
phobic domains. These hydrophobic 
domains alternate with hydrophilic 
regions that contain polyalanine 
sequences interspersed by lysine resi­
dues (28), which are potential crosslink 
sites for lysyl oxidase (Fig. 4). During 
crosslinking of tropoelastin molecules 
into insoluble elastin, unusual amino 
acids are formed (e.g. desmosine and 
isodesmosine), which are characteristic 
for elastin. A possible mechanism of 
desmosine formation is shown in Fig. 6. 
The high degree of crosslinking and the 
hydrophobic character of elastic fibers 
make them resistant to proteolytic 
destruction. 
Elastic fibers first appear as aggre­
gates of 10-12 nm microfibrils arranged 
in a parallel array. These microfibrils 
are believed to direct the morpho-
c = o 
I 
HC-CH,-CH,-CH,-C 
ι \W/ 
NH c - C 
H 
o=c I 
N-TCH2-CH2-CH2-CH2-CH 
NH 
I 
C O 
H-C-(CH2b-CH=N-(CH2)4-CH 
I I 
NH NH 
[ dehydrolysino- | 
norleucine 
Fig. 6: Possible mechanism of the formation of desmosine 
from allysine aldol and dehydrolysinonorleucine, which are 
both formed by the crosslinking of lysine and hydroxylysine 
by lysyl oxidase (see Fig 4) 
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genesis of elastic fibers (29). Tropoelastin is secreted and directed to the surface of elastic fibers, 
where it first binds to the high affinity 67-kDa elastin receptor. This cell surface-bound receptor 
mediates elastin deposition to the elastic fiber (29, 30). 
1.6 Proteoglycans and glycosaminoglycans 
Proteoglycans are a diverse family of macromolecules which consist of a protein backbone (core 
protein) to which one or more N- or O-hnked glycosaminoglycan chains are covalently attached. 
Due to their composition they should be considered as a subclass of glycoproteins. Glycosamino­
glycans are linear, strongly negatively charged carbohydrate polymers consisting of repeating 
disaccharide units (Fig. 7). The glycosaminoglycans can be divided into 5 types: hyaluronic acid, 
chondroitin sulphate, dermatan sulphate, keratan sulphate and heparan sulphate/heparin. The 
disaccharide unit consists of a hexosamine residue and an uronic acid residue. In keratan 
sulphate, uronic acid is replaced by galactose. Due to their high degree of carboxylation and 
sulphation (except hyaluronic acid), glycosaminoglycans are probably the most negatively 
charged macromolecules in vertebrates. 
R- -H o r - S O s H 
R* = - C O C H , or S 0 3 H 
R" = - H o r - ( 1 ) « - ( u c o s e 
C O O H 
О 
Г = C5-epimenzal ion 
HO C H j O R 
O R 
Heparan sulphate and Heparin 
GlcA(ß1-4)GlcNAc(u1-4) 
or lduA(al-4)GlcNAc(u1^i) 
сн,он 
^ Г ^ ' 
Keratan sulphate 
Gal(ß1-4)GlcNAc(ß1-3) 
Chondroitin- and Dermatan sulphate 
GlcA(ß1-3)GalNAc(ß1-4) 
or lduA(a1-3)GalNAc(H1-4) 
Hyaluronic acid 
GlcA(ß1-3)GlcNAc(U1-4) 
Fig. 7: Disaccharide structure of glycosaminoglycans The basic disaccharide structures of the different glycos-
aminoglycans consist of N-acetyl glucosamine (GlcNAc), glucuronic acid (GIcA), N-acetyl galactosamine 
(GalNAc), galactose (Gal) and iduronic acid (IduA). All types of glycosaminoglycans except hyaluronic acid 
can undergo O-sulphation at several positions, while only heparan sulphate and heparin can be N-sulphated 
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Except for hyaluronic acid, all glycosaminoglycans can be found attached to a core protein 
(i.e proteoglycans) The glycosaminoglycan attachment sites are characterised by a specific 
linkage region. Fxcept for keratan sulphate, this region consists of xylose-galactose-galactose-
glucuronic acid, which is attached via x>lose to a serine residue of the core protein. Besides b> 
their disaccharide composition, glycosaminoglycan types are characterized by the modifications 
they undergo. Only hyaluronic acid, which is synthesized at the plasma membrane, does not 
undergo any form of modification. All other glycosaminoglycans are synthesized and modified 
in the Golgi apparatus. Heparan sulphate and heparin are unique in their N-sulphate groups, and 
can, like chondroitin sulphate and dermatan sulphate, undergo C5-epimerisation. The structure 
of keratan sulphate differs in several aspects from that of the other members of the glycosamino­
glycan family (31). As already mentioned the uronic acid residue is replaced by galactose. The 
linkage region of keratan sulphate, which differs from the linkage region of other glycosamino­
glycan types, is N- or O- linked to asparagine or serine, respectively Keratan sulphate possesses 
a sialic acid-containing cap structure and the disaccharide units sometimes contain fucose 
residues 
KS-nch CS-nch 
в 
g^ collagen 
FN 
heparin 
10 kDa 
FN 
cell-binding 
, 'HS 
^J^^^wQw^mmmmmM^j^^ 
Fig. 8: Schematic representation of three 
proteoglycans A, cartilage-associated 
chondroitin-sulphate (CS)-keratan sul­
phate (KS) proteoglycan (aggrecan). 
which aggregates with hyaluronic acid 
(HA) to form large complexes, B, colla­
gen-associated dermatan sulphate (DS) 
I II II II II 1 
proteoglycan (decorin), with its libro- τ π щ jv ν 
ncctin (FN), heparin and cell binding 
domains (32) and C, the basement membrane-associated heparan sulphate (HS) proteoglycan (perlecan), with 
the different domains indicated by Roman numbers (see text) Note the diversity in the size of the core protein, 
and the number of glycosaminoglycan chains attached Bars indicate the molecular mass 
40 kDa 
Due to the variation in disaccharide composition, degree of N- and O-sulphation, acetylation 
and C5-epimerisation glycosaminoglycans can form a large variety of structures, with probably 
as many different functions. Furthermore, there also exists a extensive variation in the amino acid 
20 
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sequence and in the size of the core protein, as well as in the number and nature of glycosamino-
glycans attached to a core protein (Fig 8) This makes the variety within the proteoglycan family 
even larger 
Biosynthesis of heparin/heparan sulphate 
Biosynthesis of heparin and heparan sulphate takes place in the Golgi apparatus It starts with the 
synthesis of the glycosaminoglycan linkage region to a specific senne residue of the core protein 
(Fig 9) The formation of the linkage region is subsequently catalysed by four different enzymes, 
xylosyl transferase, galactosyl transferase I, galactosyl transferase II and glucuronosyl transferase 
I, which catalyze the attachment of D-xylose. D-galactose, D-galactose and D-glucuronic acid 
respectively (33, 35) This protem-tetrasaccharide structure is the first substrate to be recognized 
by the N-acetyl-glucosamine transferase and is followed by glucuronosyl transferase, resulting 
in the attachment of N-acetyl-D-glucosamine and D-glucuronic acid to the growing chain (Fig 
9) Elongation is continued to a final chain (heparosan) counting up to 50-100 disaccharide units, 
depending on the core protein and the origin and state of the cell 
During elongation, the heparosan chain is modified, starting by the interaction of a N-
deacetylase/N-sulphotransferase complex with the heparosan chain, which simultaneously 
performs N-deacetylation and N-sulphation of N-acetyl-glucosamine residues (34) (Fig 10) 
After further elongation and N-sulphation, C5-epimensation of D-glucuronic acid into L-
lduronic acid and 2-O-sulphation of L-iduromc acid residues take place concurrently (36), fol-
lowed by 6-O-sulphation of N-acetyl- and N-sulphate-glucosamine and 3-O-sulphation of N-
sulphale-glucosamine (Fig 10) (37-39) The occurrence of modification reactions and their loca-
tion in the heparosan chain are dependent on the core protein and the enzymatic potential of the 
specific cell in which the proteoglycan is synthesized Heparin has a higher content of L-iduroruc 
acid residues and a larger extent of N- and O-sulphate groups, compared to heparan sulphate 
1.7 Location and function of elastin, collagen and proteoglycans in the lung 
The constant alterations in mechanical forces exerted on the thin-walled alveoli require a high 
degree of specialisation of the alveolar extracellular matrix In human lung about 30% of the dry 
weight is elastin and 15-20% is collagen (8, 10, 41) Collagen and elastic fibers are believed to 
determine to a large extent the tensile strength and elastic recoil properties of the lung, 
respectively In the alveolar extracellular matrix - as in other extensible tissues - type I and HI 
collagens are the most abundantly present collagen types (about 65% and 30% of total lung 
collagen, respectively (42, 43)) Type I collagen is associated with type III, V, X, XII and XIV 
collagen (17, 18), which all are present in the lung Type II collagen is only present in the 
cartilage of the major airways Type IV collagen is one of the most important components of 
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formation of the linkage region 
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Fig. 9: Schematic representation of the biosynthesis of the proteoglycan linkage region, and the chain 
elongation to heparosan The linkage region consists of glucuronosyl (GIcA) (β 1-3) galactosyl (Gal) (β 
1-3) galactosyl (β 1-4) xylosyl (Xyl) (β 1-0-) serine, occasionally the xylose residue is phosphorylated 
at the 2-0 position (33) During chain elongation a total number of up to 100 N-acetyl-glucosamine 
(GlcNAc) residues and glucuronic acid (GIcA) residues are altematingly added to the linkage region 
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basement membranes The alveolar basement membrane contains the a„ a2, a3, a4 and a5 chains 
of type IV collagen (44) The a3(IV) collagen chain was discovered as the antigen in Goodpasture 
syndrome, an autoimmune disease which targets the alveolar basement membrane and the 
glomerular basement membrane (45) 
Elastic fibers in lung, as well as in other tissues, are complex structures that consists of 
several components Mature elastic fibers are chemically inert, extremely hydrophobic and nearly 
insoluble They are extremely stable under normal physiological conditions (46) In human lung, 
elastic fibers are first detected at 3 months of gestation In the area of alveoli, development of 
elastic fibers starts in association with alveolar septal primordial cells and smooth muscle cells 
(47) Elastogenesis mainly occurs in late fetal life, extending into the early postnatal period, and 
is essentially complete in the first decade of life (8, 48) The half-life of elastic fibers has been 
estimated at about 60 years (49) These observations, together with the known stability and 
resistance to degradation, led to the concept that elastic fibers may not be synthesized to any 
great extent in adult lung (50) 
Lung parenchyma contains many different types of proteoglycans at different locations (Fig 
11) Proteoglycans fill the space between the fibrous structures, and influence lung compliance 
and water balance, due to their large hydrodynamic properties and strategic locations in tissue 
(40) The hydrodynamic properties of proteoglycans have been studied best in cartilage The 
main proteoglycan of cartilage is the large chondroitin sulphate/keratan sulphate proteoglycan, 
aggrecan (Fig 8) This proteoglycan aggregates with hyaluronic acid to very large stable 
structures, which form a matrix in which collagen fibrils are embedded Due to their highly 
charged nature, proteoglycans can bind a large amount of water, and readily form hydrated gels 
(51) These hydrodynamic properties give the cartilage tissue the ability to adapt to volumetric 
changes In the lung, aggrecan/hyaluronic acid complexes are found only in the cartilage of the 
conducting airways However, it is likely that other proteoglycans of the peripheral lung tissue 
contribute to the maintenance of the shape and water balance 
Heparan sulphate proteoglycans 
The two major proteoglycans of the peripheral lung are the basement membrane-associated 
heparan sulphate proteoglycan (perlecan) and a collagen-fibnl-associated dermatan sulphate 
proteoglycan (deconn) (Fig 8 and 11 ) Besides perlecan, cell surface heparan sulphate proteo-
glycans (e g syndecans) are present in the lung Their core proteins have a molecular mass of 30-
50 kDa Cell surface proteoglycans are linked to the cell membrane either through a glycosyl-
phosphatidylinositol anchor or through membrane spanning domains of the core protein In the 
latter case, the core protein is an integral membrane protein, containing a cytoplasmatic domain, 
that communicates with the cytoskeleton and transmits signals received by the extracellular 
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Fig. 10: Polymer-modification reactions involved in the biosynthesis of heparin and heparan sulphate The 
various reactions are shown in sequential order Dashed arrows indicate rarely occurring modifications 
Modifications of the heparosan chain include N-deacetylation and N-sulphation, C5-epimensation, iduronic 
acid (IduA) 2-O-sulphation. glucosamine (GlcN) 6-O-sulphation and N-sulphated glucosamine (GlcNS03)-3-0 
sulphation These processes start during the elongation and continue after elongation is completed 
24 
Introduction 
domain The extracellular domain carries 
the glycosaminoglycans, which interact 
with extracellular matrix molecules and 
cell adhesion molecules or which bind 
growth factors, enzymes and protease 
inhibitors More than ten structurally and 
functionally different cell surface proteo­
glycans are now loiown, among which 
four members of the syndecan family 
(52-55) Members of the syndecan family 
are expressed in distinct cell-, tissue- and 
development- specific patterns (54, 55). 
Syndecan-1 and syndecan-2 (fibroglycan) 
show distinct spatial and temporal changes 
during development of mouse lung (56). 
Fibroglycan is specifically localized on 
mesenchymal cells and expressed at a later 
stage. Syndecan-1 is mainly expressed by 
the epithelial cells of the branching 
tubules and multiple distinct membrane 
heparan sulphate proteoglycans are 
synthesized by human lung fibroblast 
(57-60) and alveolar type II cells (61). 
Perlecan is present in the alveolar 
basement membrane (62). This 
proteoglycan has also been isolated from 
the extracellular matrix of cultured human 
lung fibroblast (63. 64). The core protein 
of the human basement membrane heparan 
Rai pira lory bronchiole 
HiYy 
о 
Φ 
Fig. 11: Schematic representation of normal lung paren­
chyma The inset depicts a portion of an alveolar septum 
containing a composite of proteoglycans present The 
proteoglycans are drawn to scale relative lo each other ®, 
epithelial cell BM associated heparan sulphate proteoglycan 
(HSPG), ©, endothelial cell BM associated HSPG, ®, 
endothelial cell surface HSPG ®, fibroblast chondroitm 
sulphate proteoglycan (CSPG) aggregates with hyaluronic 
acid, ©, fibroblast cell surface CSPG and HSPG, ©, 
collagen associated dermatan sulphate proteoglycan 
(DSPG), ©, mast cell heparin proteoglycan-containing 
granules, ®, elastin associated CSPG, AE, alveolar epithe­
lium, BM, basement membrane, Type I Ep, type 1 alveolar 
epithelial cell, Type II Ep, type II alveolar epithelial cell, 
Endo, endothelial cell, Fibro, fibroblast, C, collagen, E, 
elastin (adapted from Juul et al (40)) 
sulphate proteoglycan has a molecular 
mass of about 467 kDa. In this core protein five different domains can be identified, most of 
which contain internal repeats (Fig. 8). Domain I (located at the N-terminal site) contains a 
typical signal peptide sequence and a unique segment of 172 amino acid residues that contains 
three heparan sulphate attachment sites Domain II contains a low-density-lipoprotein-receptor-
like sequence including four cysteine- and acidic amino acid-rich repeats. The cysteine-rich and 
globular regions of domain III show a large similarity to those of the short arm of the laminin a-
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chain. Domain IV contains 14 repeats that are highly similar to the immunoglobulin-like repeats 
of the neural cell adhesion molecule. Domain V contains three repeats with similarity to the 
globular domain of the laminin α-chain. They are separated by epidermal growth factor-like 
regions, which are not found in the laminin α-chain (65, 66). The different domains are 
visualized by rotary shadowing electron microscopy as a pearl-rope like structure (see cover 
page), from which its trivial name "perlecan" has been deduced. The regular distribution of 
perlecan in the basement membrane provides a negatively-charged shield, surrounding the 
interstitium. In the glomerular basement membrane of the kidney, this heparan sulphate shield 
acts as a filter barrier, and prevents negatively-charged proteins (like albumin) to pass through 
(67). Enzymatic digestion of heparan sulphate or blocking the negative charge with anti-heparan 
sulphate antibodies cause proteinuria (67, 68). In the lung a heparan sulphate shield (Fig. 12) can 
perform a similar function, preventing serum proteins from leakage to the alveolar airspace, and 
toxic substances of the airspace from passing the alveolar wall (Fig. 12) (11, 69). 
Fig. 12: Electron micrographs of the alveolar wall after staining of the proteoglycans with Cuprolinic blue 
A. Heparan sulphate proteoglycans (HSPG) are located in the alveolar basement membrane (abm) as well as in 
the capillary basement membrane (cbm). Note the more regular distrubution of heparan sulphate proteoglycans 
in the alveolar basement membrane, compared to its distribution in the capillary basement membrane. 
B. Dermatan sulphate proteoglycans (DSPG) are regularly associated with collagen fibrils and are separated 
from each other according to the main banding period of collagen fibrils. 
a: alveolar airspace; cap: capillary. Bar represents 300 nm 
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Heparan sulphate and the core proteins of perlecan and cell surface proteoglycans possess 
the ability to interact with a number of proteins They bind and modulate growth factors (70-73), 
inhibit proteases (74-76) and can modulate protease inhibition by their effect on specific protease 
inhibitors (77. 78) Perlecan and cell surface heparan sulphate proteoglycans are involved in such 
diverse processes as embryogenesis (79), cell proliferation (80), filtration (67), anti-coagulation 
and lipid homeostasis (80) Alterations in the content of heparan sulphate proteoglycan have been 
related to many pathological conditions such as various kidney diseases (81, 82), Alzheimer 
disease (83-85), diabetic nephropathy (86, 87) and mucopolysaccharidosis (88, 89) 
Dei matan sulphate proteoglycan 
The most abundant aheolar wall proteoglycan is the collagen fibril-associated dermatan sulphate 
proteoglycan deconn (rig 8 and 12) This proteoglycan is named after the regular decoration of 
collagen fibrils it it is visualized by electron microscopy (90, 91) It has a relatively small core 
protein (329 amino acids, molecular mass 36 kDa) (92) Several suggestions were done about 
the function of deconn Deconn is a specific inhibitor of type I and II collagen fibnllogenesis 
(93, 94) Fur thermore, deconn exhibits a modulating effect on the mechanical properties of 
collagen fibrils It reduces the mechanical strength of collagen fibrils, and increases the relative 
stiffness of the fibril at small deformations (94, 95) Increased deconn synthesis has been 
associated with connective tissue softening of the cervix during dilatation in late pregnant women 
(96, 97) 
Deconn can bind several different molecules, e g collagen I, II and III, the collagenous 
domain of Clq -by which the activity of the CI complex is inhibited- (98), fibronectin (99), 
thrombospondin heparin and heparin cofactor II (100) The dermatan sulphate chain can interact 
with other glycosaminoglycans (101, 102) Furthermore, it can bind and neutralize transforming 
growth factor-ß (TGF-ß), whereas deconn synthesis is stimulated by TGF-ß in alveolar type II 
cells (103) Thus, deconn may be a natural regulator of TGF-ß (104, 105) 
Besides perlecan, syndecan and deconn there are a number of other proteoglycans located 
in the lung (Fig 11) Chondroitin sulphate proteoglycans are found in basement membranes and 
associated with fibrillar structures Basement membrane chondroitin sulphate proteoglycan is 
probably involved in branching morphogenesis (106), and the fibril-associated chondroitin 
sulphate proteoglycan is believed to be involved in wound healing (107-109) Furthermore, 
hyaluronic acid is also present in the alveolar wall (110) 
Interactions of proteoglycans with collagen and elastic fibers 
As already discussed, deconn is associated with type I II and III collagen, and modulates the 
assembly and mechanical characteristics of these fibrils The presence of glycosaminoglycans 
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between collagen and elastic fibers was demonstrated in rat lung prior to their tuli development 
suggesting a role in fiber assembly ( i l l ) Large elastin-associated chondroitin sulphate 
proteoglycans were observed in human lung alveoli (112) Chondroitin sulphate proteoglycans 
were also observed at wound healing and regeneration processes (107-109) The 67-kDa elastin-
binding protein is released from the cell surface of cultured smooth muscle cells and from elastic 
fibers after addition of chondroitin sulphate (but not heparan sulphate) which finally leads to 
impaired fiber assembly (30 113) These findings indicate a role for chondroitin sulphate 
pioteoglycans in elastic fiber assembly and repair Furthermore, heparin and probably also other 
glycosaminoglycans inhibit the crosslinking ol lysine residues by lysyl oxidase and the extent 
of binding of lysyl oxidase to preformed collagen fibrils (114) Heparin also decreases the soluble 
elastin content of the culture medium of neonatal rat lung fibroblasts while it increases the 
soluble elastin content ol the cell layer (115) I his altered partitioning ol soluble elastin is 
associated with an increase in steady-state elastin mRNA and an increase in the deposition of 
insoluble elastin in the extracellular matrix Chondroitin sulphate and dermatan sulphate di 11er 
from heparin in that they increase the quantity of soluble elastin in the culture medium of 
neonatal rat lung fibroblasts and decrease the deposition of insoluble elastin in the extracellular 
matrix (115) Thus, heparin, chondroitin sulphate and dermatan sulphate may participate in the 
regulation of elastin synthesis and deposition 
1.8 Pulmonary emphysema 
Pulmonary emphysema is a rather frequently T a b l e ' D e a t h c a u s e d ЬУ pulmonary emphvsema 
• , . r- . и л for males and females per 1 000 000 individuals of 
occurring disease, which manifests usually after 
the Dutch population (116) Values between 
an age of 50-60 years Shortage of breath is the ,, ., .
 c
. . , , , 
° •"
 D
 parentheses aie the percentage of total death cases 
main feature in daily life of patients with pul-
Cause of death Male Female 
monary emphysema In 1992, in the Netherlands 
a total of 8820 people died directly or indirectly p y 
by pulmonary emphysema which is about 3 6 % РГ|П1агУ 2 0 5 (2 3 ) 6 4 (° 8 ) 
of the total death cases in the Netherlands (Table secondary 298 (3 4) 63 (0 8) 
1) Furthermore, due to the reduction of their 
overall condition the quality of life of patients is severely compromised This makes pulmonary 
emphysema a disease, with high social and economic impact 
Fmphysema is a disease of the lung which is defined by the National Heart Lung and Blood 
Institute Committee (1985) as 'A condition of the lung characterized by permanent abnormal 
enlargement of the respiratory airspaces distal to the terminal bronchioles, accompanied by 
destruction of the alveolar walls without obvious fibrosis" Destruction is defined as a loss of 
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Fig. 13: Pressure/volume curves of normal (η) and emphysematous (e) lungs Important lung 
function parameters in the diagnosis of emphysema are TLC. total lung capacity, FRC, functional 
residual capacity and RV. residual volume after maximum expiration Note the increase in steepness 
of the emphysematous pressure volume curve 
the orderly appearance of the acinus, and fibrosis should not be macroscopically visible 
(microscopically visible fibrosis is not meant in this definition)(l 17, 118). 
Destruction of alveolar tissue results in reduction of the blood/air surface, disruption of lung 
architecture (Fig. 13), and increase in compliance. These alterations are reflected in changes in 
several lung function parameters. The most significant functional abnormalities have been 
defined as: expiratory air flow obstruction -usually expressed as the maximum amount of air 
which can be expirated during 1 second (FEV,), increased residual volume (RV), increased total 
lung capacity (TLC); increased compliance relative to lung volume (Fig. 14), reduction of 
diffusion capacity, and uneven distribution of inspired air. Altered elastic properties are relatively 
poor predictors of emphysema, and since the definition of emphysema is of histological nature, 
a conclusive diagnosis of emphysema only can be made after histological analysis of lung. Lung 
function tests, chest radiography and high resolution CT-scans, however, are useful tools in the 
diagnosis of emphysema (119, 120). Due to the problems to discern pulmonary emphysema 
from other obstructive lung diseases (e.g. bronchitis) with lung function tests, all chronic 
obstructive lung diseases are often referred to with the generic term "COPD" (chronic obstructive 
pulmonary disease). 
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1.9 Pathogenesis of pulmonary emphysema 
Historical overview 
The first description of airspace enlargement in men was from the Dutch physician Ruysch in 
1691 ((121), reviewed in (122)). Originally the pathogenesis of emphysema was explained by 
two major theories. In one theory it was explained by trapping of air during expiration in distal 
airspaces, due to obstructed bronchioles. In this theory chronic bronchitis was strongly associated 
with emphysema. The other (less ruling) theory explained the pathogenesis of emphysema by 
disappearance of pulmonary capillaries and the development of alveolar fenestrae, which causes 
ischemia or atrophia (122). 
Protease-antiprotease theory 
In recent research the major theory on the pathogenesis of emphysema is the unrestrained 
breakdown of the alveolar extracellular matrix by an imbalance of proteases and anti-proteases, 
favouring the action of proteases. This theory was primarily based on the discovery of a,-
antitrypsin deficiency in patients with a genetic form of pulmonary emphysema (123, 124), and 
on the induction of pulmonary emphysema in rats by intratracheal instillation of the proteolytic 
enzyme papain (125). 
Fig. 14: Macroscopic view of paper mounted whole human lung sections. Left: normal lung architecture in 
which the dense parenchymal lung tissue with small. Right: emphysematous lung, with destruction of alveolar 
walls, which results in huge alveolar airspaces (photographs are kindly provided by Dr. W.M. Thurlbeck, 
Vancouver Gen. Hosp., Vancouver, Canada. 
30 
Introduction 
The protease/anti-protease theory is often translated to an elastase/anti-elastase theory, since 
only elastolytic enzymes (enzymes with the capability to destruct elastic fibers) were shown to 
induce emphysema, after a single intratracheal instillation (126) On base of these observations 
many researchers emphasize the hypothesis that elastic fiber destruction is the primary cause of 
emphysema In this respect neutrophils are considered to be the main source of proteolytic 
enzymes, among which elastase Macrophages have also been proposed to play a potential role 
in the pathogenesis of pulmonary emphysema (127, 128) Macrophages are concentrated in the 
centnacinar zones of the lungs, the region where the centnlobular emphysema of smokers occurs 
(129, 130) Macrophages can produce a number of different proteolytic enzymes which can 
degrade extracellular matrix components, especially proteoglycans Proteoglycan degradation 
may influence elastic fiber and collagen fibril architecture during tissue repair (131) 
Pulmonary emphysema expresses in several different forms (e g distal acinar-, panacinar-
and proximal acinar emphysema) ( 122), which suggests dissimilarities in the pathogenesis Many 
efforts have been made to quantify elastin in emphysematous human lungs, serum and plasma, 
but the results are controversial (127) Decreased levels oí lung elastin have (132-134), and have 
not (135-138) been found, and elevated levels of elastin-denved peptides have (139-142), and 
have not (143-145) been observed in serum and urine of patients 
Emphysema wilhoul elastic fiber damage 
Considering the different patterns of emphysema which have been recognized in humans, the 
protease/anti-protease theory, which leads to elastic fiber degradation, is not likely to be the only 
road to emphysema (128) Although in several animal models of emphysema elastic fiber 
destruction occurs (e g elastase- and papain-induced emphysema (146-148)), other models have 
been described in which elastic fiber destruction could not be demonstrated Recently (149) it 
was reported that transgenic mice, which overexpress collagenase in their lung, developed 
emphysematous lesions Since collagenase has a rather high specificity for collagen, and cannot 
digest elastic fibers, elastic fiber destruction is not very likely in this model In contrast a single 
intratracheal instillation of collagenase is not sufficient to induce emphysematous lesions (150) 
Studies on collagen in pulmonary emphysema are scarce Malfunctioning of type IV collagen has 
been suggested to be an initial event in the pathogenesis of emphysema (151) In patients with 
Ehlers-Danlos syndrome, a genetic disease caused by mutations in type I or III collagen genes, 
occasionally pulmonary emphysema is present (152, 153) Reports on the collagen content in 
emphysematous lungs are contradictionary In human emphysema an increase in total collagen 
of lung has been found by microscopic analysis (134) An increase (154) and no increase (155) 
in total collagen of lung have been observed on base of hydroxyproline analysis 
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Emphysema can be induced by intravenous infusion of the non-elastolytic enzyme trypsin 
(156), while a single intratracheal instillation of trypsin does not cause emphysematous lesions 
(157). Mutant tight-skin mice that contain neutrophils deficient in elastase activity develop the 
same degree of severe emphysema as normal tight-skin mice (158) This indicates that neutrophil 
elastase does not cause the emphysematous lesions found in tight-skin mice. 
Cadmium-induced airspace enlargement (emphysema with fibrosis), was also not associated 
with destruction of lung elastin (159). According to the definition, this model of airspace 
enlargement with fibrosis cannot be classified as emphysema However, administration of 
cadmium together with the lathyritic agent, ß-amino-proprionitrile (BAPN) resulted in 
emphysema (airspace enlargement without fibrosis). The degree of emphysema in 
neutrophil-depleted hamsters given BAPN and CdCl2 was not different from that in control 
hamsters given BAPN and CdCl2 (160). Thus neutrophils (which are the major source of elastase 
in the lung) were not necessary for the induction of BAPN-CdCl2-induced emphysema. 
Since cigarette smoke is an important source of cadmium (161) and fibrosis is often present 
in the microbullae of the centrilobular emphysema of smokers, cadmium is considered to be an 
important pathogenic factor in the pathogenesis of pulmonary emphysema. This theory is 
supported by the positive relation between the cadmium content and the extent of emphysema 
in lung tissue (162, 163). 
Cigarette smoke 
Cigarette smoke has been established as the most important risk factor for pulmonary emphy-
sema. The relation with the grade of pulmonary emphysema illustrates the high association of 
this disease with smoking habits (Table 2). The relative risk for death from emphysema and/or 
chronic bronchitis is 3 to 18 times higher for smokers, depending on the number of cigarettes 
they smoke. For ex-smokers this risk factor decreases (compared to smokers) depending on the 
number of cigarettes they have smoked and the years of cessation (164, 165). 
Table 2: The relation between grade of pulmonary emphysema and smoking 
habits (166) 
Grade of 
emphysema 
no 
minimal 
slight 
moderate 
advanced 
never smoked 
(%) 
90 
3 8 
3 3 
2 9 
0 
Smoking habit 
1-19 
cigarettes/day 
(%) 
13 1 
164 
33 7 
25 1 
11 7 
>20 
cigarettes/day 
(%) 
0 3 
52 
42 6 
32 7 
192 
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Although not all smokers develop advanced pulmonar} emphysema, only few smokers lack 
any sign of it (Table 2) suggesting that cigarette smoke is an important trigger for the 
pathogenesis of pulmonary emphysema (166, 167) Smokers mainly develop centnlobular, but 
also panacinar emphysema, and both may reach similar values of airflow obstruction and 
parenchymal destruction (168) In rats or hamsters long term exposure to cigarette smoke, 
however, has failed to consistently produce pulmonary emphysema, indicating that smoking 
alone is not the exclusive trigger for the onset of emphysema (167) Damage to α,-antitrypsin by 
cigarette smoking, due to oxidation of this antiprotease molecule, has been proposed to be an 
important factor in the pathogenesis oí cigarette smoke-induced emphysema (169, 170) Current 
smoking and the presence of COPD were found independently associated with higher urinary 
excretion of elastin degradation products (142) This suggests that once clinically overt COPD 
is established, excess elastin degradation may be slowed, but will not be stopped by smoking 
cessation 
Oxidant-antioxidant theory 
Hyperoxia (inhalation of > 90% oxygen) (171) and a number of other oxidants like NO, (172) 
have been shown to induce airspace enlargement Under normal conditions oxidants and radicals 
can be neutralized by antioxidants and radical scavengers, respectively However excess levels 
of oxidants or free radicals can degrade a number of extracellular matrix components, as well as 
other molecules which are believed to be important in the maintenance of alveolar wall integrity, 
eg a-1-antitrypsin (169, 170 173) Cigarette smoke is an important source of oxidants and free 
radicals (174), and thus oxidants and tree radicals mav be important factors in the pathogenesis 
of cigarette smoke-induced emphysema 
The possible iole of pi oteoglycans m pulmonary emphysema 
Proteoglycans have been almost entirely neglected in research toward the pathogenesis of 
emphysema (175) The different pathomechanisms and various forms of appearance of 
pulmonary emphysema indicate that emphysema is a complex process It is not likely that 
pulmonary emphysema is caused bv a single process (ι e protease/anti-protease imbalance) 
Different kinds of disturbances may result in malfunctioning of the extracellular matrix which 
finally leads to destruction of the alveolar wall 
Proteoglycans play an active role in the maintenance of the integrity of the extracellular 
matrix Degradation or disturbed synthesis of these compounds can contribute to destruction of 
alveoli (Fig 15) In all studied animal models of emphysema (except starvation-induced 
emphysema ( 176)) glycosaminoglycan and/or proteoglycan content and/or composition were 
found to be altered In most animal models an increase of the glycosaminoglycan content was 
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observed in the lung. Elastase-induced emphysema leads to an increase of hyaluronic acid and 
heparan sulphate biosynthesis (177), endotoxin to a short term increase of hyaluronic acid and 
chondroitin sulphate, and a long term increase of dermatan sulphate (178, 179), and pronase to 
a increase of uronic acid (180), while cadmium chloride (180) and hyaluronidase/oxygen (181) 
treatment result in a decrease of the lung uronic acid content. In human emphysematous lung 
tissue galactosamine content were found to be decreased and the glucosamine / galactosamine 
ratio was increased (155). In contrast, the absence of changes in pulmonary glycosaminoglycan 
composition is also reported (137). Proteoglycans and glycosaminoglycans may have a specific 
role in the pathomechanism of pulmonary emphysema. Glycosaminoglycans (especially heparan 
sulphate) can function as strong inhibitors of neutrophil elastase (74, 182, 183), and thus 
influence the protease/anti-protease balance. This property of glycosaminoglycans was elegantly 
demonstrated by inhibition of elastase-induced emphysema in mice or hamsters by treatment 
Fig. 15: Schematic representation of the potential role of basement membrane heparan sulphate proteoglycans 
in the defense against proteases and oxidants. In the normal situation the heparan sulphate chains form a 
negatively charged shield, which can obstruct or neutralize aggressive invaders. An excess of proteases or 
oxidants, or a defective heparan sulphate shield can result in passage of these components and finally to 
destruction of the extracellular matrix. Degradation of the core protein leads to release of the three heparan 
sulphate site chains, and thus loss of their protective function. 
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with glycosaminoglycans (76, 182) Furthermore, treatment of hamster with hyaluromdase (an 
enzyme which digests hyaluronic acid, chondroitin sulphate and dermatan sulphate) prior to 
elastase-treatment, developed a more severe emphysema than treatment with elastase alone ( 184). 
indicating the protective role of proteoglycans to elastase damage The anti-protease action ot 
glycosaminoglycans makes them potentially therapeutic agents for emphysema treatment (76, 
182, 185) The core proteins of most proteoglycans are vulnerable to proteolytic digestion (14, 
186) Proteoglycans may therefore be the primary targets for excess of proteolytic activity 
(187-189) Proteolysis of proteoglycans could result in release ot glycosaminoglycans from the 
extracellular matrix, and in a loss of anti-proteolytic activity Furthermore, heparan sulphate in 
combination with interleukin-8 has a chemotactic and stimulating effect on neutrophils, but 
simultaneously inhibits the release of elastase, superoxide, ß-glucuronidase, lysozyme and other 
enzymes from stimulated neutrophils (73, 190-192) These observations suggest that heparan 
sulphate may have a dualistic function in diapedesis, ι e promotion of interleukin-8-dependent 
transmigration of neutrophils, and protection of the tissue microenvironment from damage by 
lytic enzymes released from the migrating cells (131) Macrophages can internalize heparan 
sulphate partially depolymenze it without extensive desulphation and release the product into 
the extracellular environment (193) 
Both Cu/Zn-superoxide dismutase and xanthine oxidase, enzymes which neutralize and 
produce superoxide and free radicals respectively bind to heparan sulphate proteoglycans of the 
cell surface (194, 195) Furthermore, heparan sulphate can protect polyene fatty acid-containing 
phospholipids from damage due to free radicals in vitro and thus cell membranes from oxygen 
damage (196) In this process the glycosaminoglycans are depolymenzed (197-199) or 
structurally altered (200) Treatment of hamster with hyaluromdase prior to 60% oxygen 
treatment results in development of pulmonary emphysema, whereas 60% oxygen treatment 
alone did not result in the development of emphysematous lesions (181) Alveolar basement 
membrane proteoglycans are also degraded by toxic levels of oxygen (199) This can result in 
impairment of the specific functional properties of basement membrane heparan sulphate 
proteoglycans, e g filtering of serum proteins, as was shown after in vitro incubation of lungs 
with cigarette smoke extracts (201) A selective decrease of de novo synthesis of glomerular 
proteoglycans was observed in perfused kidneys under the influence of reactive oxygen species 
(202) These findings indicate a role of glycosaminoglycans in the maintenance of the 
oxidase/anti-oxidase balance, which is partially due to the suicidal free-radical-scavenging 
activity of glycosaminoglycans 
Due to their strong binding properties to divalent metal ions (e g Cu2 , Ca3 Zn , Cd 1 , Pb", 
Μη
1
 ) glycosaminoglycans are likely to be involved in the homeostasis and action of such ions 
(203-205) Copper homeostasis is especially interesting in the pathogenesis of emphysema, since 
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this metal is a cofactor ot the enzyme lysyl oxidase which is responsible for the crosshnking of 
collagen fibrils and elastic fibers Glycosaminoglycans are able to decrease the crosshnking of 
both collagen and elastin by inhibition of lysyl oxidase in a dose dependent manner (114, 206) 
Inhibition of lysyl oxidase can lead to emphysema, as was shown in animals which were fed a 
low copper diet (207) or the lathvrogen ß-aminopropionitnle (208) or which had a detect of 
copper transport (Blotchy mouse (167)) 
As already discussed, cadmium is believed to be a potential inducer of pulmonary 
emphysema Although the mechanism of cadmium-induced airspace enlargement is not fully 
understood, the binding properties of glycosaminoglycans to cadmium could play a role in 
cadmium-induced pathology Intratracheal administration of CdCK resulted in a change of 
pulmonary proteoglycan composition (180) 
Degradation of proteoglycans and changes of their composition affect the crosshnking and 
fibnllogenesis of collagen- and clastic fibers Alterations in elastin deposition can result in an 
impaired and incomplete assembly of elastic fiber 
Changes of the binding of growth factors and cytokines to proteoglycans, which are involved 
in the regulation of the synthesis and turnover of extracellular matrix components (73, 209-211), 
may also play a role in the progressiv e destruction of lung extracellular matrix in pulmonary 
emphysema 
1.10 Aim of the study 
Proteoglycans and glycosaminoglycans are quantitatively minor components of the alveolar wall, 
but their highly specialized function in formation and maintenance of the extracellular matrix 
implicates an important role for these components in the pathogenesis of pulmonary emphvsema 
Human pulmonary emphysema is a slowly progressive disease, which takes many years to 
develop During this time extracellular matrix deformation occurs, which finally results in matrix 
and alveolar wall disruption One of the major problems in investigations ol the pathogenesis ot 
this disease is the large time span between initiation and manifestation Analytical data on tissue 
components come from degenerated emphysematous tissue containing small amounts of alveoli 
Overrepresentation of more resistant structures (blood vessels, bronchioh) hampers correct 
biochemical analysis of alveolar tissue The development of techniques which allow biochemical 
analysis of minute (microscopic) amounts of tissue could overcome this potential pitfall 
Research on proteoglycans and glycosaminogl>cans in the lung (and other tissues) is 
difficult since the present techniques fail to quantify and characterize these components with the 
required sensitivity In Chapters 2 and 3 the development of two new techniques is described 
Chapter 2 reports an assa> for heparan sulphate and total glvcosaminoglycan by a combination 
of simple spectrophotometric methods and Chapter 3 describes an electrophoretic and staining 
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procedure for the quantification and characterization of small amounts of glycosaminoglycans 
(lower limit 250 pg) The latter procedure allows analysis of the glycosaminoglycan content and 
composition in minute amounts of (alveolar) tissue, and in small samples of body fluids 
Immunocytochemical analysis of human alveolar tissue is problematic The sharp air/tissue 
transition in alveolar walls is responsible for artificial light refractions, which disturb 
lmmunoperoxidase analysis of the thin-shaped alveolar wall Immunofluorescence microscopy 
overcomes this problem, but the strong autofluorescence of elastic fibers impedes this type of 
microscopic analysis without proper precautions Chapter 4 handles about the elimination of 
autofluorescence by computerized subtraction For this purpose, and for densitometnc analysis 
of silver-stained gels (Chapter 3) a MS-Windows01 computer program was developed Its merits 
are discussed in Chapter 5 
Pulmonary emphysema is a manifestation of an extracellular matrix malfunction which is 
induced long time before A good approach to elucidate the pathomechanism of emphysema is 
to study alterations in the alveolar extracellular matrix shortly after induction of the disease in 
two animal models Chapter 6 handles about alterations in glycosaminoglycans, proteoglycans 
and other extracellular matrix components after induction of emphysema in rat lung by 
intratracheal instillation of pancreatic elastase Since proteoglycan turnover is relatively fast (a 
few hours to 1 or 2 days (110 212 213) disturbance of the proteoglycan composition can be 
achieved by inhibition of their synthesis Chapter 7 handles about the induction of emphysema 
by inhibition of the proteoglycan synthesis in rat lung by a single intratracheal instillation of p-
nitrophenyl-ß-D-xyloside This glycoside is a synthetic substrate for glycosaminoglycan 
synthesis, and thus (unctions as a competitive inhibitor for the xylosylatcd core protein As a 
secondary effect, the glycosaminoglycan synthesis is increased The altered glycosaminoglycan 
synthesis and turnover, which lead to pulmonary emphysema, in these animals is described 
During the experiments with the animal models we found that the increase of urinary glycos-
aminoglycan content observed the first days after induction showed a good correlation with the 
extent of damage which was later visible in the lung Therefore the urinary glycosaminoglycan 
contents of patients with COPD (presumably pulmonary emphysema) were examined, and 
compared to those of healthy persons, and of patients with a non-related disease, sarcoidosis In 
addition urine samples from patients with lung carcinoma with and without pulmonary 
emphysema were also analyzed (Chapter 8) Chapter 9 gives a final survey and summary 
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A spectrophotometry method for heparan sulphate 
A SPECTROPHOTOMETRIC METHOD FOR THE 
DETERMINATION OF HEPARAN SULPHATE 
Abstract 
A spectrophotometnc method tor the determination of heparan sulphate is described, which is 
based on the 1 9-dimethylmethylene blue assay Addition of bovine serum albumin to this assay 
system results in a specific decrease ot heparan sulphate-based absorbance The amount of 
heparan sulphate can be calculated by subtracting the values obtained in the presence of albumin 
from those obtained in its absence The sensitivity is 0 5 μg heparan sulphate 
Two applications are gi\cn the quantification of heparan sulphate in urine, including urine 
from patients with mucopolysaccharidosis and the evaluation of fractions from gel filtration and 
ion exchange column chromatography for isolation ot heparan sulphate proteoglycans 
Introduction 
Glvcosaminoglycans are linear strongly negativelv charged sugar chains, consisting of repetitive 
sulphaled and/or carboxylated disacchande units The glycosaminoglycans can be divided into 
7 types hyaluronic acid chondroitin 4-sulphate chondroilin 6-sulphate dermatan sulphate 
keralan sulphate heparin and heparan sulphate With the exception of hyaluronic acid, glycos­
aminoglycans are covalently attached to a protein backbone (proteoglycans) Heparan sulphate 
proteoglycans are involved in such diverse processes as embryogenesis (1), cell proliferation (2). 
filtration (3), anti-coagulation and lipid homeostasis (2) 
Two major forms of heparan sulphate proteoglycans are syndecan which is located in the 
cell membrane and perlecan which is a ma]or component of the basement membrane (4) 
Alterations in the content of heparan sulphate proteoglycan have been related to pathological 
conditions such as various kidney diseases (5-7) Alzheimer disease (8-10) diabetes (5 11) and 
mucopolysaccharide storage diseases (12 13) 
Several methods for the detection ot heparan sulphate have been described Most of them 
are based on the measurement ol the total glycosaminoglycan content lollcmed by digestion of 
heparan sulphate with hepanlinase (14, 15) or nitrous acid (16-18) Others are based on the 
electrophoretic separation of glycosaminoglycans followed by staining and quantification (1 3, 
19) In this paper we describe a simple and fast spectrophotometnc method for the quantification 
of heparan sulphate The method is based on the observation that the heparan sulphate-based 
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absorbance in the 1,9-dimethylmethyIene blue assay tor sulphated glycosaminoglycans (20-23) 
is highly reduced when bovine serum albumin is present at a specific pH and NaCl concentration 
Materials and methods 
1.9-Dimethylmethylene blue (DMMB) (80% pure) was purchased from Aldrich Chem Co , 
Bomem. Belgium, whale cartilage chondroitin4-sulphatc, shark cartilage chondroitin 6-sulphate, 
porcine skin dermatan sulphate, human umbilical cord hyaluronic acid, porcine intestinal mucosa 
heparin, bovine intestinal mucosa heparan sulphate, keratan sulphate and bovine serum albumin 
(BSA) (fraction V) from Sigma, St Louis, MO. U S A , bovine kidney heparan sulphate, 
hepantinasc (Flavobactei mm hepai mum, EC 4 2 2 7) and chondroitinase ABC (Pioleus vulgaris. 
EC 4 2 2 4) from Seikugaku Kogyo Co, Tokyo, Japan, DEAE-Sepharose Fast Flow and 
Q-Sepharose I IL 16/10 prepacked column from Pharmacia, Uppsala. Sweden and cellulose 
acetate membranes (CA 25/10) from Schleicher & Schuell, Dassel. Germany 
[ sS]glycosaminoglycans (specific activity IO4 dpm^g glycosaminoglycan) were isolated 
from rat tissues Rats were injected twice intraperitoneally with 1 μΟ Na^sSOyg body weight 
with a 4-h time span between each injection Four hours after the second injection the rats were 
sacrificed and the soft tissues (ι e . liver, kidney intestine etc ) removed Gl>cosaminoglycans 
were extracted by alkaline borohydnde (24) 
Spectrophotometry analyses were performed on a Philips PU8630 spectrophotometer 
Quantification of total sulphated glycosaminoglycan (assay I) 
The content ot sulphated glycosaminoglycans was determined using the DMMB-assay of 
Farndale et al (21) To 100 μΙ sample. 2 5 ml of DMMB reagent-1 was added and the absorbance 
at 525 nm was measured immediately Reagent-I contains 46 μΜ DMMB (initially 46 μηιοί 
DMMB was dissolved in 5 ml 96% ethanol), 40 raM glycine and 42 mM NaCl ad|usted to pH 
3 0 with 1 M HCl Chondroitin 4-sulphate was taken as a standard and included within each 
series of assays For calculations we used second order regression analysis 
Quantification of heparan sulphate (assay II) 
Heparan sulphate content was determined using an adaptation of the DMMB-assay described 
above, in which BSA is added, the pH is lowered and the salt concentration is increased (see 
results) To 100 μΐ sample, 100 μΐ 3% BSA (in deminerahzed water) and 2 4 ml of DMMB 
reagent-II was added Reagent-II contains 48 μΜ DMMB (initially 48 μιτιοί DMMB was 
dissolved in 5 ml 96% ethanol). 42 mM glycine and 63 mM NaCl, adjusted to pH 2 75 with 1 M 
HCl After 30 min at 22°C the absorbance at 525 nm was measured Chondroitin 4-sulphate was 
taken as a standard Using these assay conditions, the absorbance due to heparan sulphate is 
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greatly reduced in comparison to assay I (see results) To determine the extent of reduction a 
heparan sulphate sample was included within each series of assays The concentration of heparan 
sulphate was calculated by subtracting the glycosaminoglycan concentration determined using 
DMMB-assay II from the concentration determined using DMMB-assay I This value was 
corrected for the residual absorbance of heparan sulphate standard in assay II according to the 
formula 
[GAG] ,-[GAG] 
r r r m assay ι assay ¡I [Hb] — — 
l 
[HS] 
assay II 
standard 
[HS] = concentration of heparan sulfate 
[GAG]a„a, y = concentration of glycosaminoglycan determined with assay I 
[GAG]aisa^  „ = concentration of glycosaminoglycan determined with assay II 
[HS]sunJard = heparan sulfate concentration of the standard 
[HS]„
 n и = heparan sulfate concentration of the standard determined with assay II 
Purification ojglycosammoglycansβ от и/те 
Glycosaminoglycans were purified from urine according to the methods of Hodson et al (25) and 
Staprans et al (26, 27) with some modifications Urine was centnfuged at 2000 g for 10 min at 
4°C, 20 ml of the supernatant was diluted to 50 ml by adding 10 raM Tns-HCl, pH 6 8 1 he 
diluted samples were loaded onto a column of 5 χ 0 5 cm containing 0 5 ml DEAE-Sepharose 
Fast Flow After an initial wash with 3 ml 0 2 M NaCl/10 mM Tns-HCl (pH 6 8), glycosamino­
glycans were eluted with 1 ml 2 M NaCl/ 10 mM Tns-HCl (pH 6 8) followed by 3 ml 10 mM 
Tns-HCl (pH 6 8) The recovery of the glycosaminoglycans was monitored by adding 
15,000 dpm [35S]glycosaminoglycan to the urine Recoveries were 88-103% Salts were removed 
by ethanol precipitation ot the glycosaminoglycans Five volumes ethanol were added (final 
ethanol concentration 83%, NaCl solubility in 83% ethanol is 0 17 mM) and glycosaminoglycans 
were allowed to precipitate for 16 h at -20°C After centnfugation for 30 min at 10,000 g (-lOt), 
the precipitated glycosaminoglycans were dried and dissolved in 2 ml deminerahzed water 
Recoveries after precipitation were between 88-100% when monitored by ["Sjglycosamino-
glycan 
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Quantification of heparan sulphate b\ hepantinase digestion 
DEAE-punfied glycosaminoglycan samples from urine (100 μΐ) were lyophihzed and dissolved 
in 20 μΐ 10 mM calcium acetate 50 mM Tns-HCl (pH 8 0) with or without 0 01 U hepantinase 
Incubation was for 16 h at 37°C After lyophilization the dried samples were dissolved in 100 
μ| deminerahzed water Heparan sulphate concentration was determined by calculating the 
difference in total glycosaminoglycan content, using assay I, before and after hepantinase 
treatment 
Extiaction and partial purification of proteoglycans from tissue 
Extracellular matrix from human kidney and bovine lung were prepared by the detergent method 
according to Van den Heuvel et al (28) Proteoglycans were extracted from the extracellular 
matrix with 4 volumes of 4 M guanidine chloride/50 mM sodium acetate (pH 5 8) and dialyzed 
against 7 M urea/10 mM Tris (pH 6 8) The extract was loaded onto a column of 10 χ 2 cm 
containing 10 ml DEAE-Sepharose Fast Flow After an initial wash with 30 ml 0 2 M NaCI/10 
mM Tns-HCl (pH 6 8), proteoglycans were eluted with 50 ml 2 M NaCI/10 mM Tns-HCl 
(pH 6 8) The proteoglycan fraction was dialyzed against deminerahzed water lyophihzed and 
used for ion exchange chromatography or gel filtration 
Ion exchange chi omatography of proteoglycans 
Fifteen mg bovine lung proteoglycan (containing about 5 0 mg glycosaminoglycan) was 
dissolved in 4 ml 50 mM Tris-HCl/1 mM MgCK/100 mM Na-acetate (pH 8 0) and divided into 
two equal parts One part was treated with 0 01 U/ml chondroitinase ABC ( 16 h, 37°C) to digest 
chondroitin sulphate and dermatan sulphate, the other part was not digested Solid urea was 
added to a final concentration of 7 M and the samples were applied to a Q-Sepharose HL column 
Proteoglycans were eluted with a gradient of 0 to 1 M NaCl in 7 M urea/50 mM Tns-HCl 
(pH 6 8) (elution speed 2 ml/min) 
Gel filti alum 
One mg ol human kidney proteoglycans (containing about 300 μg glycosaminoglycan) were 
dissolved in 1 ml 4 M guanidine chloride in 50 mM sodium acetate (pH 5 8), and separated by 
gel filtration on a Sepharose CL-4B column (100 χ 1 5 cm) The column was eluted with 4 M 
guanidine chloride in 50 mM sodium acetate (pH 5 8)(elution speed 0 5 ml/min) Prior to the 
determination of gljcosaminoglycans and heparan sulphate column tractions were desalted b> 
quantitative ethanol precipitation according to Pepinsk) (29) The precipitated proteoglycans 
were dried and dissolved in deminerahzed water 
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Other procedures 
Urinary creatinine was determined using the alkaline picrate method (Sigma, St Louis, MO, 
U.S.A., procedure no. 555). 
Statistical analysis were performed by Students paired t-test. 
B. 
4 e 
pg GAG Mg GAG 
Fig. 1: Standard curves of glycosaminoglycans, in DMMB-assay 1, without (A) and with (B) addition 
of 0.12% BSA.·, bovine kidney heparan sulphate, •, bovine intestinal mucosa heparan sulphate; 
o. dcrmatan sulphate; Δ, heparin; v, keratan sulphate and 0, chondroitin-4-sulphate. Note that the heparan 
sulphate-based absorbance is greatly reduced in the presence of BSA. 
Results 
Effect of bovine serum albumin on the DMMB-assay I 
Presence of BSA in the DMMB-assay I results in a specific reduction of heparan sulphate- and 
heparin-based absorbance; absorbance caused by other glycosaminoglycans is not altered 
(Fig. 1). For heparan sulphate the reduction is about 95%, for heparin about 40%. The concen­
tration of BSA is not critical: 0 02-0.2% BSA (final concentration) reduces the heparan sulphate-
based absorbance to the same extent. Methylated BSA, as well as other proteins like 
immunoglobulins, have similar effects; protamine also eliminates chondroitin sulphate-based 
absorbance. We investigated the possibility if the protein effect could be used as base for a 
specific heparan sulphate assay in glycosaminoglycan and proteoglycan samples. Heparin is 
usually not present in these preparations. 
Determination of the optimum pH and sodium chloride concentration 
The absorbance of glycosaminoglycans in the DMMB-assay in the presence of BSA depends 
strongly on the pH and the NaCl concentration (Fig 2). Optimal conditions for the determination 
of heparan sulphate (i.e., minimal heparan sulphate-based absorbance and no change in the 
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absorbance caused by other glycosaminoglycans) are 63 mM NaCl and pH 2.75. These conditions 
are therefore applied for DMMB-assay-Π. Application of both assays (DMMB-assay I and Π) 
yields the concentration of total sulphated glycosaminoglycan as well as of heparan sulphate. 
21 mM NaCl 42 mM NaCl 
63 mM NaCl 84 mM NaCl 
pH pH 
Fig. 2: The influence of the pH and the NaCl concentration on the interaction of DMMB with different 
glycosaminoglycans in the presence of 0.12% BS A. The amount of each glycosaminoglycan is 8 μg. 
•, heparan sulphate; o. dermatan sulphate; Δ, heparin; v, keratan sulphate and 0, chondroitin 4-sulphate. 
Table 2: Concentration of total sulphated glycosaminoglycan (GAG) and heparan sulphate (HS) in urine 
of seven normal individuals. 
Sample 
nr. 
1 
2 
3 
4 
5 
6 
7 
mean ± S.D. 
Total GAG 
mg GAG/ 
mmol créât. 
0.90 
1.99 
1.37 
1.01 
1.38 
1.29 
1.23 
1.31 ±0.35 
BSA-based method 
mg HS/ 
mmol créât. 
0.21 
0.50 
0.39 
0.28 
0.34 
0.39 
0.22 
0.33 ±0.10 
%HS 
23 
25 
29 
28 
25 
30 
18 
25 ±4 
Heparitinase-
mgHS/ 
mmol creai. 
0.17 
0.55 
0.41 
0.20 
0.28 
0.51 
0.20 
0.33 ±0.16 
based method 
%HS 
19 
28 
30 
20 
20 
40 
16 
25 ± 8 
Values were determined with assays-I and II (BSA-based procedure) or with assay I before and after 
heparitinase digestion. 
56 
A spectrophotometric method for heparan sulphate 
Sodium dodecyl sulphate (up to a sample concentration of 0 5%) and urea (up to 7 M) do 
not significantly influence the BSA-effect on heparan sulphate in the DMMB-assay II (data not 
shown) Heparan sulphates from various sources (kidney, lung and intestinal mucosa) react 
similarly The sensitivity of the assay is 0 5 μg heparan sulphate 
Applications 
Quantification of heparan sulphate m urine 
We determined the concentration of heparan sulphate in urine of normal individuals (age 25-39 
years) by two procedures (Table 1) Using assay II (the modified DMMB-assay) we found a 
value of 0 33 ± 0 10 mg/mmol creatinine (mean ± S D , n=7), being 25% of the total amount of 
sulphated glycosaminoglycans (Table 1) The heparan sulphate content evaluated by hepantinase 
digestion is 0 33 ± 0 16 mg/mmol creatinine (25% of total sulphated glycosaminoglycan 
content) The two assays were compared and checked for linearity according to the linear-
regression procedure for method-comparison studies, as described by Passing et al (30), and 
were found not significantly different (P > 0 5) The intra- and inter-assay coefficient of variation 
(C V ) Of the assay is 3 3% and 7 0% respectively 
Recovery of heparan sulphate added to DEAE-punfied urine (e g 16 μg heparan sulphate 
/ ml purified urine) are 94 ± 5% (mean ± S D , n_5) 
Urines of three mucopolysaccharidosis patients (two suffering from Sanfihppo's syndrome 
and one from Scheie's syndrome) displayed an increase in total sulphated glycosaminoglycan 
content (Table 2) The patient with Scheie's syndrome displayed a moderate increase in the 
relative heparan sulphate content (48% vs 25% heparan sulphate for controls) The two patients 
with Sanfihppo's syndrome displayed a much larger increase in the relative heparan sulphate 
content (86 and 85%) (Table 2) These values were in agreement with cellulose acetate patterns 
of the urinary glycosaminoglycans (data not shown) 
Table 2 Concentration of total sulphated glycosaminoglycan (GAG) and heparan sulphate (HS), 
determined with assay I and II in urine of three mucopolysaccharidosis patients and ten controls 
(values are mean ± S D ) 
Origin urine 
Sanfihppo 
Sanfihppo 
Scheie 
Controls (n= 10) 
Age 
(>ears) 
45 
39 
22 
25 42 
mg GAG/ 
mmol créât 
32 
55 
84 
I 5 ± 0 5 
mg HS/ 
mmol créât 
27 
4 7 
4 1 
0 4 ± 0 2 
%HS 
86 
85 
48 
25 ± 4 
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Assaying column fractions for heparan sulphate 
To demonstrate that our method is not limited to heparan sulphate with a specific sulphate 
content we monitored the isolation of proteoglycans from bovine lung, since lung heparan 
sulphates vary markedly in sulphate content (31). Using anion exchange chromatography 
proteoglycans are eluted at about 0.7 M NaCl (Fig. 3a). After digestion with chondroitinase ABC, 
only heparan sulphate proteoglycans remain undigested. The about equal amounts of glycos-
aminoglycan and heparan sulphate after digestion (Fig. 3b) indicate that the heparan sulphate 
assay detects quantitatively heparan sulphates, even if they have a variable degree of sulphation. 
The glycosaminoglycan-positive, but heparan sulphate-negative material at the right part of the 
curve, represents residual dermatan sulphate, as was demonstrated by cellulose acetate 
electrophoresis according to Stevanovich et al. (32). 
Mg/ml M NaCl μα/ml 
Ю 150 н а 
M NaCl 
0 15 30 45 0 15 30 45" 
fraction number fraction number 
Fig. 3: Anion exchange chromatography of untreated (A) and chondroitinase ABC treated (B) pro­
teoglycans from bovine lung on Q-Sepharose HL (fraction size 2 ml). Total glycosaminoglycan 
concentration (—Δ—) and heparan sulphate concentration (- о -) were determined with the assays-I 
and II. 
Gel filtration of proteoglycans from human kidney, consisting predominantly of heparan 
sulphate- and dermatan sulphate proteoglycans, results in two glycosaminoglycan-positive peaks 
(Fig. 4). The peak eluting near the void volume (V0) is heparan sulphate proteoglycan, as shown 
by our heparan sulphate assay. This elution pattern is consistent with data from literature (28); 
the first peak contains high-molecular-weight heparan sulphate proteoglycan (Mol. mass 500 
kDa) and the second peak contains dermatan sulphate proteoglycan (Mol. mass 100 kDa). 
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I 
В) 4 
2 
О 10 20 30 40 50 60 70 
fraction 
Fig. 4: Gel filtration of proteoglycans extracted from human kidney on 
Sepharose CL-4B (fraction size 2 ml). Total glycosaminoglycan concentration 
(Δ) and heparan sulphate concentration (o) were determined with the assays-I 
and II 
Discussion 
In this report we show that a combination of the published DMMB-assay (20) and an adapted 
version of this assay, i.e. the addition of BSA and the use of specific pH and salt concentration, 
can be used for the determination of heparan sulphate. The procedure is useful for body fluids 
like urine and for monitoring fractions during column chromatography. The pH and ion 
concentration should be carefully controlled in assay Π. Desalting of guanidine- or sodium 
chloride- containing column fractions can be easily achieved by quantitative precipitation of 
proteins by ethanol. For urine samples, purified by anion exchange chromatography, ethanol 
precipitation can also be used for desalting. Dialysis of samples is not recommended, since it 
results in the loss of glycosaminoglycans up to 86%. The urinary glycosaminoglycan 
concentration we found after DEAE-purification is in agreement with those found using other 
methods of purification (13, 33, 34). Purification of urinary glycosaminoglycans by DEAE-
chromatography is necessary, since DMMB-assay 1 is disturbed by high protein concentrations. 
Raising the pH to overcome interference of protein, as suggested by De Jong et al. (35), may lead 
to an overestimation of urinary glycosaminoglycans since other polyanions like DNA also 
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interact with DMMB at higher pH The validity of our method to determine heparan sulphate is 
substantiated by the fact that the same value for the heparan sulphate content of human unne was 
obtained by hepantmase digestion The heparan sulphate values are in agreement with published 
data (36) The assay is useful for screening of mucopolysaccharidosis patients, as was shown for 
three patients, one having Scheie's syndrome (characterized by an increased heparan- and 
dermatan sulphate excretion (13) and two having Sanfilippo's syndrome (characterized by an 
increased heparan sulphate excretion (13)) 
The heparan sulphate assay appears to be universally applicable Heparan sulphate from 
different sources (lung, kidney, intestinal mucosa) and with a different degree of sulphation 
(heparan sulphates from lung), react similarly Small chain length does not markedly influence 
the heparan sulphate assay, since urines of mucopolysaccharidosis patients, which are markedly 
reduced in molecular mass (ι e , from 8000 for controls to 2300 for mucopolysaccharidosis 
patients (37, 38)), were correctly analyzed as was confirmed by cellulose acetate electrophoresis 
It should however, be noted that the DMMB-assay and related assays are based on the 
measurement of polysulphate polysaccharides, and low- or non-sulphated glycosaminoglycans 
will be underestimated 
The mechanism underlying the effect of BS A and other proteins is not clear The effect of 
BSA may be due to ion interactions of heparan sulphate with the positively charged protein 
More positively charged proteins like protamine sulphate (pi = 10 4) exert a stronger effect than 
BSA (pi - 4 8) which is positively charged under the assay conditions (pH = 2 75) Methylated 
BSA, however, has the same effect, indicating that other interactions like conformational ones, 
are likely to play a role Iduronic acid-containing glycosaminoglycans (heparan sulphate, heparin, 
dermatan sulphate) are more prone to the BSA-effect at low pH and low salt concentration (Fig 
2) than glycosaminoglycans which do not contain this uronic acid (e g , chondroitin sulphate, 
keratan sulphate) Only iduronic acid-containing glycosaminoglycans interact significantly with 
basic polypeptides, inducing a random coil to helix conformational change in the peptide chain 
(39) Electron microscopic observations using rotary shadowing techniques reveal glycosamino­
glycans as long strands, except tor heparan sulphate which is probably present in a globular form 
(40) The unique conformation for heparan sulphate may underlay the specificity of the assay 
described here 
In conclusion, the combination of DMMB-assays without and with albumin is a simple and 
reliable way to determine heparan sulphate and can be used for a number of applications 
including quantification ot heparan sulphate in urine and column fractions 
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Nanogram detection of glycosaminoglycans in agarose gels 
QUANTIFICATION AND CHARACTERIZATION OF 
GLYCOSAMINOGLYCANS AT THE NANOGRAM LEVEL 
BY A COMBINED AZURE A - SILVER STAINING IN 
AGAROSE GELS 
Abstract 
A rapid, sensitive and nonradioactive method has been developed for the quantification and 
characterization of glycosaminoglycans The method is based on the separation of different types 
of glycosaminoglycans in agarose gel and subsequent fixation and staining with the cationic dve 
azure A, followed by silver enhancement 
Densitometrie analysis of the silver deposition gives a linear response between 1 and 20 
ng for chondroitin- and dermatan sulphate and between 2 and 40 ng for heparan sulphate The 
detection limit is about 250 pg The staining procedure was applied for the quantification and 
characterization ol glycosaminogl>cans in human serum, urine and lung, and in mouse kidney 
glomeruli It requires only 10 μ\ serum. 2 μ\ urine and onl> a single cryosection in case of tissue 
The method is at least as sensitive as staining with radioactive markers, and about 200 times 
more sensitive than conventional glycosaminoglycan-staining methods 
Introduction 
Glycosaminoglycans arc linear, strongly negatively charged sugar chains, consisting of repetitive 
sulphaled and/or carboxylated disacchande units The glycosaminoglycans can be divided into 
5 types hyaluronic acid, chondroitin sulphate, dermatan sulphate, keratan sulphate and heparin 
/ heparan sulphate hxcept for hyaluronic acid, all glycosaminoglycans are covalently attached 
to a protein backbone, forming proteoglycans 
The application of cellulose acetate and agarose gel electrophoresis for the separation of 
glycosaminoglycans has led to an advance in the analysis of glycosaminoglycan composition in 
tissues and body fluids Several buffer systems, most of them containing divalent metal ions, 
have been used to separate the glycosaminoglycan types (1-4) To visualize glycosaminoglycans, 
cationic dyes such as alcian blue, toluidine blue and azure A have been used Cationic probes to 
which a radioactive label has been added (5, 6) or which have peroxidatic activity (7) have also 
been applied Alternatively glycosaminoglycans have been radiolabeled and detected by 
autoradiography Autoradiography is undoubtedly the most sensitive method, but the requirement 
for radiolabeled material is a serious disadvantage in most applications, and can often not be met 
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For the detection of nonradioacti\ e glycosaminoglyians, ыі ег staining seems to be the method 
of choice and has been successfully applied tor their detection in Polyacrylamide gels (8, 9) 
However, the silver staining techniques used for Polyacrylamide gels, are not compatible with 
agarose gels or cellulose acetate strips, since these matrices give rise to high background staining 
In this study we describe a sensitive, nonradioactive, staining procedure for glycosamino-
glycans. separated on agarose gels, involving fixation of the glycosaminoglycans with the 
canonie dye azure A followed by a silver staining compatible with agarose gels (10, 11) This 
method delects 250 pg of glycosaminoglycan and displays a linear range from 1 to 20 ng 1 he 
method is shown to be valuable for examining glycosaminoglycan composition and content in 
minute amounts of tissue (lung alveoli and kidney glomeruli), serum and urine 
Materials and Methods 
Universal Gel/8 1 % agarose gels were obtained from Ciba-Coming GMBH. Ternwald. German). 
whale cartilage chondroitm 4-sulphate, shark cartilage chondroitin 6-sulphate, porcine skin 
dermatan sulphate, human umbilical cord hyaluronic acid, porcine intestinal mucosa heparin, 
bovine intestinal mucosa heparan sulphate, keratan sulphate, barium acetate and azure A from 
Sigma, St Louis, MO, U S A bovine kidney heparan sulphate, chondroitinase ABC (Proteus 
vulgaris. FC 4 2 2 4), chondroitinase AC (Arthrahacter aurescens, EC 4 2 2 5) and hepantinase 
(Flavobactenum hepannum. EC 4 2 2 7) from Seikugaku Kogyo Co , Tokyo, Japan, silver nitrate 
was obtained from Drijfhout, Amsterdam, The Netherlands, 1,9-dimethylmethylene blue 
(DMMB) (80% pure) from Aldnch Chem Co , Bomem, Belgium, DEAE-Sepharose Fast How 
from Pharmacia, Uppsala, Sweden, tungstosilicic acid from Fluka Chemie, Buchs, Germany and 
sodium borohydnde from Merck, Hohenbrunn, München, Germany [3,S]Glycosaminoglycans 
(specific activity 10^  dpm/Vg glycosaminoglycan, glycosaminoglycan composition about 60% 
chondroitin sulphate, 20% dermatan sulphate and 20% heparan sulphate) were isolated from rat 
tissues Rats were injected twice intraperitoneal^ with 1 ßC\ Na,35SO\,/g body weight with a 4 h 
time span between each injection Four hours after the second injection the rats were sacrificed 
and the soft tissues (ι e , liver, kidney, intestine etc ) removed Glycosaminoglycans were 
extracted by alkaline borohydnde (12) 
Agarose gel elettrophoiesis ofglytosaminoglycans 
Precasted agarose (1 %, 0 5 mm thick) gels were washed for 30 min in deminerahzed water and 
for 30 min in 200 ml electrophoresis buffer Electrophoresis buffer consisted of 50 mM barium 
acetate (pH 5 0) In one series of experiments 0 1 M HCl was used Glycosaminoglycan samples 
were dissolved in electrophoresis butter containing 20% glycerol and 0 01% bromophenol blue 
Samples of 1 μ\ were applied to the agarose gel Electrophoresis in barium acetate buffer was 
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performed at 60 V (10 V/cm) in a Ciba-Corning electrophoresis cell (cat nr 47013200. Ciba-
Corning GMBH, Femwald, Germany) for 50 mm Electrophoresis in 0 1 M HCl was performed 
in a Pherograph-isoclectrofocussing apparatus (type mini 68 Vetter KG, Frankfurt, Germany) 
with constant refrigeration for 2 h at 60 V (6 V/cm) 
Silver staining 
Immediately after electrophoresis agarose gels were fixed and pre-stained tor 1 h with gentle 
agitation in freshly prepared 0 1% (w/v) azure A in 50 mM sodium formate/ 10 mM magnesium 
chloride (pH 3 5, adjusted with 0 1 M HCl) Gels were destained with 200 ml 10 mM sodium 
acetate buffer (pH 5 5) (two times 20 mm) and once with 200 ml deminerahzed water (20 min) 
Gels were air dried 
Silver staining was performed according to Gottlieb and Chavko ( 10) Glassware used 
during the silver staining was cleaned with 50% nitric acid for about 5 min, followed by 
thoroughly rinsing in deminerahzed water To reduce background staining the plastic backside 
of the dried gels was cleaned with a tissue wetted with 96% ethanol Gels were washed in 
deminerahzed water tor 2 mm. and stained in 100 ml silver staining solution 1 he silver staining 
solution was freshly prepared by adding 50 ml solution Λ under constant stirring to 50 ml 
solution В Solution A contains 60 mM ΝΗ,ΝΟ^, 30 mM AgNO 3 5 mM tungstosilicic acid 
and 0 15 M formaldehyde and solution В contains 0 47 M Na,CO Both solutions (A without 
formaldehyde) are stable for several months at -70 °C Staining was stopped by transferring the 
gel into deminerali/ed water for 2 nun, 1% acetic acid for 5 min and again water for 15 min 
Finally the gels were air dried 
Purification of ghtosaminoglycam fi om urine 
Urine was centnfuged at 2000 g for 10 min, 20 ml of the supernatant was diluted to 50 ml by 
adding 10 mM Tris-HCI (pH 6 8) I he diluted samples were loaded onto a column of 5 χ 0 5 cm 
containing 0 5 ml DEAE-Sepharose Tast Flow After an initial wash with 3 ml 0 2 M NaCl/10 
mM Tns-HCl (pH 6 8), glycosaminoglycans were eluted with 1 ml 2 M NaCl/ 10 mM Tns-HCl 
(pH 6 8) followed by 3 ml 10 mM Tns-HCl (pH 6 8) without NaCl to avoid precipitation of NaCl 
upon addition of ethanol The recovery of the glycosaminoglycans was monitored by adding 
15,000 dpm t3,S]glycosaminoglycan to the urine Salts were removed by ethanol precipitation 
of the glycosaminoglycans Five vol ethanol were added (final ethanol concentration 83%, NaCl 
solubility in 83% ethanol is 170 mM) and glycosaminoglycans were allowed to precipitate for 
16 h at -20 °C After centnfugation for 30 mm at 10,000 g (-10 ЧГ). the precipitated glycosamino­
glycans were dried and dissolved in 2 ml deminerahzed water Recoveries of urinary glycos­
aminoglycans were between 88-100% when monitored by [35S]glycosaminoglycans 
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Isolation of human lung alveoli and mouse kidney glomeruli 
To obtain pure alveoli, 30 μιτι human lung cryosections were defatted in diethylether / methanol 
(1 1, v/v) for 1 h, and non-alveolar tissues (bronchioh, blood vessels and pleura) were removed 
with a needle using a stereo microscope The remaining tissue consisting solely of alveoli was 
suspended in water and after lyophihzation the dry weight was determined 
Glomeruli were isolated trom mouse kidneys according to Assmann et al (13), counted 
and dried 
Extraction of glycosaminoglycans β от tissue and serum 
Glycosaminoglycans were extracted from tissue by extensive papain digestion To 500 ¿ig dried 
tissue 100 /ug papain in 200 μ\ 50 mM phosphate buffer (pH 6 5) containing 2 mM EDTA and 
2 mM cysteine was added After digestion (16 h at 56 °C) the reaction was stopped by increasing 
the temperature to 96 °C for 1 mm followed by chilling on ice 
Glycosaminoglycans were extracted from serum by alkaline borohydnde (12) To 1 ml 
serum 3 ml 1 M NaOH / 15 mM NaBH, was added After 1 h at 73 °C the mixture was 
neulrali/ed by addition of 6 M HCl After alkaline borohydnde or papain treatment the 
remaining proteins were removed by addition of 100% (w/v) trichloroacetic acid lo a final 
concentration of 6% After 2 h on ice proteins were precipitated by centnfugation (15 mm 2000 
g 4 "С) 1 о the supernatant 4 vol of 100% ethanol were added and glycosaminoglycans were 
allowed to precipitate for 16 h at -20 °C After centnfugation (30 min, 10 000 g -10 °C ) glycos­
aminoglycans were dried and dissolved in deminerahzed water 
Glycosidase tieutment 
Samples of 1 μ\ (containing about 100 ng glycosaminoglycan) were mixed with 1 μ\ 0 I IU/nil 
chondroitinase ABC chondroitinase AC or hepantinase Chondroitinase ABC digestion was 
performed in 25 mM Tris (pH 8 0) foi 16 h at 37 "С, chondroitinase AC digestion m 25 mM Tris 
(pH 7 3) lor 16 h at 37 "С and hepantinase digestion in 50 mM sodium acetate / 50 mM calcium 
acetate (pH 7 0) lor 16 h at 43 ' С The pH of all buffers was adjusted with acetic acid Alter 
digestion 2 μ\ electrophoresis butter containing 40 % glycerol and 0 01% bromophenol blue was 
added 
Quantification of total sulphaled glycosaminoglycans and heparan sulphate 
I he content of sulphated glycosaminoglycans was determined using the 1,9-dimethylmelhylene 
blue (DMMB) assay of Farndale et al (14) To 100 μ\ sample 2 5 ml of DMMB reagent was 
added and the absorbance at 525 nm was measured directly The DMMB reagent consists of 
48 μΜ DMMB (initially 48 μιτιοί DMMB was dissolved in 5 ml 96% ethanol), 42 mM glycine 
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and 42 mM NaCl, adjusted to pH 3.0 with 1 M HCl. Chondroitin 4-sulphate was taken as a 
standard and included within each series of assays. For calculations we used second order 
regression analysis. 
Heparan sulphate content was determined using the DMMB assay after digestion of 
heparan sulphate by nitrous acid. 100 μί sample was lyophilized and 20 μΐ 0.1 M nitrous acid 
was added. 0.1 M Nitrous acid was prepared by mixing equal volumes of 0.2 M HCl and 0.2 M 
sodium nitrite. After 1 h nitrous acid was removed by lyophilization and the sample was diluted 
in 100 μ\ water. The residual glycosaminoglycans were determined with the DMMB assay, and 
heparan sulphate content was calculated by subtraction of this value from the total glycosamino-
glycan content. Bovine kidney heparan sulphate was used as a reference. More than 90% of this 
heparan sulphate is digested by nitrous acid. 
Densitometrie analysis 
Gels were digitized using an HP-scanjet Π (Hewlett-Packard Company, Camas, WA USA) and 
peak areas intensities were determined using a self developed program 'ImageCalc' which is 
available as shareware. 
nut!* -HS -DS -CSA 
Fig. 1: Detection of various amounts of chondroitin 4-sulphate (CSA), dermatan sulphate (DS) and heparan sulphate 
(HS) after agarose gel electrophoresis in 50 mM barium acetate (pH 5.0) and staining by the combined azure A-
silver staining. A range from 0.125 - 20 ng was applied for CSA and DS and a range from 0.25 - 40 ng for heparan 
sulphate. Lane a to к contain 0.125,0.25, 0.5, 1,2,4,6, 8, 10, 15 and 20 ng CS and DS and the double amounts of 
heparan sulphate (bovine kidney) respectively. Note: The dark spot in lane a is an irregularity. 
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glycosaminoglycan (ng) 
Fig. 2: Staining intensity versus the amount of glycosamino-
glycan after separation by agarose gel electrophoresis in 50 mM 
barium acetate (pH 5.0) and visualization by combined azure A-
silver staining. Staining is linear from 1 to 20 ng for chondroitin 
sulphate (V) and dermatan sulphate (O) and from 2 to 40 ng for 
heparan sulphate (bovine kidney) (D). 
Results 
Staining of glycosaminoglycans in 
agarose gels 
To estimate the sensitivity and the 
linearity of the staining procedure a 
concentration range from 1.25 to 20 ng 
for dermatan sulphate and chondroitin 
4-sulphate and from 0.25 to 40 ng for 
heparan sulphate was subjected to 
agarose gel electrophoresis. The 
detection limit of the silver staining 
procedure is about 250 pg for dermatan 
sulphate and chondroitin 4-sulphate 
and about 500 pg for heparan sulphate 
(Fig. 1). Staining intensity is linearly 
correlated to the amount of glycos-
aminoglycan over a range of 1 to 20 ng 
for dermatan sulphate and chondroitin 
4-sulphate, and of 2 to 40 ng for 
heparan sulphate (r > 0.98 for all 
glycosaminoglycan types)(Fig. 2). For 
comparison, azure A staining alone has 
a detection limit of about 100 ng for 
chondroitin sulphate and dermatan 
sulphate, which is approximately 200-
400 fold less sensitive. 
Sensitivity and background 
level of the staining strongly depend on 
the use of freshly prepared azure A 
reagent and a proper destaining 
procedure. Older reagents give less 
sensitivity. Destaining at pH higher than 5.5 results in poor and slow destaining of the agarose 
matrix and higher background staining. Destaining at lower pH also gives a less sensitive 
detection. The fixation and destaining procedures described, result in low background staining 
whereas sensitivity remains high. 
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Fig. 3: Combined azure Α-silver staining of various glycosamino­
glycans after separation by agarose gel electrophoresis in 50 mM 
barium acetate (pH 5.0). DS, dermatan sulphate; CSC, 
chondroitin 6-sulphate; CSA, chondroitin 4-sulphate; KS, keratan 
sulphate; HS, heparan sulphate (bovine kidney); HA, hyaluronic 
acid and Hep, heparin. An amount of 10 ng of each glycosamino­
glycan type was applied to the gel. 
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Hep HS-bk HS-im 
Fig. 4: Combined azure Α-silver staining of various 
glycosaminoglycans after separation by agarose gel 
electrophoresis in 0.1 M HCl. At this condition (pH > 
1) glycosaminoglycans are separated solely on basis of 
their sulphation grade. DS, dermatan sulphate; CSA, 
chondroitin 4-sulphate; KS, keratan sulphate; HS-bk, 
bovine kidney heparan sulphate; HS-im, bovine 
intestinal mucosa heparan sulphate; HA, hyaluronic 
acid and Hep, heparin. An amount of 100 ng of each 
glycosaminoglycan type was applied to the gel. 
No staining was observed when azure A 
prestaining was omitted, or if glycosamino­
glycans were fixed with quaternary ammonium 
salts (e.g. cetylpyridinium chloride). Azure A 
can be replaced by other cationic dyes like 
toluidine blue, ruthenium red, safarin O, brilliant 
cresyl blue and DMMB. We found, however, no 
improvement of the staining using these dyes. 
All types of glycosaminoglycan are 
stained with our procedure. Fig. 3 shows electro-
pherograms of 10 ng chondroitin-4-sulphate, 
chondroitin 6-sulphate, dermatan sulphate, 
heparin, heparan sulphate, keratan sulphate and 
hyaluronic acid on agarose gels in 50 mM 
barium acetate (pH 5.0). All glycosaminoglycans 
display discrete bands except for hyaluronic acid 
which is separated into a smear. This is probably 
a reflection of the large molecular mass of hyaluronic acid and of a contamination of the 
hyaluronic acid sample with minute quantities of other glycosaminoglycans, as has been reported 
(15) and as could be clearly visualized using an alternative buffer system (50 mM barium acetate 
(pH 5.0) in 25% ethanol, data not shown). These contamination's could not be observed with 
conventional staining techniques. 
Beside barium acetate, other electrophoresis buffers containing divalent metal ions i.e. 
cupric acetate, may be used (data not shown). In addition, other solutions for electrophoresis, like 
0.1 M HCl (4) can be applied. The latter condition is used to separate glycosaminoglycans on 
basis of sulphation only, since carboxyl groups are fully protonated at pH 1. The uniformly 
sulphated dermatan sulphate, chondroitin 4-sulphate and keratan sulphate display discrete stained 
bands (Fig. 4), whereas heparan sulphate of different origin and heparin are separated as smears, 
which reflect the heterogeneous character of these glycosaminoglycans. Hyaluronic acid, which 
is not sulphated, has no electrophoretic mobility at this pH. 
Detection of glycosaminoglycans in serum, urine and tissue 
The major glycosaminoglycans in human serum are dermatan sulphate and chondroitin sulphate, 
while heparan sulphate is much less abundantly present (Fig. 5). Enzymatic digestion of the 
glycosaminoglycans was used to confirm their nature (Fig. 5). By use of a proper dilution range 
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the serum glycosaminoglycans could 
densitometrically be quantified 
(Table 1). Determination of chondroitin 
sulphate and dermatan sulphate in a 
single serum sample gave highly 
reproducible results (1.85 ± 0.07 mg 
chondroitin sulphate/1 serum and 0.37 ± 
0.036 mg dermatan sulphate/1 serum, 
mean ± SD, n=6) (Table 1). 
Chondroitin sulphate and heparan 
sulphate are the main glycosamino­
glycans in human urine (Fig. 6, Table 1). 
Urinary heparan sulphate displays a 
reduced electrophoretic mobility 
compared to heparan sulphate from 
bovine kidney (Fig. 6), in accordance 
with previous observations ( 16). Urine of 
patients with mucopolysaccharidosis 
display an altered glycosaminoglycan 
composition. Sanfillipo's syndrome is 
associated with an increase of urinary 
heparan sulphate (Fig. 6, Table 1), and 
Scheie's syndrome is associated with an 
increase in dermatan sulphate and 
heparan sulphate (Fig. 6, Table 1). 
Comparison of glycosaminoglycan and 
heparan sulphate values obtained by 
azure Α-silver staining with those 
obtained by DMMB assay shows no 
significant differences (P > 0.4 and 0.3 
M 3 
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Ь 
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Fig. 5: Human serum glycosaminoglycans separated by agarose 
gel electrophoresis in 50 mM barium acetate (pH 5.0) and 
stained by the combined azure Α-silver staining. M, marker 
glycosaminoglycans; lane 1 - 3 : human serum glycosamino­
glycan corresponding to 200, 50 and 10 μΐ serum respectively; 
lane 4, 5 and 6: human serum glycosaminoglycan corresponding 
to 20 μΐ serum after heparitinase, chondroitinase AC and 
chondroitinase ABC digestion respectively. Marker heparan 
sulphate was from bovine kidney. Note: heparan sulphate in 
lane 5 and 6 is only weakly visible, and that lane 1 - 3 and 4 -
6 were two different runs, which can explain the altered 
electrophoretic mobility of DS. 
M 1 
ущ^Ю· 
Fig. 6: Glycosaminoglycans isolated from tissue and urine, and 
separated by agarose gel electrophoresis in 50 mM barium 
acetate (pH 5.0) and stained by the combined azure A-silver 
staining. M, marker glycosaminoglycans; lane 1, mouse 
glomeruli (200 glomeruli); lane 2, total human lung tissue (5 μ% 
dry defatted tissue); lane 3 - 5 human urine (2 μ\) from control 
and patients with Scheie and Sanfillipo syndrome respectively. 
Marker heparan sulphate was from bovine kidney. 
for glycosaminoglycan and heparan 
sulphate respectively as determined by a paired t-test). Furthermore, comparison of the two 
assays by linear regression gives a slope of 1.0 and an intercept less than 0.04 for glycosamino­
glycan, as well as heparan sulphate (Fig. 7). This reflects a good comparability of the assays. 
In mouse glomeruli heparan sulphate is the most abundant glycosaminoglycan, while 
dermatan sulphate and chondroitin sulphate are present in smaller quantities (Fig. 6). The nature 
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1 10 100 
mg GAG/mmol creatinine 
Fig. 7: Urinary glycosaminoglycan and heparan sulphate content (mg/mmol creatinine) 
determined by densitometry after agarose gel electrophoresis in 50 inM barium acetate 
(pH S 0) and visualization by combined azure Α-silver staining, versus urinary glycos­
aminoglycan and heparan sulphate content determined by DMMB assay O, control, · . 
Sanflllipo patient and •, Scheie patient. 
of these glycosaminoglycans was confirmed by enzymatic digestion (data not shown). In Table 
1 the average value of the glomerular glycosaminoglycan composition of 5 individual mice is 
given. Only 200 mouse glomeruli are needed to evaluate the glycosaminoglycan composition, 
whereas about 15,000 glomeruli could be isolated from a single mouse kidney. 
The major glycosaminoglycans in human lung are heparan sulphate and dermatan 
sulphate (Fig. 6. '1 able 1 ) Chondroitin sulphate is more abundant in total lung compared to the 
pure alveoli (21 vs 13% respectively) (Table 1), consistent with the presence of chondroitin 
sulphate in bronchioli and blood vessels. The nature of the glycosaminoglycans was confirmed 
by enzymatic digestion (data not shown) For the characterization of glycosaminoglycan only 5 
A¿g dry defatted lung tissue is needed, which is equivalent to one cryosection of 4 χ 4 mm and 6 
μτη thick. 
Discussion 
In this paper we show that a combined azure Α-silver staining for glycosaminoglycans in agarose 
gels is a very powerful method to characterize and quantify glycosaminoglycans in minute 
amounts of tissue and body fluids as demonstrated in urine, serum, glomeruli and lung tissue. 
The staining can be used for the detection of all types of glycosaminoglycan. even the non-
sulphated hyaluronic acid, and is compatible with different electrophoresis buffers like 50 mM 
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barium acetate (pH 5 0), 0.1 M cupric acetate (pH 3 0). and with 0.1 M HCl, which makes 
application of two-dimensional electrophoresis to improve separation (3) possible This is 
especially useful when two glycosaminoglycan-types overlap (i.e. keratan sulphate and dermatan 
sulphate, Fig. 3) 
Compared to other glycosaminoglycan staining methods for agarose gels our method is 
much more sensitive Azure A staining alone has a detection limit of about 100 ng and alcian 
blue staining for glycosaminoglycans separated on cellulose acetate strips has a limit of about 
100 ng (6, 17) Staining procedures using l :" I-labeled c>tochrome с (6). ,fbRuthenium red (5) or 
cationic heme with peroxidatic activity (7) ha\e detection limits of 0.5. 2 5 and 2.5 ng 
respectivel). which are 2 to 10 times higher compared to our method. 
Analysis of the serum glycosaminoglycan composition illustrates the high dynamic range 
of the staining Only 0.8% of human serum glycosaminoglycan is characterized as heparan 
sulphate, which could stil! be visualized and quantified, and was not overshadowed by the 20 
times more abundant dermatan sulphate or the 100 times more abundant chondroitin sulphate 
(Fig 5). Staprans and Felts (18). using DBAb'-chromatography in combination with a heparan 
sulphate-bioassay and uronic acid détermination, estimated the relative amount of serum heparan 
sulphate at 0.89% of the total ghcosaminoghcan content, which is in agreement with our data 
Tabic 1: GKcosammogKcan content and composition of serum, tissue and uiine 
Specimen 
Human serum (n-6) 
Human lung 
Human lung alveoli 
Mouse glomeruli (n-
Unne 
normal 
Scheie patient 
Sanfillipo В patient 
5) 
Unit 
Aig/ml 
mg/g 
mg/g 
pg/glom 
mg/mmol creat 
mg/mmol creat 
mg mmol creat 
HS 
0 19 
1 9 
1 3 
153 + 18 
1 43 
3 05 
7 40 
Content 
DS CS 
3 7 + 0 36 18 5 + 0 70 
1 5 
1 0 
36 + 9 
0 16 
1 92 
-
0 9 
0 4 
11+4 
3 31 
1 71 
1 73 
Relative 
HS 
0 8 
43 
49 
77 + 4 
29 
46 
81 
composition (%) 
DS 
20+ 1 9 
36 
37 
18 ± 3 
3 
29 
-
CS 
7 9 x 3 0 
21 
13 
5 - 1 
68 
25 
19 
Values are mean ± SD for number of individuals between parenthesis glom, glomeruli, creat, creatinine, -, 
below detection level 
The data presented in Table 1 are in agreement with data from literature Urinary glycos­
aminoglycan composition of the control subjects was within the range as reported by Hopwood 
and Harrison (19) (i.e., <5% dermatan sulphate. 5-39% heparan sulphate and 61-95% chondroitin 
sulphate). The patients with Sanfillipo's and Scheie's syndrome display a marked increase in 
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urinary heparan sulphate, and heparan sulphate and dermatan sulphate content respectively, 
which is in agreement with data from literature (19. 20) The agreement ofgl>cosaminoglycan 
and heparan sulphate values determined by azure Α-silver staining and by the DM MB assay, 
together with the high accuracy oí intra assay determination, emphasize the analytical value oí 
our method To our knowledge, no data are available on the glycosaminoglycan composition of 
mouse glomeruli Stow et al (21) estimated the relative amount of hepantinase-digestible (ι e 
heparan sulphate) and chondroitinase ABC-digestible (ι e chondroitin sulphate and dermatan 
sulphate) fractions of radiolabeled rat glomerular glycosaminoglycan at 70 and 30% respectively 
Reddi at al (22) estimated the relative glycosaminoglycan composition oí rat glomeruli (using 
an similar method) at 82 and 15% respectively These data are comparable to our data for mouse 
glomeruli (77 and 23% respectively) 
1 he high sensitivity of the azure Α-silver staining method allows the determination ol the 
glycosaminoglycan composition of microscopic amounts of tissue (ι e 200 mouse glomeruli or 
5 Mg of human lung tissue), without the use of radiolabeling This enables morphological 
characterization of the sample and the possibility lo ìemove unwanted tissue In this way we 
could compare the glycosaminoglycan composition of pure alveoli to that of total lung 
parenchyma which in addition to alveoli contains small blood and airway \essels The 
chondroitin sulphate content of total lung parenchyma is higher than that ol alveoli proper (Table 
1), due to the high chondroitin sulphate content of blood vessels and bronchi (> 40% of total 
ghcosaminogl>can) (23) Total lung and alveolar glycosaminoglycan contents (ι e 4 3 and 2 7 
mg glycosaminoglycan/g dry defatted tissue, respectively) are in agreement with data from 
Schmid et al (23), who estimated the gl\cosaminogl}can content of total lung and a crude 
alveolar traction at 4 8 and 3 2 mg/g dry defatted tissue, respectively 
In conclusion, the combined azure A-silvcr staining for glycosaminoglycans in agarose gels 
is a powerful tool to quantify and characterize glycosaminoglycans in minute amounts of tissue 
or body fluids The method can be of special use in pharmacokinetical studies, and studies 
involving glycosaminoglycan determination in tissue and body fluids of small laboratory animals 
small biopsies and morphologically characterized areas of cryosections 
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Digital elimination of autofluorescence 
ELIMINATION OF AUTOFLUORESCENCE IN 
IMMUNOFLUORESCENCE MICROSCOPY USING DIGITAL 
IMAGE PROCESSING 
Abstract 
Autofluorescence can be a very disturbing factor in immunofluorescence microscopy We here 
present a method to eliminate dutofluorescence The method is based on the phenomenon that 
most dutofluorescenl compounds have broad-banded excitation and emission spectra whereas 
specific fluorescent probes have narrow spectra 
Two images are recorded and digitized, one at a wavelength exciting both the fluorescent 
probe and the aulofluorescent molecules, and one at a wavelength exciting only the latter 
Subtraction of images, using a self-developed computerprogram, results in an autofluorescence-
free image The procedure has been applied for the elimination of elastin-denved 
autofluorescence in human lung aheoli. and of lipofuscin-denved autofluorescence in human 
heart muscle 
The autofluorescence signal is positively correlated with tissue section thickness (r = 0 93, 
Ρ < 0 0001 ), and can be used to correct the specific fluorescence signal for section thickness 
Introduction 
Autofluorescence is a ven common and disturbing phenomenon in light microscopic 
fluorescence studies It is caused by certain biomolecules, such as elastin, fibronectin and 
lipofuscin It can be very intense, especially after aldehyde fixation (1), and often results in 
masking of the specific fluorescence signals Only few papers have delt with the elimination of 
autofluorescence most of them for application in flow cytometry Addition of crystal violet, for 
example, has been used to quench autofluorescence of macrophages in flow cytometry (2) Dual-
wavelength flow cytometry has also been applied to correct for autofluorescence ("5. 4) In 
fluorescence microscopy several parameters, such as excitation wavelengths, excitation power, 
microscope apertures and buffers have been optimized to minimize autofluorescence (5) 
Autofluorescence, however, can not be fully eliminated in this way Probably the most 
sophisticated method to eliminate autofluorescence is time-resolved fluorometry This procedure 
is based on fluorescent lanthanide chelates with long decav times, which can be used to suppress 
the fast decaying autofluorescence (6, 7) This technique, however, needs a sophisticated 
fluorescence microscope to visualize the time-resolved image (7) 
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Autofluorescence can not be avoided by simply choosing a fluorescent probe with excitation 
and emission spectra out of the range of the spectra of autofluorescent molecules, since these 
spectra are very broad. In contrast, the spectra of fluorescent probes are relatively narrow We 
used these characteristics to develop a procedure to obtain an autofluorescence-free image. 
Signals were recorded at two excitation wavelengths, one signal representing both the specific 
fluorescence and the autofluorescence, and one signal representing only the autofluorescence 
Subtraction of the latter signal from the former - applying a self-developed computer program -
results in an autofluorescence-free image. The amount of autofluorescence is positively 
correlated to the section thickness and can be used to correct the specific fluorescence for section 
thickness 
Materials and Methods 
Materials 
Human lung tissue was obtained after lobectomy trom a man 56 y of age. human quadriceps 
muscle was obtained as biopsy from a man 41 y of age, human heart tissue was obtained at 
autopsy 4 h after death of a man, age 41 y and rat quadriceps muscle was from a 3-months old 
male Wistar rat. 
Tween-20. bovine serum albumin (BSA). mouse anti-human desmin IgG and fluorescein 
isothiocyanate (Ml C)-conjugated rabbit anti-mouse Ig antibodies were obtained from Sigma Ine , 
St Louis. MO. USA: mouse monoclonal anti-heparan sulfate (JM403) antibody was a geneious 
gift from Dr .1 van den Bom (Dept of Nephrology. University of Nijmegen), and was described 
previously (8) Mouse monoclonal antibody 3H6 is a self-developed antibody which is reactive 
with intercalated disks in human heart tissue 
Immunoslammg 
Tor indirect immunofluorescence, tissue samples were frozen in isopentane cooled with liquid 
nitrogen, and stored at -70"C. Cryosections (2 to 12 μιη) were stored at -70'C Cryosections were 
rehydrated for 10 min in PBS (phosphate-buffered saline, pH 7.4), and primary and secondary 
antibodies were applied for 90 min in PBS containing 1% BSA. After each incubation, sections 
were washed in PBS (3 χ 5 min). Anti-heparan sultate antibody and FITC-conjugated secondary 
antibodies were used at a dilution of 1.100. Anti-desmin and 3H6 antibodies were used at a 
dilution of 1:50. In sections of quadriceps muscle, autofluorescence was enhanced by incubation 
with 3% formaldehyde in 150 mM phosphate buffer (pH 7.2) for 1 h (1). 
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Determination of section thickness 
Since micrometer selling of a microtome is not an accurate way to obtain sections of a certain 
thickness we measured section thickness also by determining the surface and the protein content 
of a section The surface of a crvosection was marked using a marker pen and copied by a 
photocopier onto a piece of paper The image of the sections was cut out and weighted The 
surface was calculated by using the weight of 1 cm" of paper as a standard Alter surface analysis 
the tissue section was taken up in deminerahzed water and the protein content was determined 
according to Lowry et al (9) The section thickness was expressed in ^g protein/mm" 
Digital s uhi) at tum ofauto fi noi e scene с 
Microscopic (fluorescence) images were digitized using the MagiCal hardware and TARDIS 
software of Joyce-Loebl (Gateshead UK) Images were captured with a resolution of 256 χ 256 
datapoints and 256 gray levels each The images were processed with ImageCalc, which is a MS-
Windows™ application that was designed for this purpose This program is available as 
shareware from our lab 
To subtract the autofluorescence signal two images were digitized For a FITC-
lmmunostained tissue section one image repiesenting the total fluorescence image ( I h) (ι e the 
specific Fl 1С image + the autofluorescence image) was obtained by excitation at 480 nm and 
emission at 515 nm I he second image representing the auto fluorescence image (AF) was 
obtained by excitation at 380 nm and emission at 515 nm For optimal results two additional 
background images were digitized using the same parameters and representing images of an 
object slide without tissue These images were used for noise and shading correction (10) 
Camera gain and sensiti\ it\ were adjusted to obtain optimal signal/noise ratios for both excitation 
wavelengths Both images were captured immediately after each other each image representing 
the average ofeight individual images (to reduce noise) Total image capture of both images was 
achieved within 1 sec 
Since autotluorescence intensity depends on the excitation and emission wa\elength used, a 
correction lactor tor the use of two wavelengths was applied by excitation of a non-
lmmunostained cryosection at 480 and 380 nm After determining the ratio of emission at these 
wavelengths (R4S0 j 8 0) the specific fluorescence (SF) can be calculated using the equation 
Sr-TF-(Rim wxAF) 
where TF is the total fluorescence and AF is the autofluorescence 
85 
Chapter 4 
Fig. 1: Elimination of autofluorescence (mainly caused by elastin fibers) in human lung parenchyma sections. 
Sections were stained with anti-heparan sulfate antibodies, which were deteced using FITC-labeled anti-mouse Ig 
antibodies. The autofluorescence ¡mage (B) was subtracted from the total fluorescence image (A), resulting in an 
autofluorescence-free image (C). Note that the strong autofluorescent elastin fibers mask the specific linear 
basement membrane staining of heparan sulfate (arrow), and that after subtraction of auto fluorescence there is an 
increase in contrast of heparan sulfate staining. The correction factor R4g0,380was 0.7. Bar represents 25 μπι. 
Results 
Elimination of autofluorescence 
I. Human lung parenchyma 
Human lung parenchyma sections display a very strong autofluorescence, mainly caused by 
elastin fibers (11). In contrast with kidney sections (8), this autofluorescence masks the linear 
heparan sulfate basement membrane staining with antibody JM403 (Fig. la), which is clearly 
visible on glomerular and tubular basement membranes (8). The autofluorescence image (Fig. 
lb) lacks the specific basement membrane staining. Digital subtraction of the autofluorescence 
image from the total fluorescence image reveals an autofluorescence-free image (Fig. lc), in 
which the heparan sulfate staining of the basement membrane is clearly visible. 
II. Human heart muscle 
Human heart muscle especially of older age contains the strongly autofluorescent pigment 
lipofuscin (12). Immunostaining of heart tissue sections with monoclonal antibody 3H6 shows 
a clear staining of the intercalated disks. This staining, however, is locally completely masked 
by the autofluorescent lipofuscin particles (Fig. 2a). Subtraction of the autofluorescence image 
(Fig. 2b) unmasks the specific staining of the intercalated disks (Fig. 2c). 
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Fig. 2: Elimination of autofluorescence caused by lipofuscin in human heart sections. Tissue sections were 
immunostained with the monoclonal antibody 3H6, which is reactive with intercalated disks. Antibodies were 
detected using FITC-labeled anti-mouse Ig antibodies. The total fluorescence image (A) minus the autofluorescence 
image (B) results in an autofluorescence-free image (C), completely lacking the fluorescence of lipofuscin particles. 
Note that the specific fluorescence at some intercalated disks becomes visible only after elimination of 
autofluorescence (arrow). The correction factor R48o;380 was 1.0. Bar represents 25 μιτι. 
Use of autofluorescence as measure for 
tissue thickness 
Since the autofluorescence signal can be 
obtained separately, we investigated if 
the intensity of this signal can be used as 
a measure for the thickness of the 
section. This requires an equal 
distribution of autofluorescence over the 
section. We enhanced autofluorescence 
by preincubation of sections of rat 
quadriceps muscle with formaldehyde 
( 1 ). To obtain precise measurements, the 
section thickness was accurately 
measured by analysis of surface and 
protein content. We found a positive 
correlation between the section thickness 
(measured as ßg protein/mm2) and the 
autofluorescence intensity (Fig. 3). We evaluated this observation further on sections of human 
quadriceps muscle stained with mouse anti-human desmin antibodies and FITC-labeled anti-
mouse Ig antibodies. The specific fluorescence shows a clear correlation with the apparent 
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Fig. 3: Autofluorescence as a measure for section thickness. 
Autofluorescence was established in sections of rat quadriceps 
muscle with various thickness (expressed as μg protein/mm2). 
Autofluorescence was enhanced by preincubation of the 
sections with formaldehyde. Values are mean ± SEM of 4 
individual observations. Note that there is a possitive 
correlation (r = 0.93, Ρ < 0.0001 ) between autofluorescence and 
section thickness. 
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thickness of the sections (indicated by the 
microtome) (Fig. 4). The ratio of specific 
fluorescence to autofluorescence is however 
independent of the apparent section 
thickness (Fig. 4). 
Discussion 
In this report we demonstrate that auto-
fluorescence in immunofluorescence micro-
scopy can be efficiently eliminated by sub-
traction of the autofluorescence image, 
captured using an excitation wavelength 
outside the excitation spectrum of the 
fluoroprobe. This principle has been used 
for the elimination of autofluorescence in 
flow cytometry (3, 4), and we here show 
that it is also applicable in immuno-
fluorescence microscopy of tissue sections. 
Using this technique we were able to 
eliminate the very strong autofluorescence 
of elastin and lipofuscin without affecting 
the specific fluorescence. An alternative 
way for the eliminfdsation of autofluo-
rescence is using time-delayed fluorometry 
(6) This procedure, however, needs a 
sophisticated and expensive fluorescence 
microscope (7), whereas our technique 
requires only a digitization apparatus (e.g. a CCD-camera) connected to a standard fluorescence 
microscope. 
Elimination of autofluorescence can simplify the interpretation of stained sections and 
may also be used in cases where the specific staining is weak. Since the digitization process is 
usually performed within a single second, fading of the fluorescent probe is minimized, which 
is essential for quantitative analysis (13). In addition, the specific fluorescence can be íelated to 
the section thickness, since this parameter correlates with autofluorescence (Fig. 4) 
In conclusion, autofluorescence in tissue sections treated for immunofluorescence 
microscopy can be eliminated by digitalization of the fluorescence signal at two different 
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Fig. 4: The specific fluorescence ( · ) . the autofluorescence 
(•) and the ratio of specific fluorescence and auto­
fluorescence (π) as a function of the apparent thickness of 
sections of human quadriceps muscle sLained with mouse 
anti-human desmin antibodies and Ы ГС-labeled anti-mouse 
Ig antibodies Section thickness was derived from the 
microtome setting A positive correlation is present between 
both the specific fluorescence and the autofluorescence and 
the apparent section thickness (r = 0 69. Ρ < 0 001. r = 0 51. 
Ρ < 0 01, respectively) The ratio of specific fluorescence 
(Sr) and autofluorescence (AF) is independent ol the 
thickness of the sections (P > 0 7) Autofluorescence was 
enhanced by preincubation of the sections with 
formaldehyde Values are mean ± SFM of 4 individual 
observations 
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wavelengths. Correction for section thickness and minimizing fading of the fluoroprobe makes 
this method suitable for (semi)quantitative analysis of stained sections. 
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ImageCalc: a MS-Windows application 
IMAGECALC: A MICROSOFT®-WINDOWS™ 
APPLICATION FOR QUANTITATIVE IMAGE ANALYSIS 
AND COMPARISON 
Abstract 
In this report we describe a Microsoft* Windows™-based computer program (ImageCalc) for the 
analysis oí gels and autoradiograms, and foi computation of stand alone images, and images 
which are related to each other (1 e images with the same image parameters) The program is able 
to subtract, add multiply and divide constant values or full images from another image It 
measures the intensity of (part of) an image in two ways (1) by calculation of the total intensity 
and the average intensity/pixel and (n) by line scanning 1 he program allows importation of all 
images which are stored in an 8 bit uncompressed format and saves them in a Microsoft* 
Windows""1 bitmap-format Densitometrie analysis of gels and autoradiograms, digitized using 
an ordinary optical scanner is illustrated for glycosaminoglycans separated by electrophoresis on 
agarose gels and stained with Azure A - silver and for fpP]phosphatidic acid separated by thin 
layer chromatography Another application of the program is the analysis of multiple related 
images which are resolved in time or for which different emission or excitation wavelengths are 
used (fluorescence microscopy) As an example the change of cytosohc [Ca° ] is demonstrated 
in cultured human skeletal muscle cells after stimulation with acetylcholine 
Introduction 
Digitdhzation of images is a powerful tool for analyzing two-dimensional objects In 
biochemistry, digitalization and analysis of gels and autoradiograms is a useful application For 
this purpose commercial programs are available which usually use very expensive scanning 
devices (e g laser scanners) in combination with sophisticated computer systems and/or software 
Laser scanners, however, can not be used for quantitative analysis of polychromatic or 
weakly-stained silver images (1) Digitalization using ordinary scanners applying white light and 
detection by charged-coupled device (CCD) chip, are more convenient in this respect To our 
knowledge, no public domain programs tor the analysis of digitalized images exist for Microsoft® 
Windows™-based computers, although they are available for Macintosh® computers (e g NIH 
Image) (2) We therefore developed a Microsoft® Windows™ -based computer program for the 
densitometnc analysis of gels and autoradiograms The program is also useful for the analysis of 
stand alone and related (microscopic) images 
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Methodology 
ImageCalc was written in Borland® Pascal as an application for Microsbft Windows 
(microsoft Corporation, Redmond, Wa, USA). Windows applications allow the simultaneous 
visualization and manipulation of several images and facilitate the analysis of related images. All 
image types, which are stored in an uncompressed 8 bit format (e.g. TIFF-files) can be imported. 
The applicability of the program is very general since almost every digitalization device supports 
such a format. The program can be used to perform arithmetic calculations on single images and 
on two related images. Specific areas of an image (e.g. silver-stained bands or parts of a cell) can 
be selected and analyzed. Analysis of the same area in different related images is possible, and 
is especially useful for the analysis of 
(microscopic) images which are resolved in 
time or which differ in the emis­
sion/excitation wavelengths used. 
Image digitization 
Gels or autoradiograms were digitized using 
an HP-scanjet Π optical scanner (Hew­
lett-Packard, Corvallis, OR, USA). This 
scanner uses a CCD chip and normal white 
light for digitalization. The scanning para­
meters (i.e. white level, black level and 
contrast & brightness) were set in a way that 
a linear response was achieved over the 
maximum range of the scanned object. 
Briefly, the gel was prescanned (previewed) 
to view the "raw" image, and the area to be 
scanned was selected. Most scanning 
devices can display an intensity diagram of 
the selected area, representing the number of 
pixels having a specific intensity. Contrast 
and brightness should be set in such a way 
that a linear response is obtained (usually 
this is the default setting). The black and 
white level should be set in such a way that 
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Fig. 1: Comparison of densitometric analysis of an electro-
pherogram of glycosaminoglycans (A), using a laser scanner 
plus additional software (B), and an ordinary scanner plus 
ImageCalc (C). A mixture of dermatan sulfate (DS), heparan 
sulfate (HS) and chondroitin sulfate (CS) was separated by 
agarose gel electrophoresis and stained with Azure A and 
silver (3). The marked areas in (A) visualise how band width 
and band area were selected. 
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Intensity / frequency diagram 
Fig. 2: Dialog window of an analysed image area, e g a band on a Azure A - silver stained gel All values can be 
highlighted with the mouse and copied to the clipboard by pressing <Ctrl-C>, from where they can be retrieved into 
another MS-Windows application 1 he intensity (ι) / frequency (#) diagram represents the pixel intensity frequency 
of the selected area This can be applied for determination of the background level (dashed line), or for determination 
of the most common pixel values in images with irregular patterns 
(usually this is the default setting). The black and white level should be set in such a way that all 
pixel values of the scanned area are within the interval 0 < pixel value < 255. If the scanning 
device cannot display an intensity diagram, scanning parameters should be empirically 
determined: to evaluate if the settings are correct the pixel values (which can be determined by 
ImageCalc) of the background and the most dense parts of the scan, should be between 0 and 255 
(values of about 30 for background and 220 for the densest parts assure a linear response). It 
should be noted here that the error reading of most scanning devices that generate 8-bit images 
(i.e. desktop optical scanners which are not especially designed for quantitative analysis) is about 
1 bit. The true dynamic resolution of such devices is therefore only 7-bit (128 gray levels), which 
posses some limitations to densitomelric analysis. 
Microscopic (fluorescence) images were digitized using the MagiCal™ hardware, which 
contains a sensitive 8 bit CCD camera connected to a fluorescence microscope. Image 
digitization, averaging and excitation filter settings were performed by TARDIS™ software 
(which is developed solely for the Magical hardware)(Joyce-Loebl, Gateshead, U.K.) Images 
were stored by the TARDIS™ software in a 256 χ 256 bitmap (256 gray levels) and imported into 
ImageCalc, for further analysis. For more information on the TARDISIM software and MagiCal1M 
hardware, see Reference 4. 
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Densitometrie analysis 
Densitometrie analysis of an image (e g a silver-stained gel) was performed in two ways (ι) by 
densitometry line scanning of the lanes of interest and (u) by analysis of the total intensity of an 
area occupied by a stained band 
Densitometrie line scanning analysis using ImageCalc 
A selected area of the image was line scanned in a vertical direction (1 e from top to bottom) 
through the centre of the lanes (see Fig 1 a) The scan was displayed as the average pixel intensity 
of each horizontal line of the selected area The scan data was copied to the Microsoft* 
Windows™ "clipboard" from where it was retrieved into other window applications, ι e Excel™ 
(Microsoft®), for further processing This scanning technique was compared with line scans 
performed by a laser scanner (Ultroscan™ XL laser densitometer, Pharmacia Biotech, Uppsala, 
Sweden) 
glycosaminoglycan (ng) 
Fig 3: Densitometrie analysis using ImageCalc Various amounts of three types of 
glycosaminoglycans were separated by agarose gel electrophoresis and stained with 
Azure A and silver The intensity of staining was determined using ImageCalc Staining 
is linear from 1 to 20 ng for chondroitin sulfate (Δ) and dermatan sulfate (o) and from 
1 to 40 ng for heparan sulfate (D) However measurement accuracy diminishes with 
increasing range and therefore should be carefully assessed with standards in replicate 
experiments 
Densitometrie area analysis using ImageCalc 
Areas of stained bands were selected by a rectangle fully surrounding the stained band (Fig 1 a) 
Background was determined by selection of one or more areas in the vicinity of and of similar 
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size as the band of interest. The total intensity of the stained area was calculated using ImageCalc, 
and the average pixel-background value was subtracted. 
Separation and detection of glycosaminoglycans and ['~P]phosphatidic acid 
To examine if ImageCalc could be used for the quantitative analysis of silver-stained gels, 
glycosaminoglvcans were separated by agarose gel electrophoresis using 0.05 M barium acetate 
as buffer (pH 5.0) and visualized by Azure Α-silver staining as described previously (3). 
For analysis of autoradiograms using ImageCalc, a crude mixture of lipids containing 
['2P]phosphatidic acid was separated on silicagel thin-layer chromatography (TLC) plates using 
a mixture of chloroform/acetone/acetic acid/methanol/II20 (5/2/1/1.5/5, by vol.). 
[32P]phosphalidic acid was detected by autoradiography and the bands on the TLC-plate were 
identified using the autoradiogram. The amount of 32P was determined by scratching the 
phosphatidic acid from the TLC-plate and counting the activity using a liquid scintillation 
counter. The size of the band areas for densitometry and '2P measurement were equal in size For 
background determination, a blank area of the TLC-plate/autoradiogram was taken with similar 
dimensions as the band. For a critical evaluation of the settings for analysis of gels and 
autoradiograms, see Reference 2. 
Determination of cytosolic Ca:~ concentration 
Cytosolic [Ca2"] in cultured human skeletal muscle cells was determined using the Fura-2 ratio 
technique (5,6) Fura-2 is a fluorescent Ca2 -specific probe. Fura-2 loaded cells were excited at 
340 and 380 nm, The ratio of the fluorescence at both wavelengths, is linearly correlated with the 
cytosolic [Ca2'] and is independent of the amount of Fura-2 present in the cell (4-6). Muscle cells 
were stimulated with 300 μΜ acetylcholine. 
Results and discussion 
Densitometrie line scanning analysis using ImageCalc 
To compare scanning images using a digitized gel + ImageCalc with direct scanning using a laser 
scanner, glycosaminoglycans separated b> agarose gel electrophoresis and detected by Azure A 
- silver staining were analysed (Fig. 1). The laser scanner is not able to detect the minor bands 
(Fig. lb). In contrast, scanning images using white light plus ImageCalc detects the weakly 
stained bands well (Fig. lc). However, noted that broad spectrum sources, i.e. white light, may 
give incorrect scanning results if a gel that has been stained by a specific dye like Coomassie blue 
is analysed. In such cases a small spectrum light source of the complementary colour gives best 
results. For CCD scanners a coloured transparent filter may be suitable. 
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The densitometric line scanning gives only a poor correlation between the density and the 
amount of glycosaminoglycans applied to the gel. We therefore analysed gels/ autoradiograms 
using densitometric area analysis. 
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Fig. 4: Densitometric analysis using ImageCalc. Crude mixtures of lipids containing 
[ï:P]phosphatidic acid were separated by thin-layer chromatography and the 
autoradiogram was analysed using ImageCalc The density of the [32P¡phosphatide acid 
bands on the autoradiogram is linearly related to its amount for a range of 200 to 4000 
cpm (r = 0.94). 
Densitometrie area analysis using ImageCalc 
Figure 2 displays the "measure" dialog window (as displayed by ImageCalc) of a selected ¡mage 
area. The data displayed in this dialog window is representative for the density of a selected area, 
and can be copied to other window applications. The background of the selected area can be 
directly subtracted by entering the average background level. It can also be subtracted afterwards 
by selecting a part of the image which is representative for the background. Fig. 3 represents the 
results of the densitometric area analysis performed on three different types of 
glycosaminoglycans separated by agarose gel electrophoresis and stained with Azure A - silver 
(3). The silver-stain density, as determined by digitalization with an optical scanner and 
densitometric analysis with ImageCalc, shows a very high correlation (r = 0.98) to the amount 
of glycosaminoglycan applied to the gel. Linearity is obtained for a range of 1 to 40 ng glycos-
aminoglycan. 
Another example of the use of densitometric area analysis using ImageCalc is analysis of 
exposed films, e.g. autoradiograms. To illustrate this [32P]phosphatidic acid was separated by 
TLC and the amount of 32P present in the phosphatidic acid spots of the TLC plate was compared 
with the intensity of the bands on the autoradiogram (Fig. 4). The two parameters displayed a 
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linear correlation (r = 0.94) over the range of 200 to 4000 cpm. It should be stressed, however, 
that photographic material (e.g. autoradiograms and photographs of gels) has a limited range of 
linearity (7,8). For quantitative use of photographic material the range of linearity should be 
determined using proper standards. 
Image Calculator 
Elle Edit Display Analyse Window Help 
Image A / Image В => Image С 
Fig. 5: Use of ImageCalc in the analysis of cytosolic [Ca2*] in cultured human skeletal muscle cells. Fura-2 was 
used as aCa2*-probe and cells were stimulated with acetylcholine. Fura-2 loaded cells were exited at 340 nm (A) 
and at 380 nm (B), and the ratio of the fluorescence at each wavelength was determined using ImageCalc (C). The 
ratio represents the cytosolic [Ca2*]. To maintain maximum range, the ratio values were expanded to values between 
0 and 255, and all background values (values Í 30) were rejected from the calculation. For the determination of the 
background value: see text. 
Comparison and analysis of fluorescent microscope images 
Besides densitometric analysis, ImageCalc can perform arithmetic calculations (i.e. add, subtract, 
divide, multiply and average) with the pixel values of a single image or of two related images 
(images having the same width and height parameters). An application in which this can be used 
is the analysis of related microscopic images, where the difference between the two related 
images is only due to a controlled change in one single parameter, e.g. time, excitation- or 
emission wavelengths. As an example we present the determination of the cytosolic [Ca2+] in 
cultured human skeletal muscle cells using the Fura-2 ratio technique. ImageCalc was used to 
divide the image obtained at 340 nm into the image obtained at 380 nm (Fig. 5), resulting in an 
image reflecting the cytosolic [Ca2+] in the muscle cell. Since only a value of 0-255 can be 
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Image Calculator 
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Fig. 6: Use of ImageCalc in the analysis of time-resolved images. Cytosolic [Ca2*] was determined in cultured 
human skeletal muscle cells using Fura-2 and the ratio technique. Cells were analysed before (A), during (B) and 
after (C) stimulation with acetylcholine. The graphs underneath each image represent the pixel intensity frequency 
of the selected part of the image. 
attributed to a pixel, division (or multiplication) of two images may result in loss of data. 
ImageCalc can minimize this loss by expansion of the pixel value to the full 0-255 range. 
Furthermore, since division of two background values (i.e. noise) can result in high values, and 
thus erroneous analysis of [Ca2+], a background cut-off value can be entered resulting in rejection 
of all values below this cut-off value. The background cut-off value (30 in this experiment) was 
determined by measurement of the maximum value attributable to the background. This value can 
be read from the intensity/frequency diagram of a selected background area. It can, however, also 
be selected empirically. Using ImageCalc we analysed the change in cytosolic [Ca2+] as a result 
of acetylcholine stimulation (Fig. 6). ImageCalc can also select corresponding areas of different 
images and e.g. calculate the [Ca2+] of a cultured human skeletal muscle cell at different time 
points (Fig. 6). 
In conclusion, ImageCalc is an affordable, Microsoft® Windows™-based computer program 
which allows easy analysis of digitized images. It can be used for the analysis of gels and 
autoradiograms as well as for computation and comparison of stand alone and related 
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(microscopic) images. Since all images stored in an uncompressed 8 bit format can be imported, 
ImageCalc is broadly applicable. 
Availability 
ImageCalc can be obtained by sending a blank, MS-DOS* formatted diskette (either 5.25" or 3.5" 
high or double density) with a self addressed envelope to Dr. Т.Н. van Kuppevelt, Department 
of Biochemistry, University of Nijmegen, P.O. Box 9101, 6500 UB Nijmegen, The Netherlands. 
The source code is available upon request. The program is released as "shareware", and may be 
used for non-commercial purposes only. If you find the program useful, we ask you to support 
the "Dutch Asthma Foundation", with a contribution of at least $25. 
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Proteoglycans in elastase-induced emphysema 
DIGESTION OF PROTEOGLYCANS IN PORCINE 
PANCREATIC ELASTASE-INDUCED EMPHYSEMA IN RATS 
Abstract 
Pulmonary emphysema was induced in rats by a single intratracheal instillation of pancreatic 
elastase. The short-term effects of elastase instillation on basement membrane components were 
evaluated using immunohistochemical and biochemical methods. 
Lung alveoli showed a decrease in heparan sulphate proteoglycan content (especially of 
its heparan sulphate chains) 3 h to 7 days after induction. Type IV collagen, laminin and 
fibronectin are not affected. The glycosaminoglycan content of the lung is decreased during the 
first 3 days after induction, while the glycosaminoglycan concentration in urine is increased 
during the first 4 days by an increase of heparan sulphate and dermatan sulphate. The increase in 
urinary glycosaminoglycan content is positively correlated with the extent of emphysema 
developed after 40 days. 
We conclude that proteoglycans are target molecules for elastase, and may be involved in 
the pathogenesis of emphysema. 
Introduction 
The connective tissue of lung parenchyma plays an important role in the functioning of the 
respiratory system. Alterations in the connective tissue skeleton are believed to be important in 
several chronic lung diseases, such as emphysema and fibrosis (1, 2). Major components of lung 
extracellular matrix are elastin, collagen and proteoglycans. Proteoglycans consist of a core 
protein to which one or more glycosaminoglycan chains are covalently attached. Glycosamino-
glycans are polysaccharides which are strongly negatively charged due to an abundance of 
carboxylic and/or sulphate groups. In the alveolar wall two types of proteoglycans are 
predominantly present: decorin and perlecan. Decorin is a small dermatan sulphate proteoglycan 
which is associated with collagen fibrils (3-6) and perlecan is a heparan sulphate proteoglycan 
present in basement membranes (6-9). 
The predominant theory on the pathogenesis of emphysema is the protease / anti-protease 
concept (10-12). This concept emanates from a relative excess of proteases (elastases), due to an 
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increase of proteases and/or a decrease of protease inhibitors An excess of proteases leads to the 
degradation of the connective tissue skeleton and ultimately to emphysema One has almost 
exclusively focused on elastin as the target molecule for proteases, in part because the most 
studied animal model for emphysema is elastase-induced emphysema Elastase, however, is also 
capable of degrading a number of other proteins, including proteoglycans, fibronectin and some 
types of collagen in vitro (13, 14) Digestion of proteoglycans may be of special importance, 
since a) proteoglycans are involved in fibnllogenesis of collagen and elastin and can modulate 
their mechanical characteristics (3, 4), b) proteoglycans interact with and modulate a number of 
molecules including growth factors and extracellular matrix molecules (15-21), and c) glycos-
aminoglycans can act as powerful protease inhibitors, e g for leucocyte elastase and cathepsin G 
(22-24) In addition, the close association of proteoglycans with structural elements in the 
alveolar wall (e g basement membranes, collagen fibrils and elastin fibres) indicates a protecting 
role (6, 25-28) 
In this respect, we studied the effects of an emphysema-inducing dose of pancreatic 
elastase in rats on perlecan (the core protein as well as the heparan sulphate side chains) and on 
other extracellular matrix components of the alveolar wall by immunohistochemical and 
biochemical methods Additionally we investigated the excretion of glycosaminoglycan into the 
urme following elastase treatment 
Materials and methods 
1,9-Dimethylmethylene blue (80% pure) was purchased from Aldnch Chemical Co , Bornem, 
Belgium, Universal Gel/8 1% agarose gels from Ciba-Corning GmbH, Femwald, Germany 
Aquamount from BDH Ltd, Poole, England, halothane from Apharmo, Arnhem, The 
Netherlands, pentobarbitol (Nai covet) from ICI-Farma, Rotterdam, The Netherlands, 
diethylaminoethyl (DEAE)-Sepharose Fast Flow from Pharmacia, Uppsala, Sweden, Azure A, 
Tween-20, whale cartilage chondroitin 4-sulphate, bovine kidney heparan sulphate porcine 
pancreatic elastase, bovine serum albumin (BSA), fluorescein isothiocyanate (FITC)-conjugated 
goat anti-rabbit IgG, FITC-conjugated goat anti-mouse IgM and affinity purified rabbit anti-
laminin IgG from Sigma Ine , St Louis, MO, USA, tetra-methylrhodamine isothiocyanate 
(TRITC)-conjugated goat anti-mouse Ig and FITC-conjugated donkey anti-goat IgG from Nordic 
Immunological Lab , Capistrano Beach, CA, USA, affinity purified goat anti-human type IV 
collagen antibodies from Southern Biotechnology Ass Ine , Birmingham, AL, USA, affinity 
purified rabbit anti-human fibronectin IgG from Dako, Glostrup, Denmark Rabbit anti-basement 
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membrane heparan sulphate proteoglycan and monoclonal mouse anti-heparan sulphate (JM403) 
antibody were obtained and characterized as described previously (9, 29) 
[35S]Glycosaminoglycans (specific activity δ 10 Bq^g glycosaminoglycan) were 
obtained from rats injected twice ί ρ with 37,000 Bq Na235SO./g body weight with a 4 h time 
span between each injection Four hours after the second injection the rats were sacrificed and the 
soft tissues (; e liver, kidney, intestine etc ) removed Glycosaminoglycans were extracted by 
alkaline borohydnde 
Animal accommodation 
Animals were accommodated in groups of three and fed ad libitum For urine collection, animals 
were accommodated separately in metabolic cages To avoid stress factors, animals were 
habituated to these cages for 7 days before treatment 
Induction of pulmonal y emphysema 
Male Wistar rats (weight 200 ± 10 g) were anaesthetized with 3% halothane, intubated and 
artificially ventilated according to Mauderly (30) Rats were hyperventilated, to stop intrinsic 
breathing for a few seconds, and were instilled during this time span with 0 2 IU pancreatic 
elastase / g body weight in 0 5 ml saline Control animals were instilled with 0 5 ml saline After 
instillation, rats were ventilated until they awoke 
Histology 
Animals were sacrificed by an overdose of pentobarbital injected ι ρ For morphometry studies 
lungs were dissected and fixed with 2% glularaldehyde in 150 mmol/1 phosphate buffer (pH 7 2), 
administered through a polyethylene catheter inserted into the trachea at a pressure of 25 cm 
H,0 After 30 min, lungs were fixed for an additional 24 h in 2% glutaraldehyde, dehydrated and 
embedded in paraffin Tissue sections (6 ц т ) were contrasted using the trichrome staining of 
Goldner (31) To assess the degree of emphysema, the mean linear intercept was determined 
using a Mop-videoplan image analyser (Kontron GmbH, Eching, München, Germany) Images of 
tissue sections were projected on a digitization tablet on which a line raster was applied Of each 
lung, a total of 400 intercepts, derived from two sections, were measured 
For immunofluorescence studies, lungs were dissected, and inflated through a 
polyethylene catheter inserted into the trachea with PBS at a pressure of 25 cm H20 PBS-filled 
lungs were frozen in liquid nitrogen and stored at -70°C Cryosections (6 ц т ) were stored at -
70"C Cryosections were rehydrated for 10 min in PBS, containing 1% BS A Antibodies were 
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applied for 1.5 h in PBS containing 1% BS A. After each antibody incubation sections were 
washed in PBS ( 3 x 5 min). Anti-heparan sulphate antibodies and all secondary antibodies were 
used at a dilution of 1:100. All other antibodies were used at 1:50. Double staining was 
performed using fluorescein- and rhodamine-labelled secondary antibodies. Sections were 
embedded in aquamount and examined on a Zeiss axioskop photomicroscope (Carl Zeiss, 
Oberkochen, Germany). Observations were made by two blinded observers. A "strong" decrease 
was defined by large areas in the section showing no specific antibody staining. "Weak" was 
defined by some small areas in the section which showed a reduced immunostaining. Moderate 
was defined as a moderate number of areas (between strong and weak) showing a clear, but not 
complete, absence of staining. 
Purification of urinary glycosaminoglycans. 
Rat urine was collected one day before elastase instillation, then daily for 9 days and finally on 
day 19 post instillation. Glycosaminoglycans were purified from urine by anion exchange chro­
matography. Urine was centrifuged at 2,000*g for 10 min (4 °C), and 20 ml of the supernatant 
was diluted to 50 ml by adding 10 mmol/1 Tris-HCl (pH 6.8). The diluted samples were loaded 
onto a column of 5 χ 0.5 cm containing 0.5 ml DEAE-Sepharose Fast Flow. After an initial wash 
with 3 ml 0.2 mol/1 NaCI/10 mmol/1 Tris-HCl (pH 6.8), glycosaminoglycans were eluted with 
4 ml 2 mol/1 NaCl/ 10 mmol/1 Tris-HCl (pH 6.8). Recovery of glycosaminoglycans was 
monitored by adding 9.10^ Bq [35S]glycosaminoglycan to the urine and was between 72-101%. 
Extraction of lung glycosaminoglycans. 
Glycosaminoglycans were extracted according to a modified method of Hoffman (32). Pleura, 
large airways and blood vessels were removed. The remaining tissue was defatted in 20 vol. 
acetone at -20 ÜC for 16 h, followed by extraction with 20 vol. ether / methanol (1:1) at 4 °C for 
24 h. The material was dried, pulverized with a glass rod and suspended in 40 vol. (w/v) of 0.75 
mol/1 NaOH/10 mmol/1 NaBH,. After 1 h at 73 °C, the mixture was neutralized with 6 mol/1 HCl 
and 1 g/ml trichloroacetic acid was added to a final concentration of 6%. After 1 h at 4 "C, and 
centrifugation (15 min, 2,000xg, 4 °C), the pellet was dissolved in 0.1 mol/1 NaOH. The protein 
concentration was determined according to Lowry (33). To the supernatant 5 vol. of ethanol 
(100%) were added and after 16 h at -20 °C the mixture was centrifuged (30 min, 15,000xg at 
4 UC). The precipitated glycosaminoglycans were dried and dissolved in demineralized water. 
Glycosaminoglycans were quantified using the 1,9-dimethylmethylene blue (DMMB) assay (see 
below). 
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Quantification of sulphated glycosammoglycans 
The content of sulphated glycosaminoglycans was determined using the DMMB assay of 
Famdale et al. (34, 35). To 100 μΐ sample (urine or lung extract) 2.5 ml of DMMB reagent was 
added and the absorbance at 525 nm was measured directly. The DMMB reagent consists of 
48 μηιοΐ/l DMMB (initially 48 μιτιοί DMMB was dissolved in 5 ml 96% ethanol), 42 mmol/1 
glycine and 42 mmol/1 NaCl, adjusted to pH 3.0 with 1 mol/1 HCl. Chondroitin 4-sulphate was 
taken as a standard and included within each series of assays. For calculations we used second 
order regression analysis. 
Quantification of urinary heparan sulphate content 
Urinary heparan sulphate content was determined by a nonequilibrium inhibition enzyme-linked 
immunosorbent assay (ELISA). To 100 μΙ sample 100 μΙ anti-heparan sulphate (JM403) 
(dilution 1/40,000 in Tris-buffered saline (pH 7.2) containing 0.1% Tween-20 (TBST) and 1% 
BSA) was added. After 16 h at 4UC 100 μΐ of this mixture was transferred to a heparan sulphate 
coated microtitre plate, and free anti-heparan sulphate antibodies were allowed to bind to the 
coated heparan sulphate for 2 h. The plate was washed with TBST and 100 μΐ alkaline 
phosphatase conjugated anti-mouse Ig, at a dilution of 1/2000 in TBST/BSA, was added. After 1 
h the plates were washed with TBST and alkaline phosphatase was detected using 1 mg/ml 
dinitrophenyl phosphate in 1 mol/1 diethanolamine (pH 9.8) containing 50 mmol/1 MgCl,. 
Absorbance was measured at 405 nm. Bovine kidney heparan sulphate was taken as a standard 
within each series of assay. 
Characterisation of urinary glycosammoglycans 
Purified urinary glycosaminoglycan were separated on agarose gel using 0.1 mol/1 barium acetate 
(pH 5.0) as electrophoresis buffer. Glycosaminoglycans were visualized using a combined azure 
A silver-staining (36). 
Creatinine assay 
Creatinine was measured using the alkaline picrate method, based on the Jaffé reaction (Sigma, 
procedure no. 555). 
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Statistical analysis 
Intergroup comparison was calculated using Student's t-test. Correlation analysis was performed 
using Pearson's product moment correlation test (37). All values are given as mean ± SEM. Data 
were normally distributed. 
Fig. 1 : Immunofluorescence of lung tissue stained with anti-heparan sulphate antibodies 3 h after treatment with 
elastase: A) detail and C) overview; or saline: B) detail and D) overview. Note the abrupt changes in immunostaining 
(see arrows). (Internal scale bar 100 цт) . 
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Fig. 2: Immunofluorescence double staining of rat lung tissue 1 day after elastase treatment. Panels А, С E 
and G show staining for heparan sulphate and panels B, D, F and H staining for heparan sulphate 
proteoglycan core-protein, type IV collagen, laminin and fibronectin. respectively. Note that only staining for 
heparan sulphate and heparan sulphate proteoglycan is reduced or absent compared to lung of saline-treated 
rats (see Fig. 1 for heparan sulphate). (Internal scale bar = 100 цт) . 
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Results 
General histology 
Three hours after intratracheal 
instillation of porcine pancreatic 
elastase we observed an infiltra­
tion of inflammatory cells in the 
lung accompanied by haemor­
rhages and pulmonary edema, 
indicating acute lung injury. This 
stage persisted for about 3 days. 
Lung morphology returns to nor­
mal after 5-7 days. Two weeks 
after elastase treatment the first 
emphysematous lesions could be 
intercept is increased to 81.7 ± 2 3 
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Table 1: Effects of elastase treatment on immunostaining of alveolar 
basement membrane components 
HS 
HSPG (core protein) 
Lamintn 
Fibroneclin 
Type IV collagen 
3 h 
111 
11 
-
-
-
Time after elastase treatment 
1 d 
HI 
11 
-
-
-
2 d 
HI 
1 
-
-
-
3d 
1. 
1 
ND 
ND 
ND 
5d 
1 
-
ND 
ND 
ND 
7d 
A 
ND 
ND 
ND 
HS heparan sulphate, HSPG heparan sulphate proteoglycan, ND not 
determined, - no effect, 1 weak decrease, 11 moderate decrease 
strong decrease 
observed. Forty days after elastase treatment the mean linear 
μπι (n=17), compared to 58.6 ± 1.2 μιτι (n=8) for controls 
18 19 
day after instillation 
Fig. 3: Urinary glycosaminoglycan (GAG) content after intratracheal elastase instillation 
О saline-treated rats, · elastase-treated rats * P<0 0 1 , * * P<0 005. *** P<0 0005 
Numbers of rats are indicated in bracket 
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Immunofluorescence studies of basement membrane components 
In lung parenchyma, heparan sulphate is linearly distributed in alveoli in accordance with its 
presence in basement membranes (Fig. 1). Table I summarizes the effects of elastase on 
basement membrane components. Three hours after elastase treatment large areas of the lung 
lack heparan sulphate staining (Fig. 1 A, 1С). In some cases one alveolus is completely devoid of 
heparan sulphate, while in the adjacent alveolus staining is normal (Fig. 1A). At places where 
heparan sulphate staining is reduced or absent, staining for the core protein of heparan sulphate 
proteoglycan is reduced as well, be it to a lesser extent (Fig. 2A, 2B). After 5 days most heparan 
sulphate staining has returned. At all times staining for type Г collagen, laminin and fibronectin 
is normal, even at places where heparan sulphate staining is absent (Fig. 2C-2H). Attempts to 
localize elastase using commercial antibodies were unsuccessful. The elastase used was devoid 
of heparan sulphate digesting activity as was demonstrated by incubation of heparan sulphate 
with elastase followed by assaying the molecular mass of heparan sulphate by Polyacrylamide 
gel electrophoresis (data not shown). 
Fig. 4: Separation of DEAE-purified urinary glycosaminoglycans of an individual rat by agarose gel electrophoresis. 
Lane 1, one day before; lane 2 and 3, one and three days after elastase treatment, respectively; M, marker glycos­
aminoglycans; HS: heparan sulphate; DS: dermatan sulphate; CS: chondroitin sulphate. The amounts of urinary 
glycosaminoglycans applied to the gel were derived from urine samples, containing 1.25 μg creatinine. Note the 
increase of heparan sulphate and dermatan sulphate after elastase treatment (lane 2 and 3). 
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During the first 3 days after elastase treatment the content of glycosaminoglycans in lung tissue 
is significantly decreased (2.8 ± 0.07 (n=8) vs 4.6 ± 0.2 (n=8) μg glycosaminoglycan / mg 
protein, for saline-treated rats (P < 0.0001)). Thereafter no significant changes can be observed. 
The concentration of glycosaminoglycans in urine is significantly increased during the 
first 4 days after elastase treatment, with a maximum at day 1 (Fig. 3). Agarose gel 
electrophoresis of the glycosaminoglycans shows that besides the heparan sulphate also the 
dermatan sulphate excretion is markedly increased after elastase treatment, with a maximum at 
day 1 (Fig. 4). ELISA of purified urinary glycosaminoglycans displays a significant increase in 
heparan sulphate (JM403 epitope) 1 to 3 days after elastase treatment, with a maximum level at 
day 3 (Fig. 5). The apparent discrepancy between the day of peak level of heparan sulphate 
measured by ELISA and of heparan sulphate 
determined by agarose electrophoresis may 
be explained by the specificity of the JM403 
antibody. This antibody recognizes only 
heparan sulphate from basement membranes 
and not heparan sulphate from other sources 
such as those located at the cell surface (29), 
which are probably also removed from the 
alveoli as a result of elastase treatment. So 
perhaps the heparan sulphate at day 1 (lane 2, 
Fig. 4) consists mainly of non-basement 
heparan sulphate, not detected by the JM403 
antibody. This, however, requires further 
study. 
The extent of emphysema, measured 
as the increase of mean linear intercept 40 
days after induction, is positively correlated 
to the concentration of glycosaminoglycans in 
the urine during the first four days after 
induction (the time at which glycosaminogly­
can excretion is increased) (Fig. 6). 
?7 
¡D 4 b Ì 3 
о 
5.2 
о 
á' 
ν 
18 19 
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Fig. 5: Urinary heparan sulphate-epitope JM403 content 
after intratracheal elastase instillation O. saline-treated 
rats; · : elastase treated rats (n = 6)(*: Ρ < 0 01). heparan 
sulphate content was determined by an ELISA using 
bovine kidney heparan sulphate as a standard. Note that 
the unit heparan sulphate-epitope JM403/mg creatinine is 
arbitrary; it reflects the amount of the heparan sulphate-
epitope JM403 corresponding to 1 μg bovine kidney 
heparan sulphate 
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Fig. 6: Correlation of the mean linear intercept (MLI) 
measured 40 days after treatment and the urinary glycos-
aminoglycan excretion during the first 4 days after 
treatment (P < 0 0001, r = 0 85) О saline-treated rats, · 
clastase-treated rats. 
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 г - Discussion 
The predominant theory on the pathogenesis 
of emphysema emanates from a disturbance 
of the protease/anti-protease balance, 
favouring the proteases (10-12). Elastin has 
been regarded as the target molecule in the 
extracellular matrix. In pancreatic elastase-
induced emphysema, elastin breakdown 
occurs (38). Elastase, however, is a indiscri­
minate enzyme, capable of the in vitro degra­
dation of many proteins, including proteo­
glycans, collagen, fibronectin and Iaminin 
Little is known about the in vivo effect of 
elastase on these molecules. In this study we 
have shown that in rat lungs especially 
proteoglycans are target molecules for instilled elastase. Fibronectin, type IV collagen and 
Iaminin were not affected, although small changes may have gone undetected using immuno-
histochemistry. These results are in accordance with an electron microscopical study on 
pancreatic elastase-induced emphysema showing no change in Iaminin or appearance of the 
basement membrane, but elimination of heparan sulphate (39, 40). The observation that at places 
where heparan sulphate staining is absent, staining for heparan sulphate proteoglycan core 
protein is only reduced can be explained by incomplete cleavage of the heparan sulphate 
proteoglycan core protein. Since all three heparan sulphate chains are attached to the N-terminus 
of the protein (41, 42), one cut at this end of the protein will release all heparan sulphate chains, 
whereas a large part of the core protein, and thus most of the epitopes for the polyclonal anti-
heparan sulphate proteoglycan antibodies, remain present in the basement membrane. 
It has been postulated that proteases can induce emphysematous lesions only if they 
posses elastolytic activity (43). However, several animal models for emphysema exist where 
there is no elastin breakdown, including emphysema induced by CdCI
:
 (44, 45), by 90% oxygen 
(46) or by collagenase (47), and genetic emphysema in the tight-skin mouse (48). In addition 
leucocyte elastase, implicated in the emphysematogenesis in man, has been reported to lack 
elastolytic activity (49). There is no consensus on elastin breakdown in human pulmonary 
emphysema (50-52). We suggest as an alternative possibility that degradation of proteoglycans 
(eg by leucocyte elastase) is associated with the onset of the disease. 
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Proteoglycans are implicated in a number of functions important for the integrity of the 
extracellular matrix which is compromised in emphysema The glycosaminoglycans are 
powerful inhibitors of proteases, including leucocyte elastase (20, 22, 53) and prevent leucocyte 
elastase-induced emphysema in mouse and rat (23, 24) Ultrastructurally, proteoglycans are 
present around collagen fibrils, elastin fibres and in basement membranes (6, 25, 27, 28) 
Removal of proteoglycans associated with elastin facilitates the digestion of the latter (54-56) In 
addition, proteoglycans are involved in the fibnllogenesis of the major fibrillar components 
collagen and elastin and may influence their mechanical characteristics (3, 4, 57) Proteoglycans, 
especially heparan sulphate proteoglycans, bind and modulate growth factors, including basic 
fibroblast growth factor (bFGF), interferon-γ, mterleukin-8 and transforming growth factor-ß 
(16-20) In lung parenchyma, degradation of heparan sulphate by hepantinase results in the 
release of bFGF (58) Hence, removal of proteoglycans from the alveolar wall eg by proteoly-
sis, may result in a disturbance of the extracellular matrix which may ultimately lead to 
emphysematous lesions Intratracheal instillation of hyaluronidase (which digests some types of 
glycosaminoglycan) together with 60% oxygen results in air-space enlargement after 4 days (59) 
The disappearance of heparan sulphate proteoglycan in the lung is accompanied by an 
increase of glycosaminoglycans in the urine This increase, observed during the first 4 days after 
elastase instillation, is positively correlated with the increase of the mean linear intercept, an 
indicator for parenchymal destruction, 40 days after instillation Increase of urinary glycosamino-
glycans may therefore be an indicator for tissue destruction and be of value in predicting the 
long-term outcome of acute tissue destruction (e g during exacerbations) 
In conclusion, intratracheal instillation of pancreatic elastase in rats results in digestion of 
proteoglycans but not of other basement membrane components The concomitant increase m 
urinary glycosaminoglycans is positively correlated with the degree of emphysematous lesions 
observed after 40 days The vulnerability of proteoglycans towards proteases may be of 
importance in the pathogenesis of emphysema 
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INDUCTION OF EMPHYSEMATOUS LESIONS IN RAT 
LUNG BY ß-D-XYLOSIDE, A SPECIFIC INHIBITOR OF 
PROTEOGLYCAN SYNTHESIS 
Abstract 
The possible involvement of proteoglycans in the pathogenesis of emphysema was studied in rats 
by a single intratracheal instillation of p-nitrophenyl-ß-D-xylopyranoside (ß-D-xyloside), a 
specific inhibitor of proteoglycan synthesis. The first three days after instillation are 
characterized by mild haemorrhages, some infiltration of inflammatory cells and edema. After 
one week, lung morphology is normal again. Forty days after instillation, considerable 
parenchymal destruction has occurred as determined by the mean linear intercept (81 ± 12 μηι 
vs 57 ± 5 μτη for control (P < 0.001)). Pulmonary fibrosis is not observed. 
Urinary glycosaminoglycan (GAG) content of the ß-D-xyloside-treated rats is 15-fold 
increased (576 ± 175 vs 39 ± 7 ng glycosaminoglycan/mg creatinine) during the first day after 
instillation, mainly due to elevated levels of chondroitin sulphate and dermatan sulphate. The 
increase is positively correlated to the extent of parenchymal destruction after 40 days (r = 0.71 ; 
Ρ < 0.05). At day two and thereafter, levels are normal again. A short term increase in dermatan 
and chondroitin sulphate content is also observed in serum, bronchoalveolar lavage fluid and 
lung tissue. Heparan sulphate content is decreased in bronchoalveolar lavage fluid and lung 
tissue. 
We suggest that a disturbance in proteoglycan synthesis accompanied by an increase of (β-
D-xyloside-primed) free glycosaminoglycans results in loss of stability and integrity of the 
alveolar wall, leading to parenchymal destruction and emphysematous lesions. ß-D-xyloside 
treatment may be an alternative experimental method for inducing emphysema. 
Introduction 
The predominant theory on the pathogenesis of emphysema is contained in the protease / anti-
protease concept (1-3). A relative surplus of proteases causes degradation of the alveolar elastic 
fiber matrix, leading to a destruction of the alveolar walls. Elastin degradation is believed to be 
pivotal in this respect. However, several animal models have been described in which airspace 
enlargement / emphysema, is not accompanied by elastin degradation. These include emphysema 
induced by CdCl2 (4, 5), by 90% oxygen (6) and by collagenase (7). Thus, the causes of alveolar 
destruction appear to be complex and other macromolecules of the alveolar wall should be 
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considered. A major component in the non-fibrillar part of the extracellular matrix of alveoli are 
proteoglycans. Proteoglycans consist of a core protein to which one or more strongly negatively 
charged glycosaminoglycan side chains are covalently attached. In the alveolar wall several 
proteoglycans are present including heparan sulphate proteoglycans (e.g. the basement membrane 
associated perlecan and the cell membrane associated syndecans), and dermatan/chondroitin 
sulphate proteoglycans (e.g. the collagen fibril associated decorin, and biglycan) (8). Several 
characteristics of proteoglycans make them likely candidates for playing a key role in the 
maintenance of the structural integrity of the alveolar wall. They interact with and modulate 
several classes of molecules including growth factors and extracellular matrix molecules (9-13), 
act as powerful protease inhibitors, e.g. for leucocyte elastase and cathepsin G (14-16), are 
involved in fibrillogenesis of collagen and elastin and can modulate their mechanical 
characteristics (17-19), offer protection against proteolysis of collagen and elastin (20-22) and 
have a high water-binding capacity providing resilience to the alveolar wall (23). In addition, the 
close association of proteoglycans with structural elements in the alveolar wall (e.g. basement 
membranes, collagen fibrils and elastic fibers) indicates a structural role. 
Since the structural integrity of alveoli is compromised in emphysema, alterations in the 
proteoglycan composition should be considered as a factor contributing in the pathogenesis of 
emphysema. Proteoglycans have been almost entirely neglected in emphysema (24). Previously 
we showed that proteoglycans are target molecules for pancreatic elastase instilled into rat lung 
(25). To evaluate the importance of proteoglycans in alveolar wall stability and in the 
pathogenesis of emphysema, we now studied the effect of a single intratracheal instillation of p-
nitrophenyl-ß-D-xylopyranoside, which is a specific inhibitor of proteoglycan synthesis (26). 
Materials and Methods 
1,9-Dimethylmethylene blue (80% pure) was purchased from Aldrich Chem. Co., Bomem, 
Belgium; Universal Gel/8 1% agarose gels from Ciba-Coming GMBH, Fernwald, Germany; 
halothane from Apharmo, Arnhem, The Netherlands; pentobarbital (Narcovet) from ICl-Farma, 
Rotterdam, The Netherlands; diethylaminoethyl (DEAE)-Sepharose Fast Flow from Pharmacia, 
Uppsala, Sweden; Aquamount and cetyl-trimethyl-ammonium-bromide were from BDH Ltd., 
Poole, England; Azure A, Tween-20, whale cartilage chondroitin 4-sulphate, bovine kidney 
heparan sulphate, porcine pancreatic elastase, bovine serum albumin (BSA), p-nitrophenyl-ß-D-
xylopyranoside, N-methylsuccinyl-ala-ala-pro-val 7-amino-4-methyl-coumarin and fluorescein 
isothiocyanate (FITC)-conjugated goat anti-mouse IgM and mouse anti-chondroitin sulfate 
(clone CS-56) from Sigma Inc., St. Louis, MO, USA. Mouse monoclonal anti-heparan sulphate 
(JM403) antibody was obtained and characterized as described (27). 
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[3SS]glycosaminoglycans (specific activity б-ІО3 Bq/^g glycosaminoglycan) were obtained 
from rats injected twice i.p. with 37,000 Bq Na235S04/g body weight with a 4 h time span 
between each injection. Four hours after the second injection the rats were sacrificed and the soft 
tissues (i.e. liver, kidney, intestine etc.) removed. Glycosaminoglycans were extracted by alkaline 
borohydride (28). 
Animal accommodation. 
Rats were accommodated in groups of three and fed ad libitum. For urine collection, they were 
accommodated separately in metabolic cages. To avoid stress factors, rats were habituated to 
these cages for 7 days before treatment. 
Intratracheal instillation 
Male Wistar rats (200 ± 10 g) were anaesthetized with 3% halothane, intubated and artificially 
respirated according to Mauderly (29). Rats were hyperventilated, to stop breathing for a few 
seconds, and were instilled during this time span with either 0.5 ml 200 mM ß-D-xyloside (100 
μπιοί) in 10% dimethyl sulfoxide (DMSO) in 0.14 M NaCl (initially ß-D-xyloside was dissolved 
in pure DMSO), 0.5 ml 40 mM ß-D-xyloside (20 μπιοί) in 0.14 M NaCl, or 0.5 ml porcine 
pancreatic elastase in 0.14 M NaCl (0.2 IU/g body weight). Control animals were instilled with 
0.5 ml 10% DMSO in 0.14 M NaCl or 0.5 ml 0.14 M NaCl. All solutions were administered at 
37°C. After instillation, rats were respirated until they awoke. 
Histology 
Animals were sacrificed by an overdose of pentobarbital injected i.p.. For morphometric studies 
lungs were dissected and fixed with 2% formaldehyde in 150 mM phosphate buffer (pH 7.2) 
administered through a polyethylene catheter inserted into the trachea at a pressure of 25 cm H20. 
After 30 min, lungs were fixed for an additional 24 h in 4% formaldehyde, dehydrated and 
embedded in paraffin. Tissue sections (6 μιτι) were contrasted using the trichrome staining of 
Goldner (30). To assess the degree of airspace enlargement, the mean linear intercept was 
determined using a Mop-videoplan image analyser (Kontron GMBH, Eching, München, 
Germany). 
For immunofluorescence and biochemical studies, lungs were dissected and inflated through 
the trachea with 5 ml phosphate buffered saline (pH 7.2) (PBS). PBS-filled lungs were frozen in 
liquid nitrogen and stored at -70°C. Cryosections (6 μπι) were rehydrated for 10 min in PBS, 
containing 1% BSA. Antibodies were applied for 1.5 h in PBS containing 1% BSA. After each 
antibody incubation sections were washed in PBS (3 times 5 min). Anti-heparan sulphate 
antibodies and all secondary antibodies were used at a dilution of 1:100. All other antibodies 
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were used at 1 50 Sections were embedded in aquamount and examined on a Zeiss axioskop 
photomicroscope (Carl Zeiss, Oberkochen, Germany) 
Isolation of glycosaminoglycans from urine and BAL fluid 
Bronchoalveolar lavage (BAL) fluid was obtained from the left lung, by washing the dissected 
lung once with 4 ml and 4 times with 2 ml PBS (4°C) Cells from BAL fluid were removed by 
centrifugation (1000g, 10 mm, 4°C) The total recovery of the BAL fluid was 10 ml 
Rat urines were collected one day before to 7 days after (each day) instillation Urine was 
centrifuged at 2000 g for 10 min (4°C), and 20 ml of the supernatant was diluted to 50 ml by 
adding 10 mM Tns-HCl (pH 6 8) 
Glycosaminoglycans were purified from urine and BAL fluid by anion exchange 
chromatography as described (25) Urme samples (50 ml) or BAL fluids (7 ml) were loaded onto 
a column of 5 χ 0 5 cm containing 0 5 ml DEAE-Sepharose Fast Flow After an initial wash with 
3 ml 0 2 M NaCl/10 mM Tns-HCl (pH 6 8), glycosaminoglycans were eluted with 1 ml 2 M 
NaCl/10 mM Tns-HCl (pH 6 8) followed by 3 ml 10 mM/Tns-HCl (pH 6 8) Recovery of 
urinary glycosaminoglycans was monitored by adding 9-101 Bq [35S]glycosaminoglycan to the 
urine sample and was between 72-101% 
Isolation of glycosaminoglycans from serum 
To 100 μΐ serum 8 μΐ trichloroacetic acid (TCA) solution (1 g/ml) was added After 
centrifugation for 20 mm at 10,000 g, the supernatant was removed and stored on ice The 
remaining protein-bound glycosaminoglycans were liberated from the TCA-pellet by β-
ehmination Briefly, the TCA-pellet was suspended in 100 μΐ 0 75 M NaOH and 50 mM NaBLL,, 
and incubated for 1 h at 73°C After 1 h the mixture was cooled on ice and neutiahzed with 6 M 
HCl The remaining proteins were removed by addition of 9 μΐ TCA-solution (1 g/ml) and 
centrifugation (20 min, 10,000g) The supernatants of both TCA-precipitations were pooled and 
5 vol of ethanol (100%) was added After 16 h at -20°C the mixtuie was centrifuged for 30 mm 
at 15,000g (0°C), and the precipitated glycosaminoglycans were dried, dissolved in 50 μΐ 50 mM 
barium acetate (pH 5 0)/ 40% glycerol/ 0 01% bromophenol blue, and subjected to agarose gel 
electrophoresis (see below) 
Isolation of glycosaminoglycans from parenchymal lung tissue 
Glycosaminoglycans were extracted according to a modified method of Hoffman (28) Pleura, 
large airways and blood vessels were removed from 30 μηι thick cryosections The remaining 
tissue was lyophilized, weighted and suspended in 200 μΐ 0 75 M NaOH/10 mM NaBH., After 
1 h at 73°C, the mixture was neutralized with 6 M HCl and TCA-solution (1 g/ml) was added to 
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a final concentration of 60 mg TCA /ml After 1 h at 4°C, and centnfugation for 15 mm at 2000 g 
(4°C), the protein pellet was dissolved in 100 μΐ 100 iriM NaOH and the concentration deter­
mined according to Lowry (31) To the glycosaminoglycans-containing supernatant 5 vol of 
ethanol (100%) was added and after 16 h at -20°C, the mixture was centnfuged (30 mm, 15000 g, 
4°C) The precipitated glycosaminoglycans were dried and dissolved in deminerahzed water 
Quantification of glycosaminoglycans by gel electrophoresis 
Glycosammoglycan samples from urine, BAL fluid, serum and lung tissue were separated on 
agarose gel using 0 05 M barium acetate (pH 5 0) as electrophoresis buffer Glycosaminoglycans 
were visualized using a combined azure A/silver staining as described, and quantified by densito-
metnc analysis (32) The nature of the glycosaminoglycans was established by specific degrada­
tion procedures nitrous acid for heparan sulphate, chondroitinase ABC digestion for chondroitin 
sulphate and dermatan sulphate, and chondroitmase AC digestion for chondroitin sulphate (32) 
Quantification ofsulphatedglycosaminoglycans by a I 9-dimethylmeth}lene blue assay 
The content of sulphated glycosaminoglycans was determined using the 1,9-dimethylmethylene 
blue (DMMB) assay of Farndale et al (33) To 100 μΐ glycosammoglycan sample, 2 5 ml of 
DMMB-reagent was added and the absorbance at 525 nm was measured directly The DMMB-
reagent consists of 48 μΜ DMMB (initially 48 μιηοΐ DMMB was dissolved m 5 ml 96% 
ethanol), 42 mM glycine and 42 mM NaCl, adjusted to pH 3 0 with 1 M HCl Chondroitin 4-
sulphate was taken as a standard and included within each series of assays 
Determination ofelastase in BAL fluid 
Elastase activity was determined using the fluorogenic substrate N-methylsuccinyl-ala-ala-pro-
val 7-amino-4-methyl-coumann according to Castillo et al (34), with some modifications 
Briefly, to 400 μΐ BAL fluid 100 μΐ 4 M NaCl, 500 mM Tris (pH 8 5) and 0 4% cetyl-tnmethyl-
ammonium-bromide was added After 5 min preincubation at 37°C, 5 μΐ substrate solution (10 
mM N-melhylsuccinyl-ala ala-pro-val 7-amino-4-methyl-coumann dissolved in DMSO) was 
added Fluorescence was monitored on a Shimadzu RF-5000 spectrofluorometer, at excitation 
and emission wavelengths of 375 and 440 nm, respectively Human leucocyte elastase, a 
generous gift of Dr J Schalkwijk (Dept Dermatology, University of Nijmegen), was taken as 
a standard 
Statistical analysis 
IntergToup comparison was calculated usmg Students t-test Correlation analysis was performed 
using Pearson's product moment correlation test (35) All values are given as mean ± SD 
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Fig. 1: Lung parenchyma 1 day after intratracheal instillation of a) 100 μηιοί ß-D-xyloside in 10% 
DMSO; b) 10% DMSO (control); c) 40 Ш pancreatic elastase in physiological salt; d) physiological 
salt (control). In comparison with elastase instillation, ß-D-xyloside-treated lungs show little 
haemorrhages and infiltration of inflammatory cells. Some perivascular edema (large arrows) and 
alveolar transudate (small arrows) can be observed. Bar: 100 цт. 
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Results 
General morphology 
Three hours after intratracheal instillation of 100 μηιοί ß-D-xyloside mild haemorrhages and 
some infiltration of inflammatory cells are observed in the lung. These phenomena subside three 
days after instillation and lung morphology returns to normal after one week. The extent of 
haemorrhages and infiltration of inflammatory cells is much less pronounced compared to 
elastase-treated animals (Fig. 1). Control animals also display some haemorrhages and 
inflammation, but to a smaller extent then ß-D-xyloside-treated rats. Edema is observed in 
bronchioli, blood vessels and alveolar walls until day 5, whereas control animals display only 
some edema in bronchioli and large blood vessels during the first two days. Forty days after 
treatment parenchymal destruction is observed in ß-D-xyloside-treated animals (Fig. 2). The 
mean linear intercept (MLI), a parameter of airspace enlargement, is increased to 81 ± 12 ц т 
(n=l 1), compared to 57 ± 5 μηι (n=14) for control (P < 0.001, Fig. 3). Occasionally very severe 
parenchymal destruction is present (Fig. 2c). Fibrosis is not observed. The extent of ß-D-
xyloside-induced parenchymal destruction is comparable to that induced by pancreatic elastase 
(MLI: 82 ± 11 ц т (n=12) vs 59 ± 4 ц т (n=8) for control, Fig. 3). With a lower dose of ß-D-
xyloside (20 μηιοί), only about 30% of the treated animals develop emphysematous lesions (MLI 
> 70 цт) (Fig. 3). 
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Fig. 2: Lung parenchyma 40 days after intratracheal 
instillation of a) 10% DMSO; b, c) 100 цтоі ß-D-
xyloside in 10% DMSO. Note the parenchymal 
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Fig. 3: Effect of intratracheal instillation of ß-D-xyloside and pancreatic elastase on the 
mean linear intercept (ML1), 40 days after treatment *: Ρ < 0.001 
Table 1. Effect of intratracheal instillation of 100 μτηοΐ 
ß-D-xyloside on chondroitin sulphate (CS) and 
dermatan sulphate (DS) content in serum 
Immunofluorescence studies 
Chondroitin sulphate staining is only occasionally present in normal rat lung (Fig. 4a). Three 
hours and 1 day after ß-D-xyloside treatment, however, a diffuse chondroitin sulphate-staining 
is observed in the alveolar wall (Fig. 4b), 
which changes to a more distinct staining 
pattern 3 to 7 days after treatment (Fig. 4c) 
Phase contrast microscopy indicates a 
colocalization of chondroitin sulphate-
staining with fiber-like structures, 
presumably elastic fibers (Fig 4c and d). 
Colocalization of chondroitin sulphate-
staining with these structures can also be 
observed in alveoli 2 to 14 days after 
pancreatic elastase treatment (data not 
shown). 
Heparan sulphate-staining was found linearly 
distributed in the alveolar wall, in accordance 
with its presence in basement membranes 
No obvious alterations in heparan sulphate-
Time after 
instillation 
Control (1 h) 
1 h 
3h 
1 d 
3d 
7d 
CS 
3 54 ± 0 36 
5 55 ± 0 9 8 ' 
6 87 ± 0 32* 
8 33 ± 1 04* 
4 38 ± 0 34 
3 1 7 ± 0 12 
DS 
221 ± 0 19 
5 48 ± 0 56* 
5 09 ± 0 43* 
5 12 ± 0 51* 
3 84 ± 0 41 
2 88 ± 0 44 
Values are expressed as μg/ml serum and are mean ± 
SD of 4 animals 
* Ρ < 0 05 vs control 
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staining could be detected in ß-D-xyloside-treated rats (Fig. 5). The distance between the two 
opposite alveolar basement membranes in the alveolar wall, visualized by heparan sulphate 
staining, is increased (Fig. 5.). This indicates the presence of edema in the alveolar wall (Fig. 5). 
Fig. 4: Chondroitin sulphate immunostaining of rat lung, a) control; b) 3 h after instillation of 100 μιηοΐ ß-D-
xyloside.; с) 7 days after instillation of 100 цтоі ß-D-xyloside.; d) phase contrast micrograph of the same section 
as с Note an increase in chondroitin sulphate staining after ß-D-xyloside treatment. At day 7 staining is focal and 
associated with elastin fibers (arrows in с and d). Bar: 20 μιη. 
Glycosaminoglycans in urine, serum, BAL fluid and lung 
Since ß-D-xyloside acts as an artificial initiator of glycosaminoglycan synthesis, and could cause 
an increase in the synthesis of free glycosaminoglycans (26), we examined the amount and 
composition of glycosaminoglycans in BAL fluid, serum, urine and lung tissue. 
In urine, a 15-fold increase in glycosaminoglycan content is observed at day one (Fig. 6). 
The values are 576 ± 175 μg glycosaminoglycan/mg creatinine (n=ll) vs 39 ± 7 μg glycos-
aminoglycan/mg creatinine (n=10) for control, Ρ < 0.001. At day two and thereafter urinary 
glycosaminoglycan levels are normal (Fig. 6). The increase in urinary glycosaminoglycan can 
mainly be allotted to an increase in dermatan- and chondroitin sulphate, as was determined by 
agarose gel electrophoresis (data not shown). A significant correlation is found between the 
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increase of urinary glycosaminoglycan content the first day after treatment, and the extent of 
airspace enlargement (MLI) developed after 40 days (Fig. 7). 
Fig. 5: Heparan sulphate immunostaining of rat lung 3 days after instillation of a) 10% DMSO/saline, b) 100 μιηοΐ 
ß-D-xyloside in 10% DMSO/saline. Heparan sulphate is linearly distributed in alveoli in accordance with its 
presence in basement membranes. In ß-D-xyloside-treated rats the distance between the two (heparan sulphate-
stained) basement membranes is increased, indicating edema (see arrow). Bar represents 100 μηι. 
In serum, dermatan sulphate and chondroitin sulphate are increased during the first two 
days after treatment (Table 1). Heparan sulphate, which constitutes only 0.3% of serum glycos-
aminoglycans (32), was not analysed. 
BAL fluid shows the most complex alterations in glycosaminoglycan content and 
composition (Table 2). The major glycosaminoglycan in BAL fluid from control animals is 
heparan sulphate, whereas chondroitin sulphate and dermatan sulphate are minor components. 
One hour after ß-D-xyloside treatment, dermatan sulphate and chondroitin sulphate content are 
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dramatically increased, which is even more evident after 3 h. One day after treatment chondroitin 
sulphate migrates as a narrow band, indicating less heterogeneity in charge and/or size, while 
dermatan sulphate is separated into two distinct bands. Heparan sulphate content is significantly 
decreased at day one and is further reduced 2 days after treatment. Chondroitin sulphate has 
returned to control values at day 2. The nature of the glycosaminoglycans, which were 
determined by agarose gel electrophoresis, were confirmed by enzymatic digestion (data not 
shown). 
Table 2: Lflect of intratracheal instillation of 100 μπιοί ß-D-xyloside on heparan sulphate (HS), dermatan 
sulphate (DS) and chondroitin sulphate (CS) content in BAL fluid 
Time aller instillation HS CS DS 
Control ( Ih ) 0 24 ± 0 06 0 07 ± 0 03 0.02 ± 0 02 
I h 0 19 ± 0 02 0 68 ± 0 05* 0 71 ±0.12* 
Зп 0 14 ± 0 06 1 14 ± 0 21* 0.80 ± 0 20* 
l d 0 09 ± 0 02* 0 29 ±0.06* 0 94 ± 0 13* 
2d 0.02 ±0.01* 0 08 ± 0 04 0 12 ± 0 04* 
Values are expressed as μg/ml DAL fluid and are mean ± SD of 4 animals. 
*: Ρ < 0.01 vs control. 
Table 3: bffcct of intratracheal instillation of 100 μπιοί ß-D-xyloside on heparan sulphate (HS), dermatan 
sulphate (DS) and chondroitin sulphate (CS) content in parenchymal lung tissue. 
I ime after instillation HS CS DS 
control ( Ih ) 2 05 ±0.66 ( Π ) 067±0.24(13) 2.51 ± 0 5 6 ( 1 3 ) 
I h 291(1) 074(1) 3.46(1) 
3h 1.63 ±0.43 (4) 0.84 ± 0 21 (4) 3.44 ± 0 41 (4)** 
l d 172 ±0.22 (4) 2 06 ± 0.60 (4)** 4.50 ± 0.48 (4)** 
2d 1.13 ± 0 10 (3)* 0 5 0 ± 0 0 8 ( 3 ) 3 16 ± 0 98 (3) 
7d 2.00 ± 0 63(3) 0 58 ±0.10(3) 2 44 ± 0 35 (3) 
Values are expressed as μg glycosaminoglycan/mg protein and are mean ± SD of the number of analysed animals 
between parentheses 
*: Ρ < 0 05, **. Ρ < 0.01 vs control 
Analysis on cryosections of parenchymal lung tissue showed that dermatan sulphate and 
chondroitin sulphate are increased at 3 h and 1 day, and at 1 day after treatment, respectively, 
while the heparan sulphate content is significantly decreased 2 days after treatment (Table 3). All 
values return to control levels 7 days after treatment. 
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Elastase activity in BAL fluid 
In ß-D-xyloside-treated rats, BAL fluid shows a modest increase in elastase activity one day after 
treatment (3.2 ± 0.6 (n=3) vs 2.1 ± 0.4 ng /ml BAL fluid for control (n = 6)). Levels are normal 
the second day. 
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days after instillation 
Fig. 6: Unnar> glycosaminoglycan (GAG) content after intratracheal instillation ot 100 
μιηοΙ ß-D-xyloside in 10%DMSO(*)or 10%DMSO(O) *. Ρ < 0 001). n=10 
Discussion 
In this study we show that intratracheal instillation of 100 μιηοΙ ß-D-xyloside in rats induces the 
development of emphysematous lesions. After treatment with 20 μιηοΙ ß-D-xyloside only about 
30% of the animals developed emphysematous lesions, indicating a dose-dependent effect of the 
drug. ß-D-xyloside mimics the serine-xyloside glycosaminoglycan initiation site of the core 
protein of proteoglycans, and competes as a false acceptor for glycosaminoglycan synthesis (26). 
Administration of ß-D-xyloside increases glycosaminoglycan synthesis, which is particulatly 
evident from the 15-fold increase of glycosaminoglycan content in the urine of treated rats. The 
increase comes mainly to the account of chondroitin- and dermatan sulphate, which is typical for 
the ß-D-xyloside preparation we used (p-nitrophenyl-ß-D-xylopyranoside) (36). The 15-fold 
increase of urinary glycosaminoglycan content cannot solely be attributed to an increase in the 
synthesis of glycosaminoglycans in the lung. Other organs, which possibly receive a dose of ß-D-
xyloside indirectly through the blood, may also contribute. This especially applies to the kidney, 
since the glycosaminoglycan content in serum showed only a two-fold increase. In an oigan 
Ö U U 
£ 600 
CO 
ω 
L·-
o 
en 400 
E 
О 
< 
О 200 
134 
ß-D-Xyloside-induced emphysematous lesions 
perfusion system, 2.5 mM ß-D-xyloside stimulated the synthesis of chondroitin sulphate and 
dermatan sulphate in glomeruli (37). The amount of increase in urinary glycosaminoglycan 
content one day after treatment is positively correlated to the extent of parenchymal destruction 
observed at day 40. This indicates that the degree of disturbance in the lung during the initial 
phase of the insult determines the degree of parenchymal destruction in a later phase. 
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Fig. 7: The relation between the mean linear intercept 40 days after instillation of 100 
μηιοί ß-D-xyloside and the content of urinary glycosaminoglycans (GAG) one day after 
instillation (P<0 05; r = 0 71 ) · . rats instilled with 100 μηιοί in 10%DMSO; O rats 
instilled with 10% DMSO (control). 
Although the mechanism of the parenchymal destruction due to ß-D-xyloside treatment is 
not clear, it is likely mediated by the increase in synthesis of free glycosaminoglycans and the 
concomitant decrease in proteoglycan synthesis, hi BAL fluid and parenchymal lung tissue we 
found an increase in total glycosaminoglycan content due to an increase in dermatan and 
chondroitin sulphate; heparan sulphate was decreased. We did not observe a clear decrease in 
heparan sulphate proteoglycans of the alveolar basement membrane using immunofluorescence. 
Others, however, found a 25% decrease in basement membrane proteoglycans (predominantly 
heparan sulphate proteoglycans) with ruthenium red staining in mouse submandibular salivary 
glands (38), and a 43% decrease in heparan sulphate synthesis, together with a 4-fold increase 
in chondroitin sulphate synthesis in the basement membrane producing EHS tumor in vitro (39). 
Basement membrane heparan sulphate proteoglycan is believed to function as a charge barrier 
for proteins. A probable loss of heparan sulphate proteoglycans together with an increase in total 
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glycosaminoglycans, which posses high water-binding properties, may account for the observed 
edema in the treated rat lungs. 
The observed increase in dermatan and chondroitin sulphate content may destabilize 
collagen fibrils, and reduce their tensile strength. ß-D-xyloside treatment of developing avian 
corneal stroma, which leads to a reduced synthesis of dermatan sulphate proteoglycans but an 
increase in free dermatan sulphate, resulted in a reduced collagen fibril packing and a disruption 
of lamellar organization (40). The situation may be somewhat analogous to cervical dilatation 
at the end of pregnancy, a process which is accompanied by a dramatic increase in collagen-
associated dermatan sulphate (41, 42). An increase of chondroitin sulphate content can impair 
elastic fiber assembly by inhibition of the binding of the 67 kDa elastin-binding protein to elastic 
fibers and the cell membrane (43). Glycosaminoglycans may further disturb repair of the alveolar 
matrix since they are potent inhibitors of lysyl oxidase (44), an enzyme crucial for the cross-
linking of collagen and elastin. Ex-vivo treatment of mouse embryo's with ß-D-xyloside inhibited 
branching morphogenesis in the lung (45). Availability of growth factors may also be affected 
by the increase in glycosaminoglycans; ß-D-xyloside-primed glycosaminoglycans are able to bind 
growth factors, as do glycosaminoglycans in proteoglycans (46). All these effects will 
compromise the delicate balance of alveolar wall homeostasis and will prevent an orderly repair, 
finally resulting in parenchymal destruction and emphysematous lesions. 
In ß-D-xyloside-treated rats only mild haemorrhages and inflammation were observed in 
the lung, in contrast to pancreatic elastase-treated animals. This could be an effect of dimethyl 
sulfoxide which was used as a solvent for ß-D-xyloside. Dimethyl sulfoxide acts as an 
anti-inflammatory agent and is a scavenger of free radicals (47). The increase in free elastase 
activity measured in the BAL fluid is only moderate. Apart from the mild infiltration of 
inflammatory cells this may also be an effect of the increase in glycosaminoglycans which are 
potent inhibitors of neutrophil elastase (14, 15). Haemorrhages and inflammation may not play 
an important role in alveolar tissue degradation in ß-D-xyloside-treated rats. The total free 
elastase activity in BAL fluid is 64 ng/rat, which stands small compared to the amount of 
neutrophil elastase necessary to induce pulmonary emphysema by intratracheal instillation (about 
300 μg neutrophil elastase (48)). However, some damage to the alveolar wall due to 
inflammation and neutrophil elastase cannot be excluded. 
The importance of proteoglycans in the stability of the lung parenchyma has recently been 
demonstrated. Intratracheal instillation of testicular hyaluronidase (which degrades hyaluronate 
and dermatan- and chondroitin sulphate) followed by exposure to a non-toxic concentration of 
oxygen (60%) results in a significant airspace enlargement in hamster lungs (49). Hyaluronidase 
instillation also augments pancreatic elastase-induced parenchymal destruction (50). We showed 
an increase of urinary glycosaminoglycans and a decrease of lung glycosaminoglycans and 
heparan sulphate proteoglycans shortly after pancreatic elastase instillation into rat lungs (25). 
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The urinary glycosaminoglycan content correlated also to the extent of emphysema developed 
after 40 days 
In conclusion, a single intratracheal instillation of a high dose of ß-D-xyloside results in 
the development of emphysematous lesions This effect is likely mediated by the short term 
increase of free glycosaminoglycan chains (and possibly decrease of proteoglycan content) It 
underscores the importance of proteoglycans in alveolar wall integrity and indicates their 
involvement in the pathogenesis of emphysema ß-D-xyloside treatment may be an alternative 
experimental way to induce emphysema The detrimental effect of ß-D-xyloside on the lung 
should be taken into consideration when evaluating ß-D-xyloside preparations as antithrombotic 
drugs (51) 
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Urinary heparan sulphate in COPD 
ALTERED COMPOSITION OF URINARY HEPARAN 
SULPHATE IN PATIENTS WITH CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
Abstract 
In patients with emphysema the integrity of the extracellular matrix (connective tissue 
skeleton) is compromised. In this study we analysed glycosaminoglycans, which are main 
constituents of this matrix, in urines from patients with chronic obstructive pulmonary disease 
(COPD)/emphysema. Glycosaminoglycans were purified by anion exchange chromatography 
and quantified using the 1,9-dimethyhnethylene blue assay. Heparan sulphate was assayed 
using three different chemical methods: digestion with heparitinase or with nitrous acid and 
by use of an adapted 1,9-dimethylmethylene blue assay. A specific epitope on the heparan 
sulphate molecule, defined by the monoclonal antibody JM403, was determined using an 
inhibition enzyme immunoassay. 
In patients with COPD total urinary glycosaminoglycan and heparan sulphate content 
were not altered. The JM403-epitope of heparan sulphate, however, was greatly decreased in 
patients (0.6 vs 4.1 units/mg creatinine for controls, p<0.0001). A similar pattern was 
observed when patients with bronchial carcinoma with and without emphysema were 
compared (0.4 vs 2.4 units/mg creatinine respectively, p<0.0005). Patients with sarcoidosis 
did not show a decreased epitope content. These results indicate a structural change or an 
altered processing of the heparan sulphate molecule in patients with emphysema. Taken into 
consideration the importance of heparan sulphate for the stability of the alveolar extracellular 
matrix, this change may be associated with the pathogenesis of emphysema. 
Introduction 
Airspace enlargement, destruction of alveoli and loss of elasticity are the hallmarks of 
pulmonary emphysema. A loss of the integrity of the extracellular matrix is probably 
underlying the disease. The vast majority of research has focussed on elastin. Breakdown of 
elastin, however, has not been unequivocally demonstrated in human emphysematous lung 
tissue (1), nor is there consensus about an increase in elastin-derived peptides in serum or 
urine of patients. Elevated levels of elastin-derived peptides have (2, 3), and have not (4-6) 
been observed. In laboratory animals, emphysema can be induced with and without 
destruction of elastin (reviewed in 1). 
Other alveolar extracellular matrix molecules like collagens, proteoglycans, laminin 
and fibronectin may also be of importance in the pathogenesis of emphysema. Proteoglycans 
deserve special attention since they play a key role in the integrity of the alveolar wall. They 
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are involved in the fibrillogenesis and mechanical characteristics of elastin and collagen (7-9), 
they bind and modulate growth factors and cytokines (10, 11) and they are powerful inhibitors 
of proteases, including human leucocyte elastase (12-14). 
Proteoglycans are macromolecules consisting of a core protein to which negatively 
charged glycosaminoglycans are attached. Glycosaminoglycans are a class of long 
unbranched polysaccharides, consisting of repeating disaccharides of which one is an amino 
sugar residue and the other an uronic acid residue. In the alveolar wall, different types of 
glycosaminoglycans are present (15, 16), including heparan sulphate which is located in 
basement membranes and on cell surfaces. Alterations in lung glycosaminoglycans have been 
described in experimental as well as human emphysema (17-24). The results of these studies, 
however, are contradictory, likely due to differences in experimental set up. In human lung, 
for instance, an increase (17) and a decrease (18) in the percentage of hyaluronic acid have 
been found; also in human lung an increase (19) and no increase (20) in the 
glucosamine/galactosamine ratio has been demonstrated. 
In this study we have analysed the urinary excretion of glycosaminoglycans from 
patients with COPD/emphysema, with special emphasis on heparan sulphate. For 
comparison, we also studied patients with bronchial carcinoma with and without emphysema, 
and patients with sarcoidosis. It was found that the presence of a specific epitope of heparan 
sulphate is considerably reduced in urine of emphysematous patients, despite an unchanged 
total heparan sulphate content. 
Patients, materials and methods 
Patients and control subjects 
Three groups of patients and control subjects were studied: I, patients with COPD and 
matched control subjects; II, patients with bronchial carcinoma with and without emphysema, 
and III, patients with sarcoidosis and matched control subjects. 
Physiological data for individual patients are given in Tables 1-3. In all groups 
subjects with cardiovascular, alcohol-related or renal diseases were excluded. Patients with 
a,-antitrypsin deficiency were also excluded. Control subjects did not show any sign of 
pulmonary disease, nor any other disease. Patients and controls were matched for sex, age and 
smoking habit. All subjects were studied according to guidelines of the Committee of 
Medical Ethics of the University Hospital Nijmegen and gave informed consent. 
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Table I. Physiological data of patients with COPD 
Patient 
code 
JG 
BR 
0 
HS 
JI 
V 
HX 
JA 
JB 
JH 
JD 
HZ 
H 
HU 
JE 
HP 
HV 
W 
HR 
HT 
Age (yr), 
sex 
5I.M 
63,M 
71,M 
71,F 
65,M 
82,M 
56,F 
57,F 
70,M 
60,M 
62,M 
50,M 
65,M 
74,M 
67,M 
70,M 
71,M 
61,M 
79 M 
60,F 
BMI 
(kg/m2) 
23 3 
196 
24 7 
24.6 
23.4 
29.6 
24.9 
24 7 
18 1 
20 5 
29 0 
20.1 
28 7 
20.9 
21 3 
22 9 
27 4 
174 
24.7 
180 
TLC 
(% pred) 
102 
111 
138 
104 
104 
132 
125 
94 
106 
110 
121 
110 
107 
140 
117 
113 
109 
117 
94 
116 
RV FEV, 
(%pred) (%pred) 
before S 
97 5 
135 
211 
67 
135 
177 
171 
136 
102 
196 
216 
224 
110 
174 
139 
152 
153 
198 
96 
159 
35 
43 
31 
45 
23 
46 
19 
28 
30 
11 
26 
31 
41 
31 
43 
21 
24 
19 
55 
26 
FEV, 
(% pred) 
after S 
42 
49 
31 
55 
23 
54 
21 
27 
32 
14 
24 
37 
46 
33 
43 
21 
24 
20 
57 
33 
KCO 
(% pred) 
11 
54 
54 
31 
41 
69 
20 
50 
53 
28 
67 
58 
40 
38 
29 
49 
73 
21 
61 
35 
PaO, 
(kPa) 
7.09 
n d 
n d 
12 1 
9 5 
6 8 
8 1 
78 
7 9 
8 7 
142 
11 
9 2 
11 9 
103 
9 7 
84 
7 8 
11 1 
8 9 
PaCO, 
(kPa)" 
4 
nd 
n d 
4 6 
4 7 
6 5 
5.9 
8 1 
5.7 
6.2 
4 3 
4 6 
5 1 
4 9 
4.9 
4.9 
6.3 
6.2 
4 9 
5 0 
Pack 
years 
21 
30 
20 
5 
40 
40 
40 
30 
0 
30 
35 
30 
45 
20 
35 
13 
12 
40 
10 
25 
BMI body mass index (weight/length2), TLC' total lung capacity, RV residual volume, FEV, forced expiratory 
volume in one second, S salbutamol, KCO diffusion capacity for carbon monoxide corrected for alveolar volume, 
% pred percentage of the predicted value; η d.: not determined 
Static and dynamic lung function tests were performed with a wet spirometer and with a 
closed-circuit helium-dilution method (Pulmonet III, Sensormedics, Bilthoven, the Netherlands). 
Diffusion capacity (KCO) was measured with the single breath-holding carbon monoxide method 
(Sensormedics 2450) and was corrected for actual hemoglobin. Measurements were performed at 
least 12 h after smoking. Predicted spirometrie values were derived from the E CS С.-standards 
(25). 
Arterial blood samples were taken after the patients had been sitting for at least 15 min. Pa02 
and PaC02 were measured with a Coming Ph 127 blood gas analyser (Coming Glass, Medfield, 
MA, USA). 
ad I Patients with COPD and control subjects 
Physiological data of all individual patients are shown in Table 1. Patients were characterized by 
severe airways obstruction and (in most cases) hyperinflation, and a reduced KCO. No 
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improvement of FEV, was observed after inhalation of 400 μg salbutamol. Patients were in a 
stable condition, without exacerbations during the proceeding three months. All subjects used 
inhaled β-,-sympathicomimetics and/or anticholinergics. Fourteen patients (70%) used inhaled 
corticosteroids in a mean dosage of 630 ± 240 μg daily. None used theophylline or oral 
corticosteroids. Lung function data and body measures of controls are given in Table 4. 
ad II Patients with bronchial carcinoma with and without emphysema 
Physiological data of all individual patients are shown in Table 2. Patients were characterized by a 
recently detected and histologically proven bronchial carcinoma (in all cases squamous cell 
carcinoma) Patients with bronchial carcinoma without emphysema had no radiographic or 
histological signs of emphysema, and total lung capacity and diffusion capacity were within 
predicted mean ± 1.64 SD. 
Table 2a. Physiological data of patients with bronchial carcinoma and emphysema 
Patient 
code 
15 
67 
72 
44 
71 
45 
58 
18 
Age (yr). 
sex 
64.F 
60,M 
75,M 
58,M 
66.M 
70,M 
77,M 
78,M 
TLC 
(% pred) 
113 
94 
136 
116 
112 
96 
109 
132 
RV 
(% pred) 
119 
114 
120 
157 
105 
100 
95 
89 
FEV, 
(% pred) 
before S 
44 
61 
64 
64 
42 
75 
80 
70 
FEV, 
(% pred) 
atterS 
47 
58 
68 
67 
39 
74 
78 
71 
KCO 
(% pred) 
53 
61 
78 
68 
46 
71 
52 
54 
PaO, 
(kPa) 
8 1 
106 
106 
83 
80 
8 9 
103 
9 5 
PaCO, 
(kPa) 
5 6 
5 3 
5 1 
4 6 
5 5 
5 4 
5 4 
4 9 
Pack 
years 
40 
35 
10 
20 
40 
50 
15 
20 
TLC total lung capacity, RV residual volume, FEV, forced expiratory volume in one second. KCO diffusion 
capacity for carbon monoxide corrected for alveolar volume, % pred percentage of the predicted value, S 
salbutamol 
ad III Patients with sarcoidosis and control subjects 
Physiological data of all individual patients are shown in Table 3. Patients had histologically 
proven sarcoidosis stage Π (mediastinal and/or hilar lymphadenopathy and radiographic signs of 
interstitial involvement). 6 out of 15 patients used oral corticosteroids in a dosage of 5-25 mg/day, 
whereas the other patients did not receive any medication. Lung function data and body measures 
of controls are given in Table 5. 
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Table 2b. Physiological data ot patients with bronchial carcinoma, without emphysema 
Patient Age(yr) TLC RV FEV, FEV, KCO PaO, PaCO
:
 Pack 
code se\ (% pred) (%pred) (% pred) (% pred) (% pred) (kPa) (kPa) years 
before S aftejJi 
21 
65 
37 
41 
3 
8 
56 
39 
58.M 
68,M 
72.M 
96.M 
68.M 
81,M 
64,M 
63,M 
79 
102 
96 
93 
85 
103 
66 
98 
65 
106 
86 
103 
78 
81 
65 
110 
76 
75 
104 
75 
71 
110 
47 
71 
76 
75 
104 
75 
75 
115 
50 
75 
120 
86 
123 
90 
89 
83 
93 
104 
135 
7 0 
9 8 
77 
106 
11 2 
9 2 
82 
52 
55 
4 8 
5 0 
4 5 
4 9 
56 
53 
20 
20 
10 
25 
30 
-
40 
30 
TLC total lung capacity, RV residual volume, FhV, forced expiratory volume in one second, KCO diffusion 
capacity lor carbon monoxide corrected for alveolar volume, % pred percentage of the predicted value, S 
salbutamol, - non smoker 
Table 3. Physiological data ot patients with sarcoidosis 
Patient 
code 
S2 
S3 
S4 
S5 
S6 
S7 
S8 
S9 
S10 
SII 
S12 
S13 
S14 
S15 
S16 
Age (yr), 
sex 
32.M 
55 h 
41 Г 
38,1· 
25,F 
32,F 
31,M 
60.F 
61,F 
33,M 
41,M 
59,1-
28.Г 
43,M 
32,r 
BMI 
fke/rtñ 
26 5 
28 7 
23 2 
24 7 
21 5 
30 9 
24 2 
37 3 
22 6 
20 9 
24 5 
27 1 
25 9 
27 4 
198 
TLC 
<% med) 
103 
103 
77 
90 
116 
85 
77 
87 
82 
78 
93 
93 
80 
90 
80 
RV 
<% ΌΚά) 
92 
75 
72 
66 
122 
76 
58 
5 
82 
79 
83 
71 
64 
73 
111 
FEV, 
(% urea) 
103 
107 
66 
83 
110 
91 
90 
109 
80 
53 
97 
111 
79 
86 
91 
KCO 
(%vred) 
82 
117 
101 
119 
76 
146 
127 
131 
125 
59 
125 
125 
96 
106 
95 
Pack 
vears 
_+ 
-
-
-
-
-
3 
-
-
16 
-
15 
-
-
OCS 
(ma/davi 
25 
_** 
-
5 
-
-
-
10 
5 
10 
5 
-
-
-
-
BMI body mass index (weightAength) TLC total lung capacity, RV residual volume, FFV, forced e\piratory 
volume in one second. KCO diffusion capacity tor carbon monoxide corrected for alveolar volume, % pred 
percentage of the predicted value,-* non smoker. OCS oral corticosteroids,-** no OCS 
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Table 4. Lung function data and body measures of 
controls in group I (age· 51-85 yr) 
BMI(kg/m2) 24 5 ± 4 1 
TLC(%pred) 106 ± 1 4 
FRC(%pred) 116 ± 2 6 
RV(%pred) 110 ± 3 9 
FEV, (% pred) 94 ± 2 1 
KCO (% pred) 92 ± 3 1 
Values are mean ± SD (n=24). 
BMI body mass index (weight/length2); TLC total 
lung capacity; FRC1 functional residual capacity; 
RV· residual volume; FEV,: forced expiratory 
volume in one second; KCO: diffusion capacity for 
carbon monoxide corrected for alveolar volume, % 
pred- percentage of the predicted value 
Purification of glycosaminoglycans from urine 
Urines were collected and stored at -70°C. After thawing, 20 ml samples of urine were diluted 
with an equal volume of 7 M urea/10 mM Tris-HCl pH 6.8 and applied to an ion-exchange 
column of 5 χ 0.5 cm containing 1 ml diethylaminoethyl (DEAE)-Sepharose Fast Flow 
(Pharmacia, Uppsala, Sweden). After an initial wash with 3 ml 0.2 M NaCl/10 mM Tris-HCl 
(pH 6.8), glycosaminoglycans were eluted with 1 ml 2 M NaCl/ 10 mM Tris-HCl (pH 6.8) 
followed by 3 ml 10 mM Tris-HCl (pH 6.8). The recovery of the glycosaminoglycans was 
monitored by adding 15,000 dpm [35S]glycosaminoglycans (specific activity 10 dpm^g glycos-
aminoglycan) to the urine. Salts were removed by ethanol precipitation of the glycosamino­
glycans. Five volumes of ethanol were added (final ethanol concentration 83%) and glycosamino­
glycans were allowed to precipitate for 16 h at -20°C. After centrifugation for 30 min at 10,000 g 
(-10°C), the precipitated glycosaminoglycans were dried and dissolved in 2 ml demineralised 
water. Recoveries were between 88-100%. Two cycles of freeze-thawing of urine did not 
influence the results. A third cycle occasionally gave erroneous data. 
Quantification of glycosaminoglycans 
Sulphated glycosaminoglycans were quantified according to the method of Famdale et al. (26). 
This method is based on a metachromatic shift in absorption maximum of 1,9-dimethylmethylene 
blue (DMMB) (Aldrich Chem. Co., Bomem, Belgium). To 100 μΐ glycosaminoglycan sample, 
2.5 ml of DMMB reagent was added and the absorbance at 525 nm was measured immediately. 
The DMMB reagent contains 46 μΜ DMMB (initially 46 μπιοί DMMB was dissolved in 5 ml 
Table 5. Lung function data and body measures of 
controls of group III (age. 28-61 yr) 
BMI(kg/m2) 24 4 ± 3 9 
TLC (% pred) 108 ± 1 4 
FRC (% pred) 106 ± 2 2 
RV(%pred) 112 ± 3 4 
FEV, (% pred) 108 ± 2 9 
KCO (% pred) 105 ±33 
Values are mean ± SD (n=37). 
BMI body mass index (weight/length2); TLC total 
lung capacity; FRC' functional residual capacity, 
RV: residual volume; FEV,, forced expiratory 
volume in one second; KCO1 diffusion capacity for 
carbon monoxide corrected for alveolar volume, % 
pred percentage of the predicted value 
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96% ethanol), 40 mM glycine and 42 mM NaCl, adjusted to pH 3.0 with 1 M HCl. Chondroitin 4-
sulphate (Sigma, St Louis, MO, U.S.A.) was taken as a standard and included within each series 
of assays. 
1 0 0 -
80-
60-
40-
20-
0' ' ' ' ' ' ' ' 
0 8 16 32 64 128 256 512 
ngHS 
Fig. 1: Standard curve for the inhibition immunoassay for the heparan sulphate 
epitope JM403. 
A volume of 100 μΐ containing various amounts of bovine kidney heparan 
sulphate was incubated for 16 h at 4"C with 50 μΐ of JM403 antibody Next, 100 μΐ 
of this mixture was transferred to a well previously coated with 1 μ§ heparan 
sulphate. After incubation for 2 h at 22°C, the antibodies bound to the well were 
detected by addition of alkaline phosphatase-conjugated secondary antibodies. After 
addition of substrate the colour developed was speclrophotometrically measured at 
405 run Data are means ± SD (n=3) 
Quantification of total heparan sulphate 
Three methods for the determination of heparan sulphate were used. These methods are based on 
different aspects of the heparan sulphate structure. Bovine kidney heparan sulphate (Seikagaku, 
Tokyo, Japan) was used as a standard. 
Method I is a modified version of the 1,9-dimethylmethylene blue assay and is based on 
the backbone structure of heparan sulphate (27). Addition of bovine serum albumin and 
adaptation of pH and salt concentration of the DMMB reagent results in a specific elimination of 
heparan sulphate-based absorbance. To 100 μΐ glycosaminoglycan sample, 100 μΐ 3% BSA (in 
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Χ) 
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о
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demmeralised water) and 2 4 ml of the modified DMMB reagent was added This reagent 
contains 48 μΜ DMMB (initially 48 μηιοί DMMB was dissolved in 5 ml 96% ethanol), 42 mM 
glycine and 63 mM NaCl, adjusted to pH 2 75 with 1 M HCl After 30 min at 22 "С the 
absorbance was measured at 525 nm By subtracting the value thus obtained (representing other 
glycosaminoglycans) from the total glycosaminoglycans, the content of heparan sulphate was 
calculated (27) 
Method П, digestion of heparan sulphate by hepantinase, is based on cleavage of glyco-
sidic linkages in heparan sulphate involving glucuronic acid residues To lyophihzed glycosami-
noglycan samples, 25 μΐ hepantinase (Seikagaku, Tokyo, Japan) (0 01 IU/ml containing 0 05 M 
sodium acetate and 0 05 M calcium acetate (pH 7 0)) was added Incubation was for 16 h at 43 °C 
The remaining glycosaminoglycans were quantified using the 1,9-dimethylmethylene blue assay 
(see quantification of glycosaminoglycans) By subtracting this value from the total glycosamino­
glycans the content of heparan sulphate was determined 
Method III, digestion with nitrous acid, is based on cleavage of glycosidic linkages 
involving hexosamine residues in which the amino groups are either N-sulphated or unsubstituted 
Nitrous acid digests heparan sulphate and heparin, but not other glycosaminoglycans (28) 
Purified glycosaminoglycans were treated for 90 mm at 22 °C with nitrous acid prepared by 
mixing equal volumes of 5% (w/v) NaNCX and 1 5 M HCl The residual glycosaminoglycans 
were quantified using the 1,9-dunethylmethylene blue assay (see quantification of glycosamino­
glycans) By subtracting this value from the total glycosamtnoglycan the content of heparan 
sulphate and heparin was obtained The contribution of heparin is negligible 
Quantification of the heparan sulphate JM403 epitope 
The heparan sulphate JM403 epitope, defined by monoclonal antibody JM403 (29, 30) was 
quantified using an inhibition enzyme immunoassay (Fig 1) In the wells of polystyiene microtitre 
plates (Greiner GmbH, Fnckenhausen, Germany, cat nr 655061), 100 μΐ of ascites containing 
MoAb JM403 (diluted 1 40,000 in Tns-buffered saline containing 0 1% Tween 20 and 1% (w/v) 
bovine serum albumin, pH 7 5 (TBST/BSA)) was mixed with 100 μΐ lyophihzed glycosamino-
glycan sample and incubated overnight at 4 °C Hundred μΐ of each well was transferred to a 
corresponding well of a polystyrene plate previously coated with 1 μg heparan sulphate and 
incubated for 2 h Free antibodies, ι e antibodies not bound by heparan sulphate of the sample, 
were allowed in this way to complex with the coated heparan sulphate After washing thnce with 
TBST, bound antibodies were detected by incubation for 1 h at 22 °C with 100 μΐ rabbit anti-
mouse Ig (Dako, Glostrup, Denmark) conjugated with alkaline phosphatase (diluted 1 2000 in 
TBST/BSA) After washing again, 100 μΐ of substrate (1 mg/ml p-mtrophenylphosphate in 1 M 
diethanolamine (pH 9 8) containing 50 mM MgCl·,) was added, and the reaction was allowed to 
proceed for 2 h at 22 °C The colour developed was spectrophotometncally measured at 405 nm 
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Bovme kidney heparan sulphate was taken as a standard within each series. One unit is defined as 
the amount of epitope present on 1 μg bovine kidney heparan sulphate. 
Samples were analysed in triple and at least three different two-fold dilutions were applied 
such that three points were in the steep part of the standard curve. Samples of patients and controls 
were analysed on the same microtitre plate. The intra- and inter-assay coefficient of variation were 
5.2 and 12.6%, respectively. 
Other procedures 
Urinary creatinine was determined using the alkaline picrate method (procedure no 555, Sigma, 
St Louis, MO, U.S Α.). 
Statistical analysis 
Values are given as means ± SEM, unless indicated otherwise. Intergroup comparison was 
calculated using the Mann-Whitney test (31). Correlation analysis was performed using 
Spearman's rank correlation test P-values less than 0 05 were considered significant 
Table 6: Urinary content of glycosaminoglycans, heparan sulphate and heparan sulphate JM403 epitope of 
controls and patients with COPD. 
Content 
(per mg creatinine) 
Controls 
(n=20-24) 
Patients 
(n=20) 
Significance 
Glycosaminoglycan (ng) 
Heparan sulphate 
Modified DMMB assay (μ§) 
Heparitinase assay fag) 
Nitrous acid assay fag) 
JM403 epitope (U) 
12 7± 0 9 
5 1 ±05 
5 1 ± 0 7 
3.3 ±0.5 
4 1 ±07 
11 9± 1 1 
50±05 
64±08 
3 8 ± 0.4 
06±01 
η s 
η s 
η s 
p<0 0001 
Characteristics of controls are given in Table 4, of patients m Table 1 
Values are means ± SEM η s not significant 
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Fig. 2: Glycosaminoglycan content in the urine of 
individual controls and patients with COPD D control, 
• patient with COPD 
Results 
Pilot experiments showed that the urinary content of heparan sulphate JM403 epitope and of 
heparan sulphate on base of creatinine, remained constant during the day, and from day to day 
This also holds for glycosaminoglycans, which is in agreement with data from the literature (32). 
There was no correlation between age and urinary content of heparan sulphate and glycosamino­
glycan. There was, however, a correlation between age and content of heparan sulphate JM403 
epitope (r=0.26, P<0.03). 
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Fig. 3: Heparan sulphate content in the urine of individual controls and patients with COPD measured using A 
a modified 1,9-dimethylmethylene blue assay, В nitrous acid digestion, С hepanlinase digestion D control, • 
patient with COPD 
In patients with COPD the content of urinary glycosaminoglycans was not altered 
compared to controls (Fig. 2, Table 6). The urinary content of heparan sulphate, measured by 
three different methods, was also not changed (Fig. 3, Table 6). The urinary content of the heparan 
sulphate JM403 epitope was significantly decreased in patients with COPD (Fig 4. Table 6) 
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To examine the specificity of this finding, we studied two additional groups of patients-
patients with bronchial carcinoma with and without emphysema, and patients with sarcoidosis. 
The urinary content of the heparan sulphate JM403 epitope was significantly lower in patients 
with bronchial carcinoma with emphysema compared to patients with bronchial carcinoma 
without emphysema (Fig. 5, Table 7). Urinary glycosaminoglycan and heparan sulphate content 
were not different (Table 7). Patients with bronchial carcinoma without emphysema had similar 
heparan sulphate JM403 values as controls. 
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Fig. 4: Heparan sulphate JM403 epitope content in the 
urine of individual controls and patients with COPD 
One unit is defined as the amount of epitope present on 
1 μg bovine kidney heparan sulphate D control, • 
patient with COPD 
0 1 50 60 70 80 
Age (years) 
Fig. 5: Heparan sulphate JM403 epitope content in 
the urine of individual patients with bronchial 
carcinoma with and without emphysema D patient 
without emphysema, • patient with emphysema 
Table 7: Urinary content of glycosaminoglycans, heparan sulphate and heparan sulphate JM403 epitope of 
patients with bronchial carcinoma with and without emphysema 
Content 
(per mg creatimne) 
Glycosaminoglycan ^ g ) 
Heparan sulphate 
Modified DMMB assay 
Epitope JM403 (U) 
(Mg) 
Patients without 
emphysema (n=8) 
1 6 7 ± 2 4 
6 4 ± 0 7 
2 4 ± 0 5 
Patients with 
emphysema (n= 
16 5 ± 2 2 
6 6 ± 0 7 
0 4 ± 0 1 
7) 
Significance 
η s 
η s 
p<0 0005 
Characteristics of patients are given in Table 2. 
Values are means ± SEM η s not significant 
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In urines of sarcoidosis patients no altered content of the heparan sulphate JM403 epitope 
was found (Fig. 6, Table 8). Urinaiy glycosaminoglycan and heparan sulphate concentration were 
also not changed (Table 8). 
Table 8: Urinary content of glycosaminoglycans, heparan sulphate and heparan sulphate JM403 epitope of 
control subjects and patients with sarcoidosis. 
Content Controls (n=41) Patients (n=15) Significance 
(per mg creatinine) 
Glycosaminoglycan ^ g ) 
Heparan sulphate 
Modified DMMB assay ^ g ) 
Epitope JM403 (U) 
14.3 ±0.5 
4.3 ±0.3 
2.4±04 
n.s. 
3.0 ±1.0 n.s. 
1.7 ±0.2 n.s. 
Characteristics of controls are given in Table 5, of patients in Table 3. 
Values are means ± SEM. n.s.: not significant. 
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Fig. 6: Heparan sulphate JM403 epitope content in the 
urine of individual controls and sarcoidosis patients. 
D : control; • : sarcoidosis patient. 
Discussion 
In the urine of patients with COPD we found a decreased content of the heparan sulphate JM403 
epitope together with a normal content of heparan sulphate. The major group of patients studied 
(group I) was identified on a clinical basis, including lung function tests, and had a strong 
reduction of predicted FEV,. Although we had no histological evidence, the presence of 
emphysema is likely in the lungs of patients with COPD (33). In addition, the group of patients 
154 
12.8 ±0.9 
Urinary heparan sulphate in COPD 
with bronchial carcinoma with histological proven emphysema, showed a reduced content of the 
heparan sulphate JM403 epitope 
All values were normalized to the creatinine content, but COPD patients often have a 
reduced concentration of creatinine in the unne, due to a reduced muscle mass (33) Correcting for 
this would result in a downward adjustment of the values for COPD patients This would make 
the difference between the heparan sulphate JM403/mg creatinine values of controls and COPD 
patients even greater A decreased heparan sulphate JM403 value as a result of blocking of the 
epitope by a component present in the urine is unlikely, since prior to analysis, unne samples were 
first diluted with an equal volume of 7 M urea/10 raM Tns-HCl Urea is a chaotropic agent which 
disrupts non-covalent bonds Glycosaminoglycans were subsequently purified using ion-exchange 
chromatography 
The specificity of the decreased heparan sulphate JM403 value in COPD patients was 
confirmed by data of two additional groups of patients (patients with bronchial carcinoma with 
and without emphysema, and patients with sarcoidosis) Since all but one patient in the group oí 
bronchial carcinoma are smokers, a major effect of smoking is not likely Likewise, a major effect 
of medication is also unlikely, since the group of patients with sarcoidosis who received oral 
corticosteroids had no decrease of unnary heparan sulphate JM403 epitope The content of 
heparan sulphate determined with three different assays, based on different aspects of the heparan 
sulphate molecule, showed no significant differences between patients and controls Differences in 
urinary glycosaminoglycan and heparan sulphate content, however, may be obscured by the 
relatively small contribution of glycosaminoglycan and heparan sulphate derived from the lung 
The amount of lung-derived heparan sulphate JM403 epitope may, however, be quite substantial 
Lung parenchyma is neh in basement membranes and the heparan sulphate JM403 epitope is 
basement membrane specific (29) In lung the proportion of JM403 epitope per nig heparan 
sulphate is quite high, eg in rat lung 35-fold higher than in kidney and heart (Van den Bom, 
unpublished data) 
The normal content of heparan sulphate and the decreased content of the heparan sulphate 
JM403 epitope, suggest a structural alteration in or an altered processing of the heparan sulphate 
molecule in the lungs of emphysematous patients At present, we do not know the exact nature of 
the epitope recognized by the JM403 antibody Studies on chemically and enzymatically modified 
heparan sulphate indicate that the epitope contains one or more N-unsubstituted glucosamine and 
D-glucuronic acid units, and is located in a region of the heparan sulphate chain composed of 
mixed N-sulphated and N-acetylated disacchande units (34) The biological significance of N-
unsubstituted glucosamines has recently been demonstrated in the binding of heparan sulphate to 
L-selectin (35) Blocking of the epitope m the glomerular basement membrane by injection of 
JM403 antibody leads to proteinuria in rats (30) Interestingly, microalbuminuria has recently been 
described in a small group of patients with COPD (36) 
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The etiology of pulmonary emphysema is not known. The predominant theory emanates 
from an relative excess of proteases (the protease/anti-protease concept) (37), elastin being the 
target molecule for degradation. The evidence for this, however, is largely circumstantial. Elastin 
may not be the initial target molecule since this molecule is extremely stable due to its apolarity 
and its presence in fibers. In addition, leucocyte elastase, considered to be the main protease in the 
emphysematogenesis, has been reported to lack elastolytic activity (38). Considering that the 
development of (clinically evident) emphysema is a process of several decades, the basic 
alteration may be quantitatively small in nature. The decreased content of a specific epitope of 
heparan sulphate, together with a normal content of total heparan sulphate, in the urines of 
emphysema patients hints to a small, but significant alteration. Alterations in the heparan sulphate 
molecule would have consequences for the protecting heparan sulphate-proteoglycan barrier of the 
alveolus (15). In view of the functions of heparan sulphate (anti-protease activity, binding and 
modulation of growth factors and cytokines, involvement in the fibrillogenesis of collagen and 
elastin), this could lead to a destabilization of the extracellular matrix, ultimately resulting in 
emphysematous lesions. This concept is supported by the findings in rats that specific inhibition 
of proteoglycan synthesis induces emphysematous lesions (39) and that heparan sulphate 
proteoglycans are very vulnerable towards elastase degradation (40). In a genetic model for 
emphysema, the tight-skin mouse, antibodies to heparan sulphate have been detected (41, 42). 
In conclusion, urines from patients with COPD/emphysema contain normal levels of 
glycosaminoglycans and heparan sulphate, but on the excreted heparan sulphate the expression of 
a specific epitope is decreased. Considering the physiological role of heparan sulphate in alveoli, 
this alteration may be associated with the pathogenesis of emphysema. Future research will focus 
on the usefulness of the heparan sulphate JM403 epitope for (early) diagnosis of emphysema. 
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SURVEY AND SUMMARY 
The main goal of this investigation was to get insight in the role of proteoglycans in the 
pathogenesis of pulmonary emphysema This goal was approached by research on 
experimental animal models for pulmonary emphysema and on patients with pulmonary 
emphysema, using histochemical and biochemical techniques Since both techniques 
introduced different kinds of problems, a number of new biochemical and histochemical 
methods were first developed to accomplish this research 
9.1 New methods to analyse glycosaminoglycans and proteoglycans 
Analysis of glycosaminoglycans in tissue and urine comprehended an important part of the 
investigation The existing techniques for the quantification ol glycosaminoglycans (e g 
alcian-blue precipitation methods (1)) give poorly reproducible results Purification oí 
glycosaminoglycans by anion exchange chromatography and ethanol precipitation, prior to 
determination was found crucial, especially for body fluids like urine bor the assay of urinary 
glycosaminoglycans we choose for the dimethylmelhylene blue method (2), which is specific 
tor polysulphated polysaccharides Addition of albumin to this assay - to stabilize the 
dye/glycosaminoglycan complex - was found to specifically eliminate the staining of heparan 
sulphate This effect was used to quantify heparan sulphate in column fractions and urine 
samples (Chapter 2) 
A restriction of the existing glycosaminoglycan analysis techniques is their limited 
sensitivity (about 1 μg) A higher sensitivity is needed for the analysis of glycosaminoglycans 
in small amounts of tissue (e g cryosections of lung parenchyma), in body fluids, or in 
samples in which the glycosaminoglycan concentration is very low (e g bronchoalveolar 
lavage fluid) Therefore a more sensitive analysis technique was developed, which is based on 
the separation of different types of glycosaminoglycans in a thin agarose gel and subsequent 
fixation and staining with the canonic dye Azure A, followed by silver enhancement 
Densitometrie analysis of the silver deposition gives a linear response between 1 and 20 ng for 
chondroitin- and dermatan sulphate and between 2 and 40 ng for heparan sulphate The 
detection limit is about 250 pg The staining procedure was applied for the quantification and 
characterization of glycosaminoglycans in human serum, urine and lung, and in mouse kidney 
glomeruli It requires only 10 μί serum, 2 μ\ urine and only a single cryosection in case of 
tissue (Chapter 3) 
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Since in general only limited amounts of emphysematous tissue are available, alterations 
in emphysematous tissue are difficult to characterize by standard biochemical techniques 
(Semi-)quantitative immunocytochemical analysis can be used as an alternative to analyse 
specific components Immunoperoxidase analysis of alveoli is not satisfactory since the sharp 
air-tissue transition causes light refractions Immunofluorescence microscopy may overcome 
this problem, but the strong autofluorescence of elastic fibres impedes this type of 
microscopic analysis To overcome this we developed a method to eliminate autofluorescence 
The method is based on the phenomenon that most autofluorescent compounds have broad-
banded excitation and emission spectra whereas specific fluorescent probes have narrow 
spectra This allows to discriminate between the total fluorescence signal and the autofluo­
rescence signal By digital image analysis the two signals can be subtracted, which results in 
an autofluorescence-free signal Furthermore, digitization allows quantitative analysis of the 
images Elimination of autofluorescence was established in immunofluorescence studies of 
human alveolar lung tissue, and human heart Analysis of fluorescence intensity was also 
demonstrated on human skeletal muscle tissue (Chapter 4) 
The two techniques described in Chapter 3 and 4 enable the analysis of minute amounts 
of lung tissue Both techniques can be used to analyse the glycosaminoglycan composition 
and content of control and emphysematous lung tissue 
For image analysis of the digitized fluorescent images we developed a Microsoft-
Windows® application (Chapter 5) This application can also be used to perform densitometnc 
analysis of silver stained gels, which are digitized using an ordinary scanning apparatus This 
technique was used to analyse electrophoretically separated glycosaminoglycans (Chapter 3) 
9.2 Proteoglycans and pulmonary emphysema 
9 2 1 Proteoglycans in elastase-induced emphysema 
Studies on proteoglycans in lung and urine of rats in which pulmonary emphysema was 
induced by an intratracheal instillation of pancreatic elastase, showed that proteoglycans are 
one of the first glycoproteins to be attacked (Chapter 6) Immunofluorescence microscopy 
revealed a strong decrease in heparan sulphate proteoglycan staining, while immunostaining 
of other basement membrane proteins (ι e type IV collagen, lamimn and fibronectin) was 
unaltered Digestion of heparan sulphate proteoglycans may result in an increased 
permeability of the alveolar basement membrane for serum proteins and other components 
resulting in an increased flow to the alveolar lnlerstitium and alveolar airspace (3) This may 
cause pulmonary edema, inflammation and haemorrhages, which are observed after treatment 
with pancreatic elastase Heparan sulphate displays a chemotactic and stimulating effect on 
neutrophils (in combination with interleukin-8)(4, 5), but simultaneously inhibits the released 
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neutrophil elastase (6-8), and other enzymes from the stimulated neutrophils (9). Therefore, 
liberated heparan sulphate molecules could play an important role in the recruitment of 
neutrophils, while the destructed basement membrane lacks the potency to inhibit the release 
and the activity of neutrophil derived elastase. Besides interleukin-8, glycosaminoglycans can 
bind a number of other growth factors, e.g. interferon-γ, basic fibroblast growth factor, 
transforming growth factor-ß (10-12), which play a role in extracellular matrix repair. In 
summary, proteoglycans could play a role in the protection and repair of the alveolar 
extracellular matrix. 
In elastase-induced 
emphysema in rats degra-
dation of lung proteo-
glycans is also indicated by 
the increase in urinary 
heparan sulphate and der-
matan sulphate content 
shortly after induction. This 
increase in urinary glycos-
aminoglycan content shows 
a remarkable correlation 
with the extent of emphy-
sema 40 days after elastase 
treatment, indicating that 
proteoglycan degradation is 
a potential marker for the 
extent of tissue damage. 
This potential is now being explored as an indicator for tissue damage caused by exacerbation 
of pulmonary emphysema. Progression of pulmonary emphysema in human is accelerated by 
an exacerbation of the disease, which is often accompanied by inflammation. Degradation of 
proteoglycans (as measured by an increase in urinary glycosaminoglycan content) could 
possibly be used to monitor an exacerbation and predict the extent of parenchymal destruction 
associated with it. Preliminary results on the urinary glycosaminoglycan content of patients 
with pulmonary emphysema during an exacerbation indicate that there is indeed an increase of 
urinary glycosaminoglycans during the first days of the exacerbation (Fig. 1). Further 
research should evaluate the usefulness of this observation as a diagnostic marker for 
pulmonary exacerbations in patients with pulmonary emphysema. 
M 1 2 3 4 5 6 
H S -
DS— 
CS—-" 
Fig. 1: Urinary glycosaminoglycan composition of a patient with 
emphysema during an exacerbation. The arrow indicates a strong increase of 
a nitrous acid-sensitive glycosaminoglycan (heparan sulphate or heparin) 
during the first days the patient was admitted to the hospital. The amounts of 
urine sample applied were corrected for the urinary creatinine content. 
M, marker glycosaminoglycan; HS, heparan sulphate; DS, dermatan 
sulphate and CS, chondroitin sulphate. Numbers indicate the days of 
hospitalisation. 
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9 2 2 Induction of emphysema by disturbance of proteoglycan synthesis 
Intratracheal administration of a single dose of the artificial glycosaminoglycan attachment 
substrate p-nitrophenyl-ß-D-xylopyranoside (ß-D-xyloside) leads to the induction ot 
pulmonary emphysema in rats (Chapter 7) This compound causes short-term changes of 
glycosaminoglycans in lung, broncho-alveolar lavage, serum and urine Although the 
pathomechanism for the induction of pulmonary emphysema by treatment with ß-D-xyloside 
is not clear, it is likely that the disturbance of glycosaminoglycan and proteoglycan synthesis 
plays an important role Initially the increased glycosaminoglycan content can affect the water 
and ion balance of the alveolar wall and result in extracellular matrix damage The latter may 
be partially mediated by recruitment of inflammatory cells, although the number oí 
inflammatory cells is relatively low compared to elastase-induced emphysema Alteration of 
the content of glycosaminoglycans and proteoglycans can disturb the repair of the damaged 
extracellular matrix by interfering with the fibnllogenesis of collagen fibrils and elastic fibers 
Furthermore, since glycosaminoglycans bind and modulate a number of growth factors, tissue 
repair may be compromised Thus, alterations of proteoglycan and glycosaminoglycan 
composition of the alveolar mterstitium can result in tissue damage, and influence its repair 
which results in pulmonary emphysema However, further investigations are needed to gel a 
better insight in the induction mechanism of emphysema in this model 
In both elastase- and ß-D-xyloside-induced lung injury, chondroitin sulphate 
proteoglycans associated with fibrous structures (presumably elastic fibers) have been 
observed, which are absent in saline-treated animals Preliminary data using double 
immunostaining techniques, indicate elastase-induced chondroitin sulphate (proteoglycan) 
expression at places with a decreased heparan sulphate staining (Chapter 6) In this respect a 
potential role of chondroitin sulphate proteoglycan in fibre repair is obvious (13-15) A further 
characterization of this process and identification of the proteoglycan are necessary 
9 2 3 The heparan sulphate JM403-epitope and pulmonary emphysema 
In Chapter 8 the characterization of urinary glycosaminoglycans of patients with pulmonary 
emphysema, healthy volunteers and patients with a non-related pulmonary disease is outlined 
Patients with pulmonary emphysema display a decrease in the urinary excretion of a specific 
heparan sulphate epitope (JM403, which is specific for basement membrane heparan sulphate 
(16)), while the total heparan sulphate content remains unaltered Other patients without 
pulmonary emphysema show no alterations in the excretion of this epitope 
The decrease of the JM403-epitope in urine may be a reflection of a general alteration ol 
basement membrane heparan sulphates in patients with pulmonar) emphysema It can also be 
explained by the assumption that heparan sulphate molecules of alveolar basement 
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membranes contain more JM403-epitope compared to those of other basement membranes In 
this case the reduction of alveolar tissue (as is found in pulmonary emphysema) results in a 
reduced turnover and thus a reduced excretion of the JM403-epitope In a preliminary study of 
different rat tissues Hill and van den Born (Dept Nephrology, University of Nijmegen) found 
that the content of the JM403-cpitope of extracted glycosaminoglycans was markedly higher 
in lung compared to heart, liver and kidney These data indicate that the JM403-epitope is 
more frequently present on heparan sulphate molecules of alveolar basement membrane 
compared to other basement membranes Either of the explanations for the decreased urinary 
JM403-epitope content in patients with pulmonary emphysema indicate that the JM403-
epitope is part of an important heparan sulphate structure of basement membranes in general 
or of the alveolar basement membrane in particular To date, part of the JM403-epitope has 
been characterized, as a glucosamine residue, with an unsubstituted amino group The epitope 
is likely located in regions composed of mixed N-acetylated and N-sulphated disacchande 
units with a relatively high glucuronic acid content outside the hepann-like sequences (17) 
Recently it was proposed that unsubstituted amino groups of glucosamine residues of 
endothelial heparan sulphate proteoglycans could play a role in the binding of L-selectin (18), 
and thus those groups can be biologically important 
Glycosaminoglycans as heparan sulphate could play a role in the neutralization of 
oxidants and free radicals (19) by functioning as a suicidal oxidant/free-radical scavenger In a 
recently started collaboration with dr H Garg (Harvard Medical School, Boston, USA) in 
which the effect of cigarette smoke on alveolar proteoglycans is investigated, we found that 
the JM403-immunostaining of alveolar basement membranes was markedly decreased in 
lungs of rats exposed to cigarette smoke (Fig 2) These findings indicate the importance of 
the JM403-epitope, but further research on the structure, occurrence and synthesis of this 
epitope in the alveolar basement membrane is necessary 
For further study of the possible role of the heparan sulphate JM403-epitope in the 
pathogenesis of pulmonary emphysema (and for the lung in general) the content of this 
epitope and its ratio to heparan sulphate should be quantified in normal and diseased lungs 
To achieve this goal, the techniques described in Chapter 3 and 4, and the specific 
immunoassay of the JM403-epitope (see Chapter 8) can be used 
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Fig. 2: Immunoperoxidase staining of basement membrane heparan sulphate of lungs of non-treated (left) and 
cigarette smoke-exposed (right) rats. The JM403-antibody was applied as primary antibody. 
9.3 Human pathology versus animal models 
The application of experimental animal models for specific human pathologies is doubtful in 
most cases. They can only give insight in possible mechanisms for human pathology. In the 
animal models we used, pulmonary emphysema was induced by a single treatment of a 
specific agent (i.e. pancreatic elastase or ß-D-xyloside). The acute reactions of the animals to 
these agents are hardly comparable to the chronic and slow development of emphysematous 
lesions in human pathology. However some correspondence can be observed between human 
pathology and the animal models we used. 
The decreased excretion of the JM403-epitope indicates that small changes in the glycos-
aminoglycan structure (i.e. proteoglycan) could be important in human pathology. In rats. 
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pulmonary emphysema can be induced by specific disturbance of the glycosaminoglycan and 
proteoglycan synthesis, indicating that also in animal models changes in proteoglycan and/or 
glycosaminoglycan composition lead to pulmonary emphysema 
The induction ot experimental pulmonary emphysema by a single administration ot a 
high dose of a proteolytic enzyme cannot simply be compared with the slowly progressive 
de\elopment of pulmonary emphysema in human However the induction ot pulmonary 
emphysema with elastase showed that proteoglycans are very vulnerable to proteolytic 
digestion Furthermore, there is a close relation between proteoglycan breakdown (as 
determined by glycosaminoglycan excretion) and the extent of pulmonary emphysema 
Preliminary results showed that an increased glycosaminoglycan excretion can be observed in 
human during exacerbations ot pulmonary emphysema, indicating that also in human 
pathology proteoglycan digestion occurs 
Combined these results indicate that in proteoglycans can play an important role in the 
pathogenesis of pulmonary emphvsema in human 
9.4 General conclusions 
0 The specific reduction of heparan sulphate staining by addition of BSA in the dimethyl 
methylene blue assay can be used to measure the heparan sulphate content in a sample 
(Chapter 2) 
• Glycosaminoglycans in agarose gels can be sensitively and quantitatively stained by a 
combined Azure-A/silver-staining (Chapter 3) 
9 The broad emission and excitation spectra ot auto fluorescent compounds can be used to 
distinct (and eliminate) the fluorescence signal of these compounds from the narrow 
spectral banded fluorescent probes, in fluorescence microscopy (Chapter 4) 
• Intratracheal instillation of pancreatic elastase in rats results in breakdown of lung 
proteoglycans and an increased urinary glycosaminoglycan excretion during the first 
days after instillation The increase is correlated to the extent of pulmonary emphysema 
developed after 40 days (Chapter 6) 
• Inhibition of proteoglycan synthesis by intratracheal instillation of rats with ß-D-xyloside 
(which is accompanied with a stimulation of glycosaminoglycan synthesis) leads to the 
development of pulmonary emphysema (Chapter 7) 
• Chondroitin sulphate proteoglycans associated with fibrous structures (presumably elastic 
fibers) are observed in both pancreatic elastase- and ß-D-xyloside-induced lung injury 
(Chapter 7) 
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# Human pulmonary emphysema is accompanied with a decreased urinary excretion of the 
specific heparan sulphate epitope JM403, while the heparan sulphate excretion remains 
unaltered (Chapter 8). 
9.5 Future research perspectives 
# The structure and function of the heparan sulphate domain, of which the JM403-epitope 
is a part, has to be analysed and characterized, to elucidate its possible role in the 
pathogenesis of pulmonary emphysema and its function in the lung in general 
# Urinary glycosaminoglycan and/or JM403 content could be used as a diagnostic marker 
for lung injury. Further investigation of the usefulness of these parameters in patients 
with pulmonary emphysema is needed 
# The JM403-epitope content and glycosaminoglycan composition of normal and 
emphysematous alveolar lung tissue should more carefully be analysed. This can be done 
with the techniques described in Chapter 3 and 4. 
# The pathomechanism of ß-D-xyloside-induced pulmonary emphysema has to be further 
characterized. 
# The fibre-associated chondroitin sulphate proteoglycan should be identified and its role in 
the fibrillogenesis and repair of elastic fibers and collagen fibrils should be established. 
# The involvement of alterations of proteoglycans/glycosaminoglycans in pathogenesis of 
pulmonary emphysema (e.g. via changes in divalent metal-ion binding or growth factor 
modulation) are worth to be investigated. 
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PROTEOGLYCANEN EN LONGEMFYSEEM 
Proteoglycanen zijn macromoleculen die bestaan uit een eiwitketen waaraan een of meerdere 
glycosaminoglycanen zijn gekoppeld Glycosaminoglycanen vormen een familie van lange, 
sterk negatief geladen Polysacchariden Door deze negatieve lading bezitten glycos-
aminoglycanen (c q proteoglycanen) unieke eigenschappen, die van belang zijn bij de 
integriteit en het functioneren van de alvéolaire extracellulaire matrix De twee belangrijkste 
proteoglycanen in de alvéolaire extracellulaire matrix zijn heparansulfaatproteoghcan dat 
zich in de basaalmembraan bevindt en daar o a een barnerefunctie \ervult, en het met 
collageen geassocieerde dermatansulfaatproteoglycan Proteoglycanen zijn o a betrokken bij 
de fibnllogenese van collageen en elastine en moduleren de mechanische karakteristieken van 
deze fibrillaire componenten Ze binden en moduleren groeifactoren en cytokinen en 
fungeren, via de glycosaminoglycanketens, als krachtige protease remmers Bovendien geven 
ze een beschermende werking tegen zuurstofradicalen Dit samen met hun nauwe associatie 
met collageen- en elastine vezels en hun strategische locatie in de alvéolaire wand, geeft het 
belang van proteoglycanen voor de alvéolaire extraccllulaire matrix aan Veranderingen in de 
proteoglycan samenstelling kunnen een belangrijke aanzet zijn tot verstoring van de alvéolaire 
extracellulaire matrix, wat kan leiden tot pathologie zoals longemfyseem 
De relatie tussen longemfyseem en proteoglycanen is door ons bestudeerd in twee 
dierexperimentele modellen en door onderzoek aan urine van emfyseempatienten Om deze 
relatie goed te kunnen bestuderen zijn voor de analyse van proteoglycanen en glycos-
aminoglycanen een aantal methodes ontwikkeld Allereerst is een snelle en eenvoudige spec-
trofotometrische analyse ontwikkeld voor de kwantificering van heparansultaat (Hoofdstuk 2) 
Daarnaast is een zeer gevoelige kwantitatieve gelelektroforesetechniek ontwikkeld waarmee 
zeer kleine hoeveelheden glycosaminoglycan kunnen worden gekarakteriseerd (Hoofdstuk 3) 
Voor de analyse van immunofluorescentiebeelden is een digitale beeldbewerkingstechniek 
ontwikkeld waarmee hinderlijke autofluorescentie (die in longweelsel veelvuldig voorkomt) 
kan worden geëlimineerd (Hoofdstuk 4) Om deze techniek te verwezenlijken is een 
computerprogramma (ImageCalc) ontwikkeld, dat bovendien gebruikt kan worden voor de 
densitometnsche analyse van gekleurde gelen (Hoofdstuk 5) 
De relatie lussen longemfyseem en proteoglycanen is allereerst onderzocht in een ratte 
model, waarbij longemfyseem wordt geïnduceerd door intratracheale instillatie met elastase 
(Hoofdstuk 6) Uit ïmmunohistochemisch onderzoek blijkt dat 3 uur na instillatie de kleuring 
van heparansulfaat in de long plaatselijk zeer sterk is afgenomen Na ongeveer 5 dagen is het 
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beeld weer nagenoeg normaal. Deze afname kan verklaard worden door de afbraak van het 
eiwitdeel van heparansulfaatproteoglycan waardoor de heparansulfaatketens loslaten, 
immunokleuring op het eiwitdeel blijkt inderdaad afgenomen te zijn. Immunokleuring op 
andere basaalmembraancomponenten (collageen type IV, laminine en fibronectine) is niet 
veranderd, ook niet op de plaatsen waar de heparansulfaatkleuring wel is afgenomen. Deze 
resultaten geven aan dat juist heparansulfaatproteoglycanen in vivo erg gevoelig zijn voor 
proteolytische afbraak. Uit biochemisch onderzoek blijkt dat het glycosaminoglycangehalte 
van de longen van elastase behandelde ratten is afgenomen. De glycosaminoglycan-
concentratie in urine neemt gedurende 4 dagen sterk toe. De gemiddelde toename over deze 4 
dagen vertoont een sterke correlatie met de mate van emfyseem dat zich na 40 dagen heeft 
ontwikkeld. Dit duidt er op dat er een verband bestaat tussen proteoglycanafbraak in de eerste 
dagen na elastase instillatie en de mate van emfyseem die zich later ontwikkelt. 
In de rat konden door intratracheale instillatie van een specifieke remmer van de proteo-
glycansynthese (p-nitrofenyl-ß-D-xylopyranoside (ß-D-xyloside)) emfysemateuze laesies 
worden opgewekt (Hoofdstuk 7). Deze remmer is een artificieel substraat voor de start van 
glycosaminoglycansynthese. Hierdoor wordt de synthese van vrije glycosaminoglycanen 
gestimuleerd, terwijl de synthese van intacte proteoglycanen wordt geremd. Gedurende de 
eerste dag na instillatie van ß-D-xyloside is de glycosaminoglycanconcentratie in de urine 
sterk verhoogd. Ook in dit model vertoont de mate van toename in urinaire glycos-
aminoglycanen gedurende de eerste dag na behandeling een significante correlatie met de 
mate van emfyseem die zich na 40 dagen heeft ontwikkeld. Er bestaat dus een direct verband 
tussen de verstoring van de proteoglycansynthese (c.q. stimulatie van de glycos-
aminoglycansynthese) en de mate van emfyseem dat zich later ontwikkelt. Verstoring van de 
proteoglycansynthese (c.q. stimulering van de glycosaminoglycansynthese) blijkt een 
destabiliserend effect te hebben op de alvéolaire extracellulaire matrix, wat resulteert in de 
vorming van emfysemateuze laesies. 
Naast dierexperimentele modellen zijn ook patiënten met COPD/longemfyseem 
bestudeerd (Hoofdstuk 8). In de urine van deze patiënten is, in vergelijking met gezonde 
controle personen, het gehalte aan een specifiek epitoop (JM403) van het heparansulfaat-
molecuul sterk verlaagd. De totale hoeveelheid heparansulfaat en glycosaminoglycan zijn 
echter niet veranderd. Dezelfde specifieke afname wordt ook waargenomen in urines van 
patiënten met zowel een bronchiaal carcinoma als longemfyseem, terwijl in urines van 
patiënten met alleen een bronchiaal carcinoma geen afname kan worden geconstateerd. In 
urines van patiënten met de niet aan longemfyseem gerelateerde longziekte sarcoïdose, kan 
eveneens geen afname van het specifieke heparansulfaatepitoop worden waargenomen. De 
gevonden verandering in de samenstelling van het heparansulfaat in de urine heeft dus een 
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relatie met longemfyseem De waargenomen verminderde uitscheiding van het heparan-
sulfaatepitoop kan veroorzaakt worden door een relatief verminderde bijdrage van heparan-
sulfaat van de longbasaalmembraan of door een structurele verandering van dit 
glycosaminoglycan in de basaalmembraan Het verlaagde gehalte van het 
heparansulfaatepitoop (JM403) in de urine kan mogelijk gebruikt worden voor (vroege) 
diagnose van longemfyseem 
Concluderend kan gesteld worden, dat uit ons dierexperimenteel onderzoek blijkt dat 
verstoring van de proleogl>canen in de long leidt tol emfysemateuze laesies De in de urine 
\an longemtyseempatienten gevonden verlaagde hoeveelheid van een specifiek heparan-
sulfaatepitoop wijst er op, dat ook in de menselijke situatie afwijkingen in samenstelling en/ot 
metabolisme van proteoglycanen van belang kunnen zijn bij de Pathogenese van long-
emfyseem 
177 
ABBREVIATIONS 
BAL 
BSA 
COPD 
CS 
CSPG 
DMMB 
DMSO 
DS 
DSPG 
GAG 
HA 
Hep 
HS 
HSPG 
KS 
MLI 
PBS 
PG 
TCA 
ß-D-xyloside 
broncho alveolar lavage 
bovine serum albumin 
chronic obstructive pulmonary disease 
chondroitin sulphate 
chondroitin sulphate proteoglycan 
1,9-dimethylmethylene blue 
dimethyl sulfoxide 
dermatan sulphate 
dermatan sulphate proteoglycan 
glycosaminoglycan 
hyaluronic acid 
heparin 
heparan sulphate 
heparan sulphate proteoglycan 
keratan sulphate 
mean linear intercept 
phosphate buffered saline 
proteoglycan 
trichloroacetic acid 
p-nitrophenyl-ß-D-xylopyranoside 
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